



(86) Date de dépôt PCT/PCT Filing Date: 2004/06/03  
(87) Date publication PCT/PCT Publication Date: 2004/12/09  
(85) Entrée phase nationale/National Entry: 2005/12/01  
(86) N° demande PCT/PCT Application No.: AU 2004/000759  
(87) N° publication PCT/PCT Publication No.: 2004/106517  
(30) Priorités/Priorities: 2003/06/03 (60/475,827) US;  
2003/06/17 (60/479,616) US;  
2003/11/14 (2003906281) AU;  
2004/03/05 (60/550,504) US;  
2004/03/10 (2004901258) AU;  
2004/03/17 (60/553,920) US;  
2004/04/30 (2004902279) AU

(51) Cl.Int./Int.Cl. *C12N 15/11* (2006.01)  
(71) Demandeur/Applicant:  
BENITEC AUSTRALIA LIMITED, AU  
(72) Inventeurs/Inventors:  
GRAHAM, MICHAEL WAYNE, AU;  
REED, KENNETH CLIFFORD, AU;  
RICE, ROBERT NORMAN, AU;  
HARRISON, BRUCE THOMAS, AU;  
ROELVINK, PETRUS, US;  
SUHY, DAVID, US;  
KOLYKHALOV, ALEXANDER, US  
(74) Agent: FETHERSTONHAUGH & CO.

(54) Titre : ACIDE NUCLEIQUE DOUBLE BRIN  
(54) Title: DOUBLE-STRANDED NUCLEIC ACID

(57) **Abrégé/Abstract:**

The invention is directed towards constructs for RNAi techniques. The invention provides a ribonucleic acid (RNA) for use as interfering RNA in gene silencing techniques to silence a target gene comprising in a 5' to 3' direction at least a first effector sequence, a second effector sequence, a sequence substantially complementary to the second effector sequence and a sequence substantially complementary to the first effector sequence, wherein the complementary sequences are capable of forming double stranded regions with their respective effector sequences and wherein at least one of these sequences is substantially identical to the predicted transcript of a region of the target gene, and a nucleic acid construct encoding such an RNA.



## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
9 December 2004 (09.12.2004)

PCT

(10) International Publication Number  
**WO 2004/106517 A1**

(51) International Patent Classification<sup>7</sup>: **C12N 15/11**

**SUHY, David** [US/US]; 22751 Canyon Terrace Drive, Castro Valley, CA 94552 (US). **KOLYKHALOV, Alexander** [US/US]; 18591 Montpere Way, Saratoga, CA 95070 (US).

(21) International Application Number:  
PCT/AU2004/000759

(22) International Filing Date: 3 June 2004 (03.06.2004)

(74) Agent: **FREEHILLS CARTER SMITH BEADLE**; Level 43, 101 Collins Street, Melbourne, VIC 3000 (AU).

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/475,827	3 June 2003 (03.06.2003)	US
60/479,616	17 June 2003 (17.06.2003)	US
2003906281	14 November 2003 (14.11.2003)	AU
60/550,504	5 March 2004 (05.03.2004)	US
2004901258	10 March 2004 (10.03.2004)	AU
60/553,920	17 March 2004 (17.03.2004)	US
2004902279	30 April 2004 (30.04.2004)	AU

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): **BEN-ITEC AUSTRALIA LIMITED** [AU/AU]; Suite 4, 242 Hawken Drive, St Lucia, Queensland 4067 (AU).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **GRAHAM, Michael, Wayne** [AU/AU]; 42 Raglan Street, St Lucia, Queensland 4067 (AU). **REED, Kenneth, Clifford** [AU/AU]; 12 Fifth Avenue, St Lucia, Queensland 4067 (AU). **RICE, Robert, Norman** [AU/AU]; 39 Foley Place, Sinnamon Park, Queensland 4073 (AU). **HARRISON, Bruce, Thomas** [AU/AU]; 6 Devon Street, Eastern Heights, Queensland 4305 (AU). **ROELVINK, Petrus** [NL/US]; 180 Michael Drive, Campbell, CA 95008 (US).

Published:

— with international search report

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: DOUBLE-STRANDED NUCLEIC ACID

(57) Abstract: The invention is directed towards constructs for RNAi techniques. The invention provides a ribonucleic acid (RNA) for use as interfering RNA in gene silencing techniques to silence a target gene comprising in a 5' to 3' direction at least a first effector sequence, a second effector sequence, a sequence substantially complementary to the second effector sequence and a sequence substantially complementary to the first effector sequence, wherein the complementary sequences are capable of forming double stranded regions with their respective effector sequences and wherein at least one of these sequences is substantially identical to the predicted transcript of a region of the target gene, and a nucleic acid construct encoding such an RNA.



**WO 2004/106517 A1**



## DOUBLE-STRANDED NUCLEIC ACID

The present invention relates to a nucleic acid containing complementary sequences which may form multiple double stranded regions. The present invention also relates to sequences and constructs encoding such a nucleic acid  
5 and the uses of such a nucleic acid or construct to modify gene expression, particularly to reduce or inhibit gene expression.

Certain single stranded nucleic acid molecules are able to form a self-complementary double stranded region where part of the nucleotide sequence is able to interact with another part of the sequence by Watson-Crick base pairing  
10 between inverted repeats of the sequence. Where the repeated regions are adjacent or in close proximity to each other, the double stranded regions may form structures known as hairpin structures. The hairpin structure forms with an unpaired "loop" of nucleotides at one end of the hairpin structure, with the inverted repeat sequence annealed. The loop may also facilitate the folding of the nucleic  
15 acid chain.

Hairpin RNA sequences have become a powerful tool for basic and applied research. In particular these sequences have been used in interfering RNA and gene silencing technologies. Such techniques are described in the specification of PCT/AU99/00195 (US patent application serial number 09/646,807 and US patent  
20 no. 6,573,099) and PCT/AU01/00297, the contents of which are herein incorporated by reference. In summary, RNA interference (RNAi) hairpin RNA sequences may be synthesised within a cell from DNA constructs coding these sequences, hereafter termed "hairpin DNA constructs".

While many hairpin DNA constructs have proved effective in gene silencing,  
25 other DNA constructs only show partial gene silencing activity. Increasing the degree of gene inactivation produced by RNAi hairpin RNA would be advantageous, for example in gene therapy. Furthermore, in many situations, it would be advantageous to be able to silence two or more separate genes or gene regions simultaneously, particularly in respect of gene therapy applications.

30 Reference to any prior art in this specification is not, and should not be taken as, an acknowledgment or any form of suggestion that this prior art forms part of the common general knowledge of one skilled in the art.

There is a need for improved RNA hairpin sequences to be used in interfering RNA and gene silencing technology. Furthermore, there is a need for a DNA construct that is capable of producing hairpin RNA transcripts with an improved gene silencing activity and a need for a DNA construct encoding hairpin  
5 RNA capable of inactivating two or more separate genes. There is further a need for improved methods for the synthesis of such DNA constructs. It is an object of the present invention to overcome, or at least alleviate, one or more of these needs in light of the prior art.

In one aspect the present invention provides a ribonucleic acid (RNA)  
10 suitable for use as interfering RNA in gene silencing techniques comprising in a 5' to 3' direction at least a first effector sequence, a second effector sequence, a sequence substantially complementary to the second effector sequence and a sequence substantially complementary to the first effector sequence, the complementary sequences capable of forming double stranded regions with their  
15 respective effector sequences, and further including one or more spacing sequences of one or more nucleotides.

In one embodiment, the first effector sequence is spaced from the second effector sequence by a first spacing sequence. In another embodiment, the sequence substantially complementary to the second effector sequence is spaced  
20 from the sequence substantially complementary to the first effector sequence by a second spacing sequence. Accordingly, RNA according to this aspect of the present invention can fold so that at least double stranded RNA region is spaced from an adjacent double stranded RNA region by spacing sequences, the spacing sequences being non-annealing and forming a so-called bubble. The terms  
25 "hybridising" and "annealing" refer to nucleotide sequences capable of forming Watson-Crick base pairs between complementary bases, as discussed further below.

In a further aspect the present invention provides a ribonucleic acid (RNA) suitable for use as interfering RNA in gene silencing techniques comprising at  
30 least a first effector sequence, a second effector sequence, a sequence substantially complementary to the second effector sequence and a sequence substantially complementary to the first effector sequence, the complementary sequences capable of forming double stranded regions with their respective



effector sequences. Accordingly, at least one double stranded RNA region is directly adjacent to at least one other double stranded RNA region thereby producing at least two effector regions suitable for use in producing interfering RNA in the gene silencing technique, without intervening spacing sequences. In  
5 one preferred embodiment, the RNA further includes a spacing sequence between the second effector sequence and the sequence substantially complementary to it, the spacing sequence forming a loop about which the RNA folds to form the double-stranded regions.

In another aspect the present invention provides a ribonucleic acid (RNA)  
10 for use as interfering RNA in gene silencing techniques to silence a target gene comprising in a 5' to 3' direction at least a first effector sequence, a second effector sequence, a sequence substantially complementary to the second effector sequence and a sequence substantially complementary to the first effector sequence, wherein the complementary sequences are capable of forming double  
15 stranded regions with their respective effector sequences and wherein at least one of these sequences is substantially identical to the predicted transcript of a region of the target gene. Preferably, the RNA further comprises a spacer sequence of one or more nucleotides, wherein any two of the sequences are spaced by the spacing sequence. More preferably, the RNA further comprises an additional  
20 spacer sequence of one or more nucleotides.

In another aspect the present invention provides a ribonucleic acid (RNA) suitable for use as interfering RNA in gene silencing techniques comprising in a 5' to 3' direction at least a first effector sequence, a second effector sequence, a sequence substantially complementary to the second effector sequence and a  
25 sequence substantially complementary to the first effector sequence, the complementary sequences capable of forming double stranded regions with their respective effector sequences, the sequence substantially complementary to the second effector sequence being spaced from the sequence substantially complementary to the first effector sequence by one spacing sequence of one or  
30 more nucleotides, and the first effector sequence being spaced from the second effector sequence by another spacing sequence of one or more nucleotides. In one embodiment of this aspect of the present invention, both spacing sequences are included and do not anneal.



In a further aspect the present invention provides a ribonucleic acid (RNA) suitable for use as interfering RNA in gene silencing techniques comprising in a 5' to 3' direction at least a first effector sequence, a second effector sequence, a sequence substantially complementary to the second effector sequence and a sequence substantially complementary to the first effector sequence, the complementary sequences capable of forming double stranded regions with their respective effector sequences, the first effector sequence being spaced from the second effector sequence by a first spacing sequence of one or more nucleotides. In one embodiment, the sequence substantially complementary to the second effector sequence is spaced from the sequence substantially complementary to the first effector sequence by a second spacing sequence of one or more nucleotides, the second spacing sequence not being hybridisable with the first spacing sequence. Accordingly, the RNA according to this aspect of the present invention can fold so that at least one strand of at least one double stranded RNA region is spaced from an adjacent double stranded RNA region by a spacing (non-pairing) sequence, the spacing sequence forming a so-called bubble.

By an RNA "suitable for use as interfering RNA" is meant an RNA that may directly act as interfering RNA or that may be processed to produce RNA molecules that are active in RNA interference. Such RNA is suitable for genetic silencing techniques.

In another embodiment, there is provided a nucleic acid construct comprising at least a first effector sequence, a first complementary sequence that is substantially complementary to the first effector sequence, a second effector sequence and a second complementary sequence that is substantially complementary to the second effector sequence, wherein both first and second effector sequences form double stranded portions with their corresponding complementary sequences, the double stranded regions being spaced by a spacer sequence, usually a shorter sequence than the first effector sequence.

In preferred embodiments, one double stranded portion will have its two strands connected by a loop sequence forming the bend in the so-called hairpin structure. In this embodiment, the double stranded portion has this loop at one end, i.e. the loop is formed by a spacing sequence between one of the effector sequences and its substantially complementary sequence. Preferably, the nucleic



acid also has a pair of spacing sequences between the double stranded portions, forming a "bubble".

Preferably, the spacer sequence is shorter than either effector sequence. The spacer sequence is preferably 1 to 20, more preferably 1 to 10, more preferably 1 to 7 and most preferably 2 to 7 nucleotides long. Even more preferably, in one embodiment one spacer sequence is 2 nucleotides long and another spacer sequence is four nucleotides long.

As the ribonucleic acid or nucleic acid construct contains at least two effector sequences, the invention extends to such constructs containing three or more effector sequences, each with corresponding complementary sequences. The effector sequences and corresponding complementary sequences may be spaced from each other by spacing (non-pairing) sequences with the spacing sequence forming a bubble when the effector sequences base pair with the complementary sequences. In preferred embodiments, the ribonucleic acid or nucleic acid construct contains three effector sequences and three corresponding complementary sequences, each separated by a spacing sequence forming a bubble; four effector sequences and four corresponding complementary sequences, each separated by a spacing sequence forming a bubble; or five effector sequences and five corresponding complementary sequences, each separated by a spacing sequence forming a bubble. In further preferred embodiments, the ribonucleic acid or nucleic acid construct contains three effector sequences and three corresponding complementary sequences; four effector sequences and four corresponding complementary sequences; or five effector sequences and five corresponding complementary sequences without intervening spacing sequences between adjacent effector and complementary sequences. There may similarly be six, seven, eight, nine, ten or more effector sequences and complementary sequences in an RNA or nucleic acid construct of the invention. The effector sequences may be the same or different and directed to the same or different target genes, different regions of the same target gene or a combination of these.

In another embodiment, there is provided a ribonucleic acid suitable for use as interfering RNA in gene silencing techniques comprising in a 5' to 3' direction at least a first effector sequence, a second effector sequence, a sequence

substantially complementary to the second effector sequence and a sequence substantially complementary to the first effector sequence, the complementary sequences capable of forming double stranded regions with their respective effector sequences, the second effector sequence being spaced from the  
5 sequence substantially complementary to the second effector sequence by a spacing sequence of one or more nucleotides.

In the context of the present invention, "target gene" refers to a gene which is targeted for silencing by RNA interference techniques. The RNA product of the gene may be a messenger RNA (mRNA) capable of being translated to form an  
10 amino acid sequence, or it may be a non-translated RNA, such as a ribosomal RNA, small uracil-rich RNA, or ribozyme.

Reference herein to a "gene" or "genes" is to be taken in its broadest context and includes:

- 15 (i) a classical genomic gene consisting of transcription and/or translational regulatory sequences and/or coding region and/or non-translated sequences (i.e. introns, 5'- and 3'-untranslated sequences); and/or
- (ii) DNA and RNA viral genes; and/or
- (iii) cDNA corresponding to the coding regions (i.e. exons) and/or 5'- and  
20 3'- untranslated sequences,

whether naturally occurring or synthesised. Furthermore, "gene" includes within its scope both a nucleic acid coding for an amino-acid encoding RNA (i.e. mRNA) as well as a nucleic acid encoding a RNA that does not code for an amino acid sequence.

25 By "substantially identical" is meant about 70% identical to a portion of the target gene. Preferably, it is at least 80-90%, more preferably at least 95 - 100% identical, and includes 100% identity. Thus a sequence substantially identical to a region of a target gene has this degree of sequence similarity. Generally, a double-stranded RNA region of the invention may be subjected to mutagenesis to  
30 produce single or several nucleotide substitutions, deletions or additions without substantially affecting its ability to modify gene expression.



It is known that RNAi is generally optimised by identical sequences between the target and the RNAi construct, but that the RNA interference phenomenon can be observed with less than 100% homology. As is understood by those skilled in the art, the strands comprising the double-stranded regions must be sufficiently homologous to each other to form the specific double stranded regions. The precise structural rules to achieve a double-stranded region effective to result in RNA interference have not been fully identified, but approximately 70% identity is generally sufficient. Greater identity in the central portion of the effector sequence as opposed to the end portions is required as explained below. Another consideration is that base-pairing in RNA is subtly different from DNA in that G will pair with U, although not as strongly as it does with C, in RNA duplexes.

By "substantially complementary" is meant that the sequences are hybridisable or annealable. Moreover, it is known that hybridisation is affected by the conditions of the solution. In general, substantially complementary sequences will have at least 70% Watson-Crick base pairing.

The two sequences of an RNA duplex or double-stranded region are referred to as the "sense" strand and "antisense" strand, even though they may be different portions of one polynucleotide (eg. where it forms a hairpin). The "sense" strand is the one where the sequence is broadly related to the relevant region of the target gene (ie, one that is substantially the predicted transcription product), and the sequence annealing to the sense strand sequence is termed "antisense". For RNAi efficacy, it is more important that the antisense strand be homologous (ie, exactly complementary) to the target sequence. In some circumstances, it is known that 17 out of 21 nucleotides is sufficient to initiate RNAi, but in other circumstances, identity of 19 or 20 nucleotides out of 21 is required. It is believed, at a general level, that greater homology is required in the central part of a double stranded region (i.e. duplex) than at its ends. Some predetermined degree of lack of perfect homology may be designed into a particular construct so as to reduce its RNAi activity which would result in a partial silencing or repression of the target gene's product, in circumstances in which only a degree of silencing was sought. In such a case, it is envisaged that only one or two bases of the antisense strand of the RNA construct would be changed. On the other hand, the other, sense strand of the RNA construct is more tolerant of mutations. It is believed this is due



to the antisense strand being the one that is catalytically active. Thus, less identity between the sense strand and the transcript of a region of a target gene will not necessarily reduce RNAi activity, particularly where the antisense strand perfectly hybridises with that transcript. Mutations in the sense strand (such that it is not identical to the transcript of the region of the target gene) may be useful to assist sequencing of hairpin constructs and potentially for other purposes, such as modulating dicer processing of a hairpin transcript or other aspects of the RNAi pathway.

The terms "hybridising" and "annealing" (and grammatical equivalents) are used interchangeably in this specification in respect of nucleotide sequences and refer to nucleotide sequences that are capable of forming Watson-Crick base pairs due to their complementarity. The person skilled in the art would understand that non-Watson-Crick base-pairing is also possible, especially in the context of RNA sequences. For example a so-called "wobble pair" can form between guanosine and uracil residues in RNA. "Complementary" is used herein in its usual way to indicate Watson-Crick base pairing, and "non-complementary" is used to mean non-Watson-Crick base pairing, even though such non-complementary sequences may form wobble pairs or other interactions. However, in the context of the present invention, reference to "non-pairing" sequences relates specifically to sequences between which Watson-Crick base pairs do not form. Accordingly, embodiments of spacing or bubble sequences according to the present invention are described and illustrated herein as non-pairing sequences, regardless of whether non-Watson-Crick base pairing could theoretically or does in practice occur.

The term "effector sequence" and "effector" in the context of this specification relates to either DNA or RNA, depending on the context, and the term is used to denote a sequence that anneals to form a double-stranded region, due to complementarity of bases in the annealed region. The double-stranded region may determine the region of the target gene to which the construct is directed where the effector sequence, or the sequence substantially complementary to the effector sequence, is substantially identical to a region of the target gene.

In several preferred embodiments, the double stranded regions are



interfering RNA (RNAi) sequences. Preferably, at least one of the effector sequences is substantially identical to at least a region of a target gene in the case of an RNA gene, or substantially identical to the predicted transcript of at least a region of a target gene in the case of a DNA gene. Preferably, the first effector  
5 sequence has this characteristic. In another preferred embodiment, the effector sequences are each separately substantially identical to different regions of a single target gene, or their predicted transcripts, as the case may be. In another preferred embodiment, the effector sequences are each separately substantially identical to regions of different target genes. In this context, "transcript" includes  
10 RNA which could theoretically be encoded by a DNA sequence, also called a "predicted transcript" regardless of the actual method of generation of that RNA sequence. In the DNA described in the embodiments below, at least one of the effector sequences is substantially identical or complementary to a region of the target gene (where the target gene is DNA). In this context, such a sequence may  
15 be called the "targeting sequence" where it is directed to a region of the gene to be silenced. Such a sequence may also be referred to structurally as an "intramolecular self-complementary targeting sequence".

Alternatively, a double-stranded region may form a so-called "stem" sequence. In some embodiments, one or more of the effector sequences will  
20 have a different length to the sequence substantially complementary to it. In such a case, the unpaired portion may function as a spacer sequence. For example, where the effector sequence is generated by identity (or substantial identity) to a region of a target gene and the sequence substantially complementary to it is longer or shorter, the unpaired sequence will still be substantially identical to the  
25 corresponding region of the target gene, but may function as a spacer (e.g. loop or bubble) in the RNA, rather than as part of the effector sequence. In one embodiment, the effector sequence and the sequence substantially complementary to it are adjacent on the polynucleotide, in which case the region between these two sequences forms a loop comprised by either:

30 (i) the 3' end of the effector sequence and the 5' end of the complementary sequence; or

(ii) an unpaired sequence.

Similarly, where the effector and complementary sequences are not



adjacent, but separated by one or more other double-stranded regions, the unpaired sequence may form a bubble.

The effector sequences may be of the same or different lengths. Preferably, effector sequences are at least 10 nucleotides in length, preferably 10-  
5 200 nucleotides in length. More preferably, they are 17 to 30 and most preferably 21 to 23 nucleotides in length. In different embodiments, the effector sequences are 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 nucleotides in length, respectively, or any combination of two or more of these lengths.

It will also be understood that the term "comprises" (or its grammatical  
10 variants) as used in this specification is equivalent to the term "includes" and should not be taken as excluding the presence of other elements or features.

Where the first effector sequence is longer than a second effector sequence, it has been found that the activity of the double-stranded sequence may be enhanced. In such a situation, the second effector sequence (which  
15 usually is not designed to be substantially identical to any particular target) can be called a "stem". Preferably, the stem sequence is 1 to 50 nucleotides in length. A suitable stem sequence is GACUGAA and its complement.

Bubbles are formed by two unpaired, or partially unpaired, strands (which may also be spacing sequences) containing at least a single unpaired base that  
20 bridge or link the double stranded regions on the nucleic acid. Further, a bubble may form where one strand of the nucleic acid includes one or more spacer nucleotides between the double stranded regions and the other strand includes no such spacer nucleotides. In this case, as the end nucleotides on that other strand near the junction of the double-stranded regions form the bubble with the one or  
25 more spacer nucleotides. Preferably the RNA according to this aspect of the present invention includes one loop region and one or more bubble regions. Preferably the bubble regions comprise 1 to 20 unpaired nucleotides per RNA strand. More preferably, the bubble regions comprise 2 to 10 unpaired nucleotides. In a preferred embodiment the bubble region includes the nucleotide  
30 sequence AA, UU, UUA, UUAG, UUACAA or  $N_1AAN_2$ , where  $N_1$  and  $N_2$  are any of C, G, U and A and may be the same or different. In a further preferred embodiment, the opposing sequence to each of these to form the bubble is AA, UU, UUG, UUGA, UUGUUG, and  $N_1AAN_2$  respectively, where  $N_1$  and  $N_2$  are any



of C, G, U or A and may be the same or different.

In a preferred embodiment, a nucleic acid according to the present invention comprises two double stranded RNA regions separated by a bubble region and a loop at one end of the double stranded RNA region. In another preferred embodiment, the nucleic acid according to the present invention  
5 comprises five double stranded RNA regions, with the first and second, second and third, third and fourth and fourth and fifth double stranded regions, respectively, being separated by a bubble region and with a loop at one end of the fifth double stranded RNA region.

10 In another preferred embodiment, there is provided a construct including sequence -X-A-Y-L-Y'-B-X'-, wherein:

X is a nucleotide sequence substantially identical to a first region, or a transcript of a region, of a target gene;

Y is a nucleotide sequence of one or more nucleotides;

15 A is a nucleotide sequence shorter than X;

B is a nucleotide sequence shorter than X and non-complementary to A;

L is a loop sequence;

X' is substantially complementary to X; and

Y' is substantially complementary to Y.

20 Additional effector sequences, with complementary sequences to form duplexes, and with or without spacer sequences like A in this embodiment may be added.

In another preferred embodiment, there is provided a construct including sequence -X-A-Y-L-Y'-X'-, wherein:

25 X is a nucleotide sequence substantially identical to a first region, or a transcript of a region, of a target gene;

Y is a nucleotide sequence of one or more nucleotides;

A is a nucleotide sequence shorter than X;

L is a loop sequence;

X' is substantially complementary to X; and

Y' is substantially complementary to Y.

In another preferred embodiment there is provided a construct including sequence -X-Y-L-Y'-X'-, wherein:

5 X is a nucleotide sequence substantially identical to a first region, or a transcript of a region, of a target gene;

Y is a nucleotide sequence of one or more nucleotides;

L is a loop sequence;

X' is substantially complementary to X; and

10 Y' is substantially complementary to Y.

In a further embodiment, L comprises -P-Q-R-S-T-, wherein P, Q, R, S and T each represent a nucleotide sequence of one or more nucleotides and Q and S are hybridisable with each other, P and T do not hybridise so forming a bubble and R is an unpaired loop region. P is preferably one of UU, UUA, UUAG or UUACAA.  
 15 Preferably, the opposing sequence to each of these to form the bubble is UU, UUG, UUGA and UUGUUG respectively or vice versa. In one preferred embodiment, R is UUCAAGAGA.

In one embodiment, Y is substantially identical to a second region, or a transcript of a region, of a target gene, the target gene being the same or different  
 20 from the gene referred to in the definition of X. Where the target genes are the same, typically different regions will be targeted by X and Y.

In another preferred embodiment, there is provided a construct further including the sequences C and D in the form -C-X-A-Y-L-Y'-B-X'-D-, wherein:

C is a nucleotide sequence shorter than X;

25 D is a nucleotide sequence shorter than X non-complementary to C.

In another preferred embodiment, there is provided a construct including sequence -S-A-T-A-U-A-V-A-W-L-W'-B-V'-B-U'-B-T'-B-S'-, wherein:

S, T, U, V and W are nucleotide sequences each substantially identical to a region, or a transcript of a region, of a target gene;



A is a nucleotide sequence shorter than S, T, U, V and W (each **A** may be the same or different) ;

B is a nucleotide sequence shorter than S, T, U, V and W and non-complementary to **A** (each **B** may be the same or different, but each **B** is non-complementary to its opposed **A** sequence when a double-stranded construct is formed about sequence L by annealing of S,T,U,V and W with their respective complements);

L is a loop sequence;

S', T', U', V' and W' are nucleotide sequences substantially complementary to S, T, U, V and W.

As will be appreciated by one skilled in the art, it is not necessary that the entire construct is generated as one sequence. For example, in one embodiment of the invention, the at least first and second effector sequences, together with any spacing sequence, are generated (eg, transcribed by one DNA sequence), and the sequences substantially complementary to the effector sequences, together with any spacing sequence, are generated (eg, transcribed from a separate DNA sequence). The two or more DNA sequences may be under the control of separate promoters. Any loop sequence may be attached to either transcript or part of the loop attached to the 3' end of one transcript and the 5' end of the other transcript, and a ligation performed. In circumstances where the RNA construct is to be delivered by a DNA construct to a cell, in this embodiment, the two transcripts would be separately generated, and then would hybridise through annealing between the at least first and second effector sequences and their complements.

In a further aspect of the present invention there is provided a nucleic acid construct encoding any of the ribonucleic acids described above. In a preferred embodiment, this construct is a deoxyribonucleic acid (DNA) construct. In one embodiment, the DNA construct includes a sequence encoding a ribonucleic acid (RNA) suitable for use as interfering RNA in gene silencing techniques, the construct comprising in a 5' to 3' direction at least a first effector-encoding sequence, a second effector-encoding sequence, a sequence substantially complementary to the second effector-encoding sequence and a sequence

substantially complementary to the first effector-encoding sequence, the complementary sequences' transcripts capable of forming double stranded regions with the respective effector-encoding sequences' transcripts. In an embodiment of this aspect of the invention, the first effector-encoding sequence is  
5 spaced from the second effector-encoding sequence by a first spacing sequence of one or more nucleotides. Preferably, the sequence substantially complementary to the second effector-encoding sequence is spaced from the sequence substantially complementary to the first effector-encoding sequence by a second spacing sequence of one or more nucleotides. Preferably, the second  
10 spacing sequence does not anneal with the first spacing sequence. Accordingly, the RNA of, or encoded by, the nucleic acid construct according to this embodiment can fold so that at least one double stranded RNA region is spaced from an adjacent double stranded RNA region by a spacing (non-pairing) sequence, the spacing sequence forming a so-called bubble. Preferably, the  
15 nucleic acid construct further includes a spacing sequence between the second effector sequence and the sequence substantially complementary to it, wherein the RNA of, or encoded by, the nucleic acid construct according to this embodiment forms a loop about which the RNA folds to form the double-stranded region between the second effector sequence and the sequence substantially  
20 complementary to the second effector sequence.

In a further aspect the present invention provides a nucleic acid construct including a sequence encoding a ribonucleic acid (RNA) suitable for use as interfering RNA in gene silencing techniques to silence a target gene, the construct comprising in a 5' to 3' direction at least a first effector-encoding  
25 sequence, a second effector-encoding sequence, a sequence substantially complementary to the second effector-encoding sequence and a sequence substantially complementary to the first effector-encoding sequence, wherein the transcripts of the complementary sequences are capable of forming double stranded regions with the transcripts of their respective effector-encoding  
30 sequences and wherein at least one of these sequences is substantially identical to a region of the target gene.

Preferably, the nucleic acid construct further comprises a spacing sequence of one or more nucleotides wherein any two of the encoding sequences are



spaced by a spacing sequence. In preferred embodiments, the first effector-encoding sequence is spaced from the second effector-encoding sequence by the spacing sequence and/or the sequence substantially complementary to the first effector-encoding sequence is spaced from the sequence substantially complementary to the first effector-encoding sequence by the spacing sequence.

In a further preferred embodiment the nucleic acid construct further comprises an additional spacing sequence. In a preferred embodiment, the first effector-encoding sequence is spaced from the second effector-encoding sequence or the sequence substantially complementary to the second effector-encoding sequence is spaced from the sequence substantially complementary to the first effector-encoding sequence by the additional spacing sequence and the transcript of the first spacing sequence is not annealable with the transcript of the additional spacing sequence.

The nucleic acid construct or an RNA according to the invention will usually be a recombinant or isolated molecule.

In a further preferred embodiment, the nucleic acid construct comprises a spacing sequence of one or more nucleotides between the second effector encoding sequence and the sequence substantially complementary to the second effector-encoding sequence.

Preferably, the nucleic acid construct further includes a loop coding sequence between the second effector-encoding sequence and the sequence substantially complementary to the second effector-encoding sequence. The loop forms the "hinge" of the hairpin. In one embodiment, the loop's sequence is 5'TTCAAGAGA3'. In a further embodiment, the loop sequence is 5'TTTGTGTAG3'.

Preferably the construct is derived from a DNA vector selected from the group consisting of a plasmid, a bacteriophage and a viral-based vector. Preferably the DNA construct is suitable for producing RNA suitable for use as interfering RNA in gene silencing technologies. More preferably, the construct can be introduced into a cell where gene silencing is to take place and interfering RNA can be transcribed within this cell.

Preferably the first effector sequence or its complementary sequence is

substantially identical or substantially complementary to a region of a target gene. In one embodiment, the second effector sequence or its complementary sequence is substantially identical to the same or a different region of the same or a different target gene. In another embodiment, the second effector sequence or its  
5 complementary sequence is substantially identical to a region of a different target gene.

In another embodiment, the DNA construct comprises up to five effector-encoding sequences. Each of the encoded effector sequences or their complementary sequences is substantially identical to a region of a target gene.  
10 The encoded effector sequences or their complementary sequences may be substantially identical to regions of different target genes, or to different regions in the same target gene.

The construct according to the present invention may further contain one or more regulatory elements to allow transcription of the RNA to take place.  
15 Preferably at least one of the regulatory elements is a promoter, which is operably linked with the portion of the construct encoding the nucleic acid according to the present invention. A variety of promoters may be included in the polynucleotide vector. Factors influencing the choice of promoter include the desire for inducible transcription of the oligonucleotide or oligonucleotide and polynucleotide  
20 sequences, the strength of the promoter and the suitability of the promoter to induce expression in the in vivo or in vitro environment in which the transcription is to take place. In a preferred embodiment the promoter is an RNA polymerase III (pol III) promoter such as U6 or H1 promoters.

One or more of the regulatory elements of the construct according to the  
25 present invention may be a terminator sequence. Such a terminator sequence may be operably linked with the portion of the construct encoding the nucleic acid of the present invention in order to determine the sequence of the 3' end of the transcribed nucleic acid. Terminators for the various classes of RNA polymerase as known to those skilled in the art. In one embodiment, the terminator is a pol II  
30 terminator. In another embodiment, the terminator is a pol III terminator. Preferably, the pol III terminator includes the sequences TTTTTT or TTTTTT.

As will be appreciated, such constructs will often also include selection



markers or sequences (eg, Ampicillin resistance) and/or restriction enzyme sites.

In a preferred embodiment, the nucleic acid construct includes a transcriptional unit comprising a promoter; at least a first effector-encoding sequence; a second effector-encoding sequence; a sequence substantially  
5 complementary to the second effector-encoding sequence; a sequence substantially complementary to the first effector-encoding sequence and a terminator sequence, the promoter, effector sequences, sequences complementary to the effector sequences and terminator being operably linked. The nucleic acid construct may include in addition to the transcriptional unit  
10 described above at least one further transcriptional unit encoding RNA suitable for use as interfering RNA for use in gene silencing techniques. By "operably linked" in the context of the present invention means that the transcription of a nucleic acid is modulated by the regulatory element with which it is connected. Preferably these are incorporated within a vector.

15 The DNA construct may have regulatory and other elements inserted by methods known in the art so as to optimise the transcription of the RNA suitable for use as interfering RNA in gene silencing techniques.

It will be apparent to the person skilled in the art that deoxyribonucleic acids (DNA) and ribonucleic acids (RNA) may include modified nucleotides. Thus RNA  
20 in the context of the present invention includes nucleic acid containing principally any or all of the ribonucleotides uracil (U), guanosine (G), cytosine (C) and adenosine (A), however modified or otherwise altered nucleotides and nucleotide analogues may also be included within an RNA sequence. Likewise, DNA contains principally any or all of the deoxyribonucleotides thymidine (T), guanosine  
25 (G), cytosine (C) and adenosine (A), however modified or otherwise altered nucleotides and nucleotide analogues may also be included within a DNA sequence.

In another aspect of the present invention there is provided a method of producing RNA from the construct according to the present invention. The RNA is  
30 preferably RNAi for use in gene silencing techniques. The RNA may be produced from the construct according to the present invention in vitro, or by in vivo techniques after introduction of the construct into a cell. In this specification, "silence" means reduced expression, but is not limited to prevention of expression.



In another aspect of the present invention there is provided a method of inhibiting the expression of a target gene by introducing the nucleic acid or construct of the present invention into a cell or other system or environment permitting expression of a target gene (including for example a cell lysate, tissue, *in vitro* system etc) containing a target gene to be silenced using RNAi techniques. In a preferred embodiment, multiple target genes or multiple gene targets are silenced.

A variety of vectors may be used to introduce the nucleic acid or construct encoding the nucleic acid of the present invention into a cell. Virus-based vectors, such as those related to adenovirus, lentivirus or retrovirus, may be used. The expression of the nucleic acid according to the present invention may be *in vitro*, *ex vivo* or *in vivo*. The expression of the nucleic acid after introduction of the construct according to the present invention into a cell may be stable (that is, long-term) or transient. Adeno-associated virus is one preferred vector. Other preferred vectors are retroviral and lentiviral vectors.

The use of the method of this aspect of the present invention has applications in gene therapy strategies where multiple gene inactivation and/or complete inactivation of a gene (for example, an oncogene) would be advantageous. For example, viruses may be controlled by targeting two or more regions of a viral genome, or genes of a virus; thereby decreasing the likelihood that the virus might mutate to become resistant to the effect of a particular DNA construct. Furthermore, multiple site in a single viral gene may be targeting using the nucleic acid or construct according to the present invention. Another potential use in viral control might be to design a single construct inactivating both viral genes and also host genes involved in viral replication. Such uses and methods are within the scope of the invention. Accordingly, the method of the present invention may be used to inactivate two or more genes of the human immunodeficiency virus (HIV) or to inactivate one or more HIV genes and one or more HIV receptors on the host cell, for example the CCR4 receptor.

In cancers, mutations frequently occur in multiple genes. For gene therapy approaches, inactivation of two or more critical genes involved in tumour development are likely to prove more effective in controlling cancer cell proliferation than DNA constructs inactivating a single gene. For example, the



development of a particular type of tumour may be accelerated by the cumulative effect of two signalling pathways controlled by two different genes. The simultaneous inactivation of the two genes may result in more immediate control of tumour growth. Furthermore, the tumour development may involve two  
5 alternative pathways controlled by different genes, whereby the inhibition of both pathways would be a requirement for the effective inhibition of tumour development.

The method according to this aspect of the present invention may be useful for the treatment and/or prevention of disease in plants and animals, including  
10 humans. This method has the advantage over many other treatments in that the gene can be targeted with high specificity, reducing the possibility for side-effects.

Multiple gene inactivation strategies are also likely to have uses in target definition and gene function studies. For example, DNA constructs according to the present invention may be designed whereby the construct can inactivate a  
15 single gene **A** by possessing a target sequence for that gene. In order to establish the phenotypic effects of inhibiting the expression of a particular gene in the environment where gene **A** is not expressed, other sequences can be included in the multiple target construct. For example, random shotgun library sequences can be cloned into the DNA construct already possessing the target sequence for gene  
20 **A**. Therefore, such a library can be used to screen for genes of unknown functions in a background where the first gene is also inactivated.

Regions of target genes targeted by RNAi techniques may be predicted, including empirically or by various algorithms. Where there is more than one optimal target sequence, all such target sequences may be included in one  
25 construct.

Different non-complementary bubble-forming or bubble-encoding sequences in the constructs or nucleic acids of the present invention may have different activity in respect of gene silencing. Accordingly, random libraries of bubble sequences may be generated to determine the optimal sequences required  
30 for gene silencing activity for any given application or system. Such a method may involve inserting one or more randomised nucleotides into specific defined positions along a bubble sequence in a DNA construct and testing the activity of the interfering RNA encoded by the adjacent double-strand forming region. Such



bubble sequences may be up to ten nucleotides in length or more. Preferably the bubble sequence is four or six nucleotides in length.

Constructs inactivating multiple target genes may also be used in transgenic systems to screen directly for the effects of inactivating two known  
5 genes. Such an approach may circumvent the requirement of complex breeding programs to generate individual animals possessing multiple gene inactivation.

The nucleic acid or construct according to the present invention may be introduced into a cell in a suitable context. The carriers, excipients and/or diluents utilised in delivering the subject nucleic acid or constructs to a host cell should be  
10 acceptable for human or veterinary applications. Such carriers, excipients and/or diluents are well-known to those skilled in the art. Carriers and/or diluents suitable for veterinary use include any and all solvents, dispersion media, aqueous solutions, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like. Except insofar as any conventional media or agent  
15 is incompatible with the active ingredient, use thereof in the composition is contemplated. Supplementary active ingredients can also be incorporated into the compositions.

In another aspect of the present invention there is provided a method of inhibiting the expression of a target gene by introducing RNA produced from the  
20 construct of the present invention into a cell containing a target gene to be silenced using RNAi techniques.

A viral delivery system based on any appropriate virus may be used to deliver the RNA or nucleic acid construct of the present invention. In addition, hybrid viral systems may be of use. The choice of viral delivery system will  
25 depend on various parameters, such as the tissue targeted for delivery, transduction efficiency of the system, pathogenicity, immunological and toxicity concerns, and the like. Given the diversity of infections, diseases and other conditions that are amenable to interference by the RNA and RNA encoded by the nucleic acid constructs of the present invention, it is clear that there is no single  
30 viral system that is suitable for all applications. When selecting a viral delivery system to use in the present invention, it is important to choose a system where the interfering RNA-containing viral particles are preferably: 1) reproducibly and stably propagated; 2) able to be purified to high titres; and 3) able to mediate



targeted delivery (delivery of the interfering RNA to the tissue or organ of interest without widespread dissemination).

In general, the five most commonly used classes of viral systems used in gene therapy can be categorized into two groups according to whether their  
5 genomes integrate into host cellular chromatin (oncoretroviruses and lentiviruses) or persist in the cell nucleus predominantly as extrachromosomal episomes (adeno-associated virus, adenoviruses and herpes viruses). This distinction is an important determinant of the suitability of each vector for particular applications; non-integrating vectors can, under certain circumstances, mediate persistent gene  
10 expression in non-proliferating cells, but integrating vectors are the tools of choice if stable genetic alteration needs to be maintained in dividing cells, for example where the target cells are rapidly proliferating cancer cells.

For example, in one embodiment of the present invention, viruses from the Parvoviridae family are utilized. The Parvoviridae is a family of small single-  
15 stranded, non-enveloped DNA viruses with genomes approximately 5000 nucleotides long. Included among the family members is adeno-associated virus (AAV), a dependent parvovirus that by definition requires co-infection with another virus (typically an adenovirus or herpes virus) to initiate and sustain a productive infectious cycle. In the absence of such a helper virus, AAV is still competent to  
20 infect or transduce a target cell by receptor-mediated binding and internalization, penetrating the nucleus in both non-dividing and dividing cells.

Once in the nucleus, the virus uncoats and the transgene is expressed from a number of different forms—the most persistent of which are circular monomers. AAV will integrate into the genome of 1-5% of cells that are stably transduced  
25 (Nakai, et al., J. Virol. 76:11343-349 (2002)). Expression of the transgene can be exceptionally stable and in one study with AAV delivery of Factor IX, a dog model continues to express therapeutic levels of the protein 4.5 years after a single direct infusion with the virus. Because progeny virus is not produced from AAV infection in the absence of helper virus, the extent of transduction is restricted only to the  
30 initial cells that are infected with the virus. However, unlike retrovirus, adenovirus, and herpes simplex virus, AAV appears to lack human pathogenicity and toxicity (Kay, et al., Nature 424: 251 (2003) and Thomas, et al., Nature Reviews Genetics 4:346-58 (2003)).



Typically, the genome of AAV contains only two genes. The “rep” gene codes for at least four separate proteins utilized in DNA replication. The “cap” gene product is spliced differentially to generate the three proteins that comprise the capsid of the virus. When packaging the genome into nascent virus, only the  
5 Inverted Terminal Repeats (ITRs) are obligate sequences; rep and cap can be deleted from the genome and be replaced with heterologous sequences of choice. However, in order produce the proteins needed to replicate and package the AAV-based heterologous construct into nascent virion, the rep and cap proteins must be provided in trans. The helper functions normally provided by co-infection with  
10 the helper virus, such as adenovirus or herpes virus mentioned above, also can be provided in trans in the form of one or more DNA expression plasmids. Since the genome normally encodes only two genes it is not surprising that, as a delivery vehicle, AAV is limited by a packaging capacity of 4.5 single stranded kilobases (kb). However, although this size restriction may limit the genes that can be  
15 delivered for replacement gene therapies, it does not adversely affect the packaging and expression of shorter sequences such as RNAi nucleic acids.

However, technical hurdles must be addressed when using AAV as a vehicle for nucleic acid constructs. For example, various percentages of the human population may possess neutralizing antibodies against certain AAV  
20 serotypes. However, since there are several AAV serotypes, some of which the percentage of individuals harbouring neutralizing antibodies is vastly reduced, other serotypes can be used or pseudo-typing may be employed. There are at least eight different serotypes that have been characterized, with dozens of others which have been isolated but have been less well described. Another limitation is  
25 that as a result of a possible immune response to AAV, AAV-based therapy may only be administered once; however, use of alternate, non-human derived serotypes may allow for repeat administrations. Administration route, serotype, and composition of the delivered genome all influence tissue specificity.

Another limitation in using unmodified AAV systems with a nucleic acid  
30 construct is that transduction can be inefficient. Stable transduction in vivo may be limited to 5-10% of cells. Yet, different methods are known in the art to boost stable transduction levels. One approach is utilizing pseudo typing, where AAV-2 genomes are packaged using cap proteins derived from other serotypes. One



group of investigators exhaustively pseudotyped AAV-2 with AAV-1, AAV-3B, AAV-4, AAV-5, and AAV-6 for tissue culture studies. The highest levels of transgene expression were induced by virion which had been pseudotyped with AAV-6; producing nearly 2000% higher transgene expression than AAV-2. Thus,  
5 the present invention contemplates use of a pseudotyped AAV virus to achieve high transduction levels, with a corresponding increase in the expression of the interfering RNA.

Another viral delivery system useful with the nucleic acid construct of the present invention is a system based on viruses from the family Retroviridae.  
10 Retroviruses comprise single-stranded RNA animal viruses that are characterized by two unique features. First, the genome of a retrovirus is diploid, consisting of two copies of the RNA. Second, this RNA is transcribed by the virion-associated enzyme reverse transcriptase into double-stranded DNA. This double-stranded DNA or provirus can then integrate into the host genome and be passed from  
15 parent cell to progeny cells as a stably-integrated component of the host genome.

In some embodiments, lentiviruses are the preferred members of the retrovirus family for use in the present invention. Lentivirus vectors are often pseudotyped with vesicular stomatitis virus glycoprotein (VSV-G), and have been derived from the human immunodeficiency virus (HIV), the etiologic agent of the  
20 human acquired immunodeficiency syndrome (AIDS); visna-maedi, which causes encephalitis (visna) or pneumonia in sheep; equine infectious anemia virus (EIAV), which causes autoimmune hemolytic anemia and encephalopathy in horses; feline immunodeficiency virus (FIV), which causes immune deficiency in cats; bovine immunodeficiency virus (BIV) which causes lymphadenopathy and lymphocytosis  
25 in cattle; and simian immunodeficiency virus (SIV), which causes immune deficiency and encephalopathy in non-human primates. Vectors that are based on HIV generally retain <5% of the parental genome, and <25% of the genome is incorporated into packaging constructs, which minimizes the possibility of the generation of reverting replication-competent HIV. Biosafety has been further  
30 increased by the development of self-inactivating vectors that contain deletions of the regulatory elements in the downstream long-terminal-repeat sequence, eliminating transcription of the packaging signal that is required for vector mobilization.



Reverse transcription of the retroviral RNA genome occurs in the cytoplasm. Unlike C-type retroviruses, the lentiviral cDNA complexed with other viral factors—known as the pre-initiation complex—is able to translocate across the nuclear membrane and transduce non-dividing cells. A structural feature of the viral cDNA—a DNA flap—seems to contribute to efficient nuclear import. This flap is dependent on the integrity of a central polypurine tract (cPPT) that is located in the viral polymerase gene, so most lentiviral-derived vectors retain this sequence. Lentiviruses have broad tropism, low inflammatory potential, and result in an integrated vector. The main limitations are that integration might induce oncogenesis in some applications. The main advantage to the use of lentiviral vectors is that gene transfer is persistent in most tissues or cell types.

A lentiviral-based construct that may be used to express the RNA according to the present invention preferably comprise sequences from the 5' and 3' LTRs of a lentivirus. More preferably the viral construct comprises an inactivated or self-inactivating 3' LTR from a lentivirus. The 3' LTR may be made self-inactivating by any method known in the art. In a preferred embodiment, the U3 element of the 3' LTR contains a deletion of its enhancer sequence, preferably the TATA box, Sp1 and NF-kappa B sites. As a result of the self-inactivating 3' LTR, the provirus that is integrated into the host cell genome will comprise an inactivated 5' LTR. The LTR sequences may be LTR sequences from any lentivirus from any species. The lentiviral-based construct may also incorporate sequences for MMLV or MSCV, RSV or mammalian genes. In addition, the U3 sequence from the lentiviral 5' LTR may be replaced with a promoter sequence in the viral construct. This may increase the titre of virus recovered from the packaging cell line. An enhancer sequence may also be included.

Adenoviruses are non-enveloped viruses containing a linear double-stranded DNA genome. While there are over 40 serotype strains of adenovirus--most of which cause benign respiratory tract infections in humans--subgroup C serotypes 2 or 5 are predominantly used as vectors. The adenovirus life cycle normally does not involve integration into the host genome, rather it replicates as episomal elements in the nucleus of the host cell and consequently there is no risk of insertional mutagenesis. The wild type adenovirus genome is approximately 35 kb of which up to 30 kb can be replaced with foreign DNA. There are four early



transcriptional units (E1, E2, E3 and E4), which have regulatory functions, and a late transcript, which codes for structural proteins. Progenitor vectors have either the E1 or E3 gene inactivated, with the missing gene being supplied in trans either by a helper virus, plasmid or by an integrated gene in a helper cell genome.

- 5 Second generation vectors additionally use an E2a temperature sensitive mutant or an E4 deletion. The most recent "gutless" vectors contain only the inverted terminal repeats (ITRs) and a packaging sequence around the transgene, all the necessary viral genes being provided in trans by a helper virus.

Adenoviral vectors are very efficient at transducing target cells in vitro and  
10 in vivo, and can be produced at high titres ( $>10^{11}$ /ml). With the exception of one study that showed prolonged transgene expression in rat brains using an E1 deletion vector, transgene expression in vivo from progenitor vectors tends to be transient. Following intravenous injection, 90% of the administered vector is degraded in the liver by a non-immune mediated mechanism. Thereafter, an MHC  
15 class I restricted immune response occurs, using CD8<sup>+</sup> CTLs to eliminate virus infected cells and CD4<sup>+</sup> cells to secrete IFN-alpha which results in anti-adenoviral antibody. Alteration of the adenoviral vector can remove some CTL epitopes; however, the epitopes recognized differ with the host MHC haplotype. The remaining vectors, in those cells that are not destroyed, have their promoter  
20 inactivated and persisting antibody prevents subsequent administration of the vector.

Approaches to avoid the immune response involving transient immunosuppressive therapies have been successful in prolonging transgene expression and achieving secondary gene transfer. A less interventionist method  
25 has been to induce oral tolerance by feeding the host UV inactivated vector. However, it is more desirable to manipulate the vector rather than it is to manipulate the host through immunosuppression. Although only replication deficient vectors are used, viral proteins are expressed at a very low level, which are then presented to the immune system. The development of vectors containing  
30 fewer genes--culminating in the "gutless" vectors which contain no viral coding sequences--has resulted in prolonged in vivo transgene expression in liver tissue. However, the initial delivery of DNA packaged within adenovirus proteins--the majority of which will be degraded and presented to the immune system--may still



cause problems for clinical trials.

Until recently, the mechanism by which the adenovirus targeted the host cell was poorly understood. Tissue-specific expression was therefore only possible by using cellular promoter/enhancers, e.g., the myosin light chain 1  
5 promoter or the smooth muscle cell SM22a promoter, or by direct delivery to a local area. Uptake of the adenovirus particle has been shown to be a two-stage process involving an initial interaction of a fibre coat protein in the adenovirus with a cellular receptor or receptors, which include the MHC class I molecule and the coxsackievirus-adenovirus receptor. The penton base protein of the adenovirus  
10 particle then binds to the integrin family of cell surface heterodimers allowing internalization via receptor mediated endocytosis. Most cells express primary receptors for the adenovirus fibre coat protein, however internalization is more selective. Methods of increasing viral uptake include stimulating the target cells to express an appropriate integrin and conjugating an antibody with specificity for the  
15 target cell type to the adenovirus. However, the use of antibodies increases the production difficulties of the vector and the potential risk of activating the complement system.

Another virus that may be used as a basis for a viral delivery vector in the present invention is the Herpes simplex virus-1. HSV-1 is a double-stranded DNA  
20 virus with a packaging capacity of 40kb, or up to 150 kb (helper dependent). HSV-1 has strong tropism for neurons, but also has a high inflammatory potential. HSV-1 is maintained episomally. Replication defective HSV-1 vectors generally are produced by deleting all, or a combination, of the five immediate-early genes (ICP0, ICP4, ICP22, ICP27 and ICP47), which are required for lytic infection and  
25 expression of all other viral proteins. Unfortunately, the ICP0 gene product is both cytotoxic and required for high level and sustained transgene expression. As such, the production of non-toxic quintuple immediate-early mutant vectors is a trade-off against efficient and persistent transgene expression. An HSV-1 protein that is activated during latency has recently be shown to complement mutations in  
30 ICP0 and overcome the repression of transgene expression that occurs in the absence of ICP0. Substitution of this protein in place of ICP0 might facilitate efficient transgene expression without cytotoxicity in non-neuronal cells. Long-term expression can be achieved in the nervous system by using one of the HSV-



1 neuron-specific latency-activated promoters to drive transgene expression.

Other viral or non-viral systems known to those skilled in the art may be used to deliver the RNA or nucleic acid constructs of the present invention to cells of interest, including but not limited to gene-deleted adenovirus-transposon  
5 vectors that stably maintain virus-encoded transgenes in vivo through integration into host cells (see, Yant, et al., Nature Biotech. 20:999-1004 (2002)); systems derived from Sindbis virus or Semliki forest virus (see Perri, et al, J. Virol. 74(20):9802-07 (2002)); systems derived from Newcastle disease virus or Sendai virus; or mini-circle DNA vectors devoid of bacterial DNA sequences (see Chen, et  
10 al., Molecular Therapy. 8(3):495-500 (2003)). In addition, hybrid viral systems may be used to combine useful properties of two or more viral systems.

To deliver a viral-based nucleic acid construct into target cells, the nucleic acid construct first must be packaged into viral particles. Any method known in the art may be used to produce infectious viral particles whose genome comprises  
15 a copy of the viral construct. For example, certain methods utilize packaging cells that stably express in trans the viral proteins that are required for the incorporation of the nucleic acid construct into viral particles, as well as other sequences necessary or preferred for a particular viral delivery system (for example, sequences needed for replication, structural proteins and viral assembly) and  
20 either viral-derived or artificial ligands for tissue entry. In such a method, a nucleic acid construct is ligated to a viral delivery vector and the resulting viral nucleic acid construct is used to transfect packaging cells. The packaging cells then replicate viral sequences, express viral proteins and package the viral nucleic acid constructs into infectious viral particles. The packaging cell line may be any cell  
25 line that is capable of expressing viral proteins, including but not limited to 293, HeLa, A549, PerC6, D17, MDCK, BHK, bing cherry, phoenix, Cf2Th, or any other line known to or developed by those skilled in the art. One packaging cell line is described, for example, in U.S. Pat. No. 6,218,181.

Alternatively, a cell line that does not stably express necessary viral  
30 proteins may be co-transfected with two or more constructs to achieve efficient production of functional particles. One of the constructs comprises the nucleic acid construct of the present invention, and the other plasmid(s) comprises nucleic acids encoding the proteins necessary to allow the cells to produce functional



virus (replication and packaging construct) as well as other helper functions. This method utilizes cells for packaging that do not stably express viral replication and packaging genes. In this case, the nucleic acid construct is ligated to the viral delivery vector and then co-transfected with one or more vectors that express the viral sequences necessary for replication and production of infectious viral particles. The cells replicate viral sequences, express viral proteins and package the viral nucleic acid constructs into infectious viral particles.

The packaging cell line or replication and packaging construct may not express envelope gene products. In these embodiments, the gene encoding the envelope gene can be provided on a separate construct that is co-transfected with the viral nucleic acid construct. As the envelope protein is responsible, in part, for the host range of the viral particles, the viruses may be pseudotyped. As described supra, a "pseudotyped" virus is a viral particle having an envelope protein that is from a virus other than the virus from which the genome is derived. One with skill in the art can choose an appropriate pseudotype for the viral delivery system used and cell to be targeted. In addition to conferring a specific host range, a chosen pseudotype may permit the virus to be concentrated to a very high titre. Viruses alternatively can be pseudotyped with ecotropic envelope proteins that limit infection to a specific species (e.g., ecotropic envelopes allow infection of, e.g., murine cells only, where amphotropic envelopes allow infection of, e.g., both human and murine cells). In addition, genetically-modified ligands can be used for cell-specific targeting.

After production in a packaging cell line, the viral particles containing the nucleic acid constructs are purified and quantified (titred). Purification strategies include density gradient centrifugation, or, preferably, column chromatographic methods.

In another aspect of the present invention there is provided a method of testing nucleic acid sequences for efficacy in RNAi comprising the steps of inserting DNA encoding RNAi regions to be tested into the construct according to the present invention; introducing the construct into a cell containing the target gene corresponding to the RNAi region; allowing RNA to be produced from the construct and evaluating the effect on the expression of the target gene.

In a further aspect of the present invention there is provided a method for



the production of a construct according to the present invention using long range PCR techniques. In one embodiment there is provided a method of adding a predetermined oligonucleotide to a polynucleotide, the oligonucleotide being divided into a first sub-sequence and a second sub-sequence, by a polymerase  
5 chain reaction process including:

providing a first primer having at its 3' end a fixing part hybridizable under polymerase chain reaction conditions with at least a first part of the polynucleotide and at its 5' end an effector part identical to the first sub-sequence, and a second primer having at its 3' end a fixing part hybridizable with at least a second part of  
10 the polynucleotide that is adjacent the first part of the polynucleotide and at its 5' end an effector part identical to the second sub-sequence,

introducing the primers to the nucleotide under polymerase chain reaction conditions such that the fixing parts of each primer hybridizes with the polynucleotide;

15 conducting a multiple polymerase chain reaction to produce an amplification product which includes the effector parts of the primers at the ends of a double-stranded sequence; and

ligating the ends of the effector parts together to form a combined polynucleotide and oligonucleotide sequence.

20 For additional clarification, in this description of this embodiment of the invention directed towards production of a construct, the term "effector" is used for convenience and as an appropriate term, but in a different context from that in which it is used in describing the RNA and DNA constructs themselves above. It is thus used in a different context from the way in which it is described in the  
25 paragraph above that commences "The term 'effector sequence' and 'effector' in the context of...". The term "effector" in this embodiment and the related claims should be construed in context without importing the limitations of the meaning of "effector" described above. It may also be referred to as the "variable" sequence as it largely contains the sequence that will vary from construct to construct.

30 By "oligonucleotide" in this process is meant a nucleic acid sequence of 40 to 100, preferably less than 100 nucleotides in length. The oligonucleotide may be single or double-stranded. Preferably the oligonucleotide is DNA.

By "polynucleotide" in this process is meant a nucleic acid sequence of at least about 1000 nucleotides in length. The polynucleotide may be single or double-stranded depending on the stage of the process according to the present invention. The polynucleotide may have a double-stranded circular conformation  
5 or a linear form, or may be the linearized form of a previously circular double stranded sequence. Preferably the polynucleotide is DNA. In a preferred embodiment of the present invention, the polynucleotide is a DNA vector selected from the group consisting of a plasmid, a bacteriophage and a viral-based vector.

It will be appreciated by a person skilled in the art that the efficiency of the  
10 polymerase chain reaction (PCR) can be modified, for example by altering the denaturation, annealing and polymerisation temperatures, the timing of the cycles and the salt concentration in the reaction mixture. Variations of these and other conditions that allow the PCR reaction to take place are encompassed in the term "polymerase chain reaction conditions". It will be further appreciated by a person  
15 skilled in the art that a range of products may be produced from a given PCR reaction. These products may be separated by size or weight by methods known in the art, such as gel electrophoresis. In a preferred embodiment of the present invention the desired PCR product is isolated from solution.

The long range PCR method of this aspect of the present invention can be  
20 used to insert a DNA oligonucleotide into a DNA polynucleotide that is a vector in order to form a construct which enables the oligonucleotide to be transcribed into a ribonucleic acid sequence (RNA). The transcription may take place from the oligonucleotide only or the RNA transcript may be the result of the transcription of a combination of oligonucleotide and polynucleotide sequences. The transcribed  
25 RNA may further be translated into protein, or may also remain as untranslated RNA. In a preferred embodiment of this aspect of the present invention the primers have a homology with a restriction enzyme site in the polynucleotide sequence. In a further preferred embodiment of this aspect of the present invention, the primers are phosphorylated and the ligation of the amplification  
30 product is catalysed by T4 DNA ligase.

The polynucleotide used in the methods according to this long-range PCR process may contain one or more regulatory elements to allow transcription to take place. Preferably at least one of the regulatory elements is a promoter. A



variety of promoters may be included in the polynucleotide vector. Factors influencing the choice of promoter include the desire for inducible transcription of the oligonucleotide or oligonucleotide and polynucleotide sequences, the strength of the promoter and the suitability of the promoter to induce expression in the *in vivo* or *in vitro* environment in which the transcription is to take place. In a preferred embodiment the promoter is an RNA polymerase III (pol III) promoter such as U6 or H1 promoters

In a preferred embodiment of this aspect of this process, the oligonucleotide codes for an RNA sequence capable of forming a double-stranded hairpin structure due to the presence an inverted repeat sequence. Preferably, the first primer contains approximately one half of the inverted repeat sequence in its effector part and the second primer contains approximately the other half of the inverted repeat sequence in its effector part. More preferably, the first and second primers further contain at least one nucleotide at their 5' ends that forms the loop region of the hairpin-loop RNA structure.

In another embodiment of this aspect of the present invention, the effector parts are at least partially complementary, such that upon transcription (following transfection of a cell by a vector which incorporates a polynucleotide as described above) their respective RNA transcripts may hybridise with each other due to the complementarity of their sequences.

In a further preferred embodiment the oligonucleotide used in the method according to this aspect of the present invention is capable of coding RNA suitable for use as interfering RNA in gene silencing techniques. Such techniques are described in the specification of PCT/AU99/00195. Preferably the RNA has a hairpin-loop structure.

In another embodiment the oligonucleotide encodes a restriction site and the addition of the oligonucleotide to the polynucleotide results in the a restriction site being inserted into the combined oligonucleotide and polynucleotide sequence. It will be appreciated by a person skilled in the art the where the polynucleotide is a vector, such as a plasmid, the insertion of a restriction site would have many advantages in the subsequent use of the plasmid, particularly for subcloning purposes.

In a further embodiment the oligonucleotide includes an intron, or non-coding, sequence of a gene. The polynucleotide may include the coding sequence of the gene. Accordingly, the addition of the oligonucleotide to the polynucleotide using the method of the present invention may allow the insertion of the intron at  
5 the appropriate site in the coding sequence of the gene. Insertion of an intron into a coding sequence of a gene has a number of practical applications. For example, insertion of introns into DNA constructs has been shown to increase transgene expression. Another possible application is to use introns as a means of delivering double stranded RNA to induce gene silencing.

10 In another aspect of this aspect of the present invention there is provided a DNA construct produced by the addition of an oligonucleotide to a polynucleotide according to the method of the present invention. The DNA construct may be useful for further subcloning purposes whereby a second oligonucleotide of interest may be introduced by, for example known subcloning techniques. The  
15 DNA construct may also be an expression construct for the further production of RNA and/of protein. Preferably the DNA construct is suitable for producing RNA suitable for use as interfering RNA in gene silencing technologies. More preferably, the construct can be introduced into a cell where gene silencing is to take place and interfering RNA can be transcribed within this cell.

20 In another aspect of the present invention there is provided primers suitable for use in the method according to the present invention. In a further aspect of the present invention there is provided a kit comprising a polynucleotide and a primer pair for producing a polynucleotide containing an additional oligonucleotide.

In a further embodiment of this aspect of the invention there is provided a  
25 method for the large scale production of large numbers of hairpin DNA plasmids using the long range PCR method of the present invention with automation procedures. The simplicity of the long range PCR method lends itself to automation, using a robotics system to amplify DNA templates and ligate these to prepare DNA vectors. Such vectors can also be used to transform bacteria to grow  
30 substantial copy numbers of the vectors. In this way large numbers of plasmids, for example targeting different regions of a single gene could be rapidly prepared.

In a further aspect of the invention, a method for preparing libraries of sequences using long range PCR techniques is provided. In this instance, portions



of one or both of the forward and reverse primers are synthesised using redundant oligonucleotides. Following amplification, ligation and transformation of bacteria, individual colonies contain unique hairpin DNA constructs reflecting the particular redundancies incorporated into individual plasmid by individual amplification  
5 primers. In this way libraries with, for example, random loop sequences are prepared and individual plasmids from the library are analysed for gene silencing activity in order to define loop sequences that enhance the activity of hairpin DNA constructs.

In another aspect of the present invention there is provided a kit for  
10 constructing a nucleic acid construct using the long range PCR method of the present invention comprising the polynucleotide, a polymerase, a first primer, a second primer and a ligating enzyme in proportions suitable for the long range PCR method according to the present invention.

In another aspect of the present invention there is provided a kit for  
15 inhibiting the expression of a target gene, including a vector suitable for use in producing a construct according to the present invention. Such a vector may include regulatory elements and facility for insertion of a cassette encoding a nucleic acid designed according to the present invention.

Without being bound by any theory or mode of action, it is believed that the  
20 invention is mediated by enzymes including Dicer and Drosha. At least these two ribonucleases, both members of the RNase III class, play a central role in the processing of double stranded RNA into siRNAs.

Dicer is the best characterized component. Dicer is a thought to be a cytoplasmic protein. It can cleave double-stranded RNA to produce approx 21  
25 nucleotide (nt) dsRNAs with a 2 nt 3' overhang; this overhang is a characteristic of RNase III - type enzymes. The precise requirements that allow dsRNA to act as an efficient substrate for Dicer remain unclear. miRNA precursors are one such substrate - they naturally form a hpRNA structure, but typically contain regions of mismatch, ie they do not form perfect double stranded structures, in contrast to  
30 hpRNAs designed to produce siRNAs from expression constructs. Dicer appears normally to process hpRNAs from the base of the hairpin, but definitive proof of this is not yet available. Dicer probably plays other roles in the RNAi process. It

has recently been shown that the enzyme plays a role in RISC, ie it might play a role in cleavage of the target mRNA.

Drosha is another RNase III enzyme implicated in RNA interference. Much less is known about its function compared to Dicer. The enzyme is nuclear and  
5 may be nucleolar, since Drosha is known to play a role in rRNA maturation, which is a nucleolar process. The precise role of Drosha in RNAi is unknown. It is known to play a role in processing of miRNAs and may play a role in processing longer dsRNAs in RNAi. Current models suggest that Drosha may recognize loop structures in RNA, bind to these, then cut hp RNAs about 19- 21 nt downstream of  
10 the loop. Most RNase IIIs are thought to act by recognising loop structures, although it is recognised that the model described above for Dicer processing contradicts this view.

A hp RNA expressed from a pol III promoter thus may have 2 potential pathways by which it might enter RISC, namely:

15 (i) direct exit from the nucleus to the cytoplasm where the hpRNA is presumably processed by Dicer from the base of the hairpin and enters RISC. This appears to be at least the major pathway operating on hpRNAs expressed from short hpRNAs of 19 nts.

(ii) processing in the nucleus (possibly nucleolus) by Drosha, followed  
20 by export to the cytoplasm. This processing may involve recognition of the loop and will result in the formation of a stem sequence carrying a 2 nt 3' overhang. Once exported this Drosha processed RNA is probably processed by Dicer as above.

These models are currently incomplete and are possibly not mutually  
25 exclusive, ie a longer hpRNA might be processed by both pathways, some is processed by Drosha then Dicer, some only by Dicer. Moreover some hpRNAs are expressed with a 5' leader sequence ("U6 + 27") which may target the hpRNA to the nucleolus, ie it is preferentially processed by Drosha before Dicer.

Without being bound by any theory or mode of action it is believed that  
30 improved therapeutic efficacy and safety of RNAi constructs can be achieved by optimising the length of effector sequences. This may assist the cleavage enzymes, such as Dicer and Drosha, cleaving at the same, predictable position,



thereby providing predictability of result and reduction of side effects and/or variability of efficacy within and between patients.

The present invention will now be more fully described with reference to the accompanying examples and drawings. It should be understood, however, that the description following is illustrative only and should not be taken in any way as a  
5 restriction on the generality of the invention described above.

In the Figures:

Figure 1 shows maps of the construct pU6.cass. **A** shows a map of a region of the construct. The human U6 promoter is shown as a grey arrow, binding sites  
10 of the U6FR1 and U6 R T5 Xba primers are shown below this. The positions of Eco RI, Bsm BI and Hind III restriction sites are shown. **B** shows a map of the entire plasmid which was constructed by inserting the Eco RI / Hind III fragment shown in **A** into the vector pBluescript II SK+ (Stratagene).

Figure 2 shows maps of the construct pU6.ACTB-A hp. This construct was  
15 used as a negative control in some experiments. **A** Map of the plasmid is shown as in Figure 1B. The relative positions of elements within the hairpin DNA transcription unit, namely the transcription start site, the ACTB-A sense, loop, ACTB-A antisense and pol III terminator sequences are shown, as are the positions of the Eco RI and Hind III restriction sites. **B** shows a map of a portion of  
20 the U6 transcriptional unit. Elements within the hairpin DNA transcription unit are shown; the sense and antisense regions of the hairpin are shown as arrows, the loop sequence is denoted as a stippled arrow and the terminator as a line below the map. **C** shows the predicted hairpin RNA produced from this construct which targets the ACTB-A site of  $\beta$  actin mRNA. The 5' G ribonucleotide of the predicted  
25 transcript is required for U6 promoter activity, the pol III terminator is predicted to incorporate the 3' sequence UU which is also not base paired in the hairpin transcript. The transcript is predicted to produce a 19 nt double-stranded RNA structure homologous to  $\beta$  actin mRNA, where the vertically aligned sequences denote potential base pairing. The loop sequence is 9 bases, the first and second  
30 bases can potentially pair with the eight and ninth bases, but for clarity this is not shown. In addition, the 5' G might potentially base pair with the second-to-last 3' U residue, but this is also not shown for clarity. The convention that all unpaired

sequences are shown in this way is used throughout this specification.

Figure 3 shows the general approach of using long-range PCR to modify plasmids **A**. Either circular or linear DNA can be used as amplification templates, although the latter is preferred. DNA is amplified with oligonucleotide primers (LRPCR primers) containing "clamp" sequences that can hybridize to the templates (thin lines) and sequences corresponding to roughly half of the desired inserts (thick lines). When combined these will form the insert, typically a hpRNA encoding insert. **B**. Template DNA is amplified using conditions suitable for long range PCR reactions. The favoured polymerase is *PfuUltra* (Stratagene), due to its low error rate, although other polymerases or mixtures can be used. **C**. The amplified DNA fragment is then circularised via an intramolecular ligation using T4 DNA ligase. For this step 5' phosphorylation of at least one end is required, which can be achieved using phosphorylated oligonucleotides for the amplification, or by post-amplification treatment with T4 polynucleotide kinase. Flush ends are also required for efficient circularisation, *Pfu* polymerase produces flush ends, alternatively ends might be polished by post-amplification treatment with T4 DNA polymerase.

Figure 4 shows the insertion of an *Asc* I restriction site into a plasmid. The oval lines at the top represent the plasmid used for insertion. The binding position and orientation of the LRPCR primers are also shown (diagrammatically, not to scale) around the point of sequence insertion is also shown. The sequence of a region of the plasmid is shown below this, as are the sequences of the LRPCR primers, the *Asc* I restriction site is shown as a bold underline.

Figure 5 shows the insertion of a hp DNA sequence, containing inverted repeat and loop sequences into a plasmid as in Figure 4. Partial sequence of the insert and primers is also shown as in Figure 4; antisense and sense hp sequences are shown as bold underline.

Figure 6 shows the method of increasing the length of an inverted repeat in a plasmid. The Figure is shown as in Figure 4, except only 1 primer is used. Partial sequences of the inserts and primers is also shown as in Figure 4.

Figure 7 shows the insertion of a mouse IgE3 intron into a cloned insert in a plasmid as in Figure 4.



Figure 8 shows a map of the plasmid pU6.cass lin. **A** shows a map of a region of the construct corresponding to the U6 promoter and pol III terminator sequences. The positions of Bmg BI, Bgl II and Bsm I restriction sites are shown. **B** shows a map of the entire plasmid.

5        Figure 9 shows maps of the construct pU6.Rluc hp; this targets humanised Renilla luciferase mRNA (Accession Number U47298) for degradation. **A** shows a map of a portion of the U6 transcriptional unit. Elements within the hairpin DNA transcription unit are shown as in Figure 2B. **B** shows the predicted hairpin RNA produced from this construct as in Figure 2C.

10        Figure 10 shows a map of pU6.Rluc/ACTB TTA. **A** shows a map of the hairpin DNA transcriptional unit. The position of "bubble" and "loop" sequences within the transcriptional unit are shown as stippled arrows. In this instance "stem" sequences, derived from  $\beta$  Actin (ACTB) and Renilla luciferase (Rluc) have been incorporated into the construct. **B** shows the predicted hairpin RNA produced from  
15 this construct as in Figure 2C. In this and other examples the bubble sequences, which are not capable of conventional base pairing, are shown above and below those potentially base paired sequences in the transcript. The convention of showing no base pairing between sequences in the bubbles regardless of the potential of the bases in these sequences to form Watson-Crick or non-Watson-  
20 Crick base pairs, is used throughout this specification. Sequences at the base of the hairpin target Renilla luciferase mRNA, sequences nearer the loop target  $\beta$  actin mRNA.

Figure 11 shows a map of pU6.Rluc/ACTB TTAG. **A** shows a map of the hairpin DNA transcriptional unit as for Figure 10A. **B** shows the predicted hairpin  
25 RNA produced from this construct as in Figure 10B.

Figure 12 shows a map of pU6.ACTB/Rluc-TTA. **A** shows a map of the hairpin DNA transcriptional unit as for Figure 10A. **B** shows the predicted hairpin RNA produced from this construct as in Figure 10B.

Figure 13 shows a map of pU6.ACTB/Rluc TTAG. **A** shows a map of the  
30 hairpin DNA transcriptional unit as for Figure 10A. **B** shows the predicted hairpin RNA produced from this construct as in Figure 10B.

Figure 14 shows a map of pU6.ACTB/AD1 hp. This construct was used as

a negative control for some experiments. **A** shows a map of the hairpin DNA transcriptional unit as for Figure 10A. **B** shows the predicted hairpin RNA produced from this construct as in Figure 10B.

Figure 15 shows a map of pU6 Rluc/ACTB/AD1 hp. **A** shows a map of the hairpin DNA transcriptional unit as for Figure 10A. In this instance sequences, targeting Renilla luciferase (Rluc),  $\beta$  Actin (ACTB), and ADAR-1 (AD-1) have been incorporated into the construct. **B** shows the predicted hairpin RNA produced from this construct as in Figure 10B.

Figure 16 shows a map of pU6 ACTB/Rluc/AD1. **A** shows a map of the hairpin DNA transcriptional unit as for Figure 10A. **B** shows the predicted hairpin RNA produced from this construct as in Figure 10B.

Figure 17 shows a map of pU6 ACTB/ADAR/Rluc hp. **A** shows a map of the hairpin DNA transcriptional unit as for Figure 10A. **B** shows the predicted hairpin RNA produced from this construct as in Figure 10B.

Figure 18 shows a map of pU6 ACTB/ADAR/GFP hp. This construct was used as a negative control for some experiments. **A** shows a map of the hairpin DNA transcriptional unit as for Figure 10A. **B** shows the predicted hairpin RNA produced from this construct as in Figure 10B.

Figure 19 shows a map of pU6.Rluc/ACTB/AD1/GFP hp. **A** shows a map of the hairpin DNA transcriptional unit as for Figure 10A. **B** shows the predicted hairpin RNA produced from this construct as in Figure 10B.

Figure 20 shows a map of pU6.ACTB/Rluc/AD1/GFP hp. In this and the following examples sequences, derived from  $\beta$  Actin (ACTB), Renilla luciferase (Rluc), ADAR1 (AD1) and GFP have been incorporated into the construct. **A** shows a map of the hairpin DNA transcriptional unit as for Figure 10A. **B** shows the predicted hairpin RNA produced from this construct as in Figure 10B.

Figure 21 shows a map of pU6.ACTB/AD1/Rluc/GFP hp. **A** shows a map of the hairpin DNA transcriptional unit as for Figure 10A. **B** shows the predicted hairpin RNA produced from this construct as in Figure 10B.

Figure 22 shows a map of pU6.ACTB/AD1/GFP/Rluc hp. **A** shows a map of the hairpin DNA transcriptional unit as for Figure 10A. **B** shows the predicted



hairpin RNA produced from this construct as in Figure 10B.

Figure 23 shows a map of pU6.ACTB/AD1/GFP/HER2 hp. **A** shows a map of the hairpin DNA transcriptional unit as for Figure 10A. **B** shows the predicted hairpin RNA produced from this construct as in Figure 10B.

5        Figure 24 shows a map of pU6.Rluc/ACTB/AD1/GFP/HER2 hp. **A** shows a map of the hairpin DNA transcriptional unit as for Figure 10A. In this instance sequences, derived from  $\beta$  Actin (ACTB), ADAR1 (AD1), Renilla luciferase (Rluc), HER2 and GFP have been incorporated into the construct. **B** shows the predicted hairpin RNA produced from this construct as in Figure 10B.

10       Figure 25 show a map of pU6.ACTB/Rluc/AD1/GFP/HER2 hp. **A** shows a map of the hairpin DNA transcriptional unit as for Figure 10A. **B** shows the predicted hairpin RNA produced from this construct as in Figure 10B.

Figure 26 shows a map of pU6.ACTB/AD1/Rluc/GFP/HER2 hp. **A** shows a map of the hairpin DNA transcriptional unit as for Figure 10A. **B** shows the  
15       predicted hairpin RNA produced from this construct as in Figure 10B.

Figure 27 shows a map of pU6.ACTB/AD1/GFP/Rluc/HER2 hp. **A** shows a map of the hairpin DNA transcriptional unit as for Figure 10A. **B** shows the predicted hairpin RNA produced from this construct as in Figure 10B.

Figure 28 shows a map of pU6.ACTB/AD1/GFP/HER2/Rluc hp. **A** shows a  
20       map of the hairpin DNA transcriptional unit as for Figure 10A. **B** shows the predicted hairpin RNA produced from this construct as in Figure 10B.

Figure 29 shows a map of pU6.ACTB/AD1/GFP/HER2/LAM hp. **A** shows a map of the hairpin DNA transcriptional unit as for Figure 10A. In this instance, sequences derived from lamin A/C (LAM) have been incorporated into the  
25       construct. **B** shows the predicted hairpin RNA produced from this construct as in Figure 10B.

Figure 30 shows a graph describing the activity of double hairpin constructs targeting Renilla luciferase. Data are shown corrected to the relative Renilla luciferase activity in transgenic cells transfected with the construct pU6.cass (n=5,  
30        $\pm$  SD). The white bars denote activities of negative control constructs, namely pU6.cass, pU6.ACTB-A hp and pU6.ACTB/AD1 hp. The black bars denote

activities of constructs targeting Rluc, namely pU6.Rluc hp and the double hairpin constructs pU6.Rluc/ACTB TTA, pU6.Rluc/ACTB TTAG, pU6.ACTB/Rluc TTA and pU6.ACTB/Rluc TTAG.

Figure 31 shows the activity of triple hairpin constructs targeting Renilla  
5 luciferase as in Figure 30. In this experiment the negative controls, shown as white bars, were pU6.cass, pU6.ACTB-A hp and pU6.ACTB/AD1/GFP hp; the test constructs, shown as black bars, were pU6.Rluc hp and the triple hairpin constructs pU6.Rluc/ACTB/AD1 hp, pU6.ACTB/Rluc/AD1 hp and pU6.ACTB/AD1/Rluc hp.

10 Figure 32 shows the activity of constructs targeting 4 and 5 genes, with Renilla luciferase at position 4 or 5, adjacent to the loop as in Figure 30. In this experiment the negative controls, shown as white bars, were pU6.cass, pU6.ACTB-A hp and pU6.ACTB/AD1/GFP hp; the test constructs, shown as black bars, were pU6.Rluc hp, pU6.ACTB/AD1/GFP/Rluc and  
15 pU6.ACTB/AD1/GFP/HER2/Rluc.

Figure 33 shows a map of pU6.GF-2 which targets both the Akt1 and Akt2 genes for inactivation. **A** shows a map of the hairpin DNA transcriptional unit as for Figure 10A. **B** shows the predicted hairpin RNA produced from this construct as in Figure 10B.

20 Figure 34 shows Western blots demonstrating reductions in Akt1 and Akt2 proteins in cells transfected with the double hairpin construct pU6.GF-2. The Western blots were probed with antibodies specific to Sec5, which acts as a loading control, and antibodies specific to the targets, either Akt1 or Akt2. Lanes probed (l-r) were control, non-transfected C2C12 and cells transfected with  
25 pU6.GF-2, both lanes probed with Sec5 and Akt1 antibodies and non-transfected C2C12 cells and cells transfected with pU6.GF-2, both lanes probed with Sec5 and Akt2 antibodies.

Figure 35 shows a map of pU6.GG-2 which targets the Akt 2a site. **A** shows a map of the hairpin DNA transcriptional unit as for Figure 10A. **B** shows  
30 the predicted hairpin RNA produced from this construct as in Figure 10B.

Figure 36 shows a map of pU6.GG-3. **A** shows a map of the hairpin DNA transcriptional unit as for Figure 10A. **B** shows the predicted hairpin RNA



produced from this construct as in Figure 10B.

Figure 37 shows a map of pU6.GG-4 which targets both the Akt 2a and Akt 2b sites of Akt 2. **A** shows a map of the hairpin DNA transcriptional unit as for Figure 10A. **B** shows the predicted hairpin RNA produced from this construct as  
5 in Figure 10B.

Figure 38 Western blots showing enhanced reductions in protein in cells transfected with pU6.GF-2. The Western blot was probed with antibodies specific to Sec 5, which acts as a loading control, and antibodies specific to the target Akt2. Lanes probed (l-r) were control non-transfected C2C12 cells, and cells  
10 transfected with the constructs pU6.GG-2, pU6.GG-3 and pU6.GG-4.

Figure 39 shows maps of the construct pU6.ACTB-A48 hp. **A** shows a map of the hairpin DNA transcriptional unit as in Figure 2B. **B** shows the predicted hairpin RNA produced from this construct as in Figure 2C. This hairpin RNA potentially targets the ACTB-A site of  $\beta$  actin mRNA as well as the next 29 nts of  
15 the mRNA. The transcript is predicted to produce a 48 nt double-stranded RNA.

Figure 40 shows maps of the plasmid pU6.AD1-A. **A** shows a map of the hairpin DNA transcriptional unit as in Figure 2B. **B** shows the predicted hairpin RNA produced from this construct as in Figure 2C. This transcript potentially targets the ADAR 1-A site of ADAR 1 mRNA.

20 Figure 41 shows maps of the plasmid pU6.AD2-C. **A** shows a map of the hairpin DNA transcriptional unit as in Figure 2B. **B** shows the predicted hairpin RNA produced from this construct as in Figure 2C. This transcript potentially targets the ADAR 2-C site of ADAR 2 mRNA.

Figure 42 shows maps of the plasmid pU6.AD2-A. **A** shows a map of the  
25 hairpin DNA transcriptional unit as in Figure 2B. **B** shows the predicted hairpin RNA produced from this construct as in Figure 2C. This transcript potentially targets the ADAR 2-A site of ADAR 2 mRNA.

Figure 43 shows maps of the plasmid pU6.AD1/2-B. **A** shows a map of the hairpin DNA transcriptional unit as in Figure 2B. **B** shows the predicted hairpin  
30 RNA produced from this construct as in Figure 2C. This transcript potentially targets both the ADAR 1-B site of ADAR 1 mRNA and the ADAR 2-B site of ADAR 2 mRNA.

Figure 44 shows maps of the plasmid pU6.AD1&2-A/UU. **A** shows a map of the hairpin DNA transcriptional unit as in Figure 10A, the position of “bubble” and loop sequences within the transcriptional unit are shown as stippled arrows. **B** shows the predicted hairpin RNA produced from this construct as in Figure 10B.

5 Sequences at the base of the hairpin target the ADAR 1-A site of ADAR 1 mRNA, sequences nearer the loop target the ADAR 2-A site of ADAR 2 mRNA.

Figure 45 shows maps of the plasmid pU6.AD1&2-A/UUA. **A** shows a map of the hairpin DNA transcriptional unit as in Figure 10A. **B** shows the predicted hairpin RNA produced from this construct as in Figure 10B.

10 Figure 46 shows maps of the plasmid pU6.AD1&2-A/UUACAA. **A** shows a map of the hairpin DNA transcriptional unit as in Figure 10A. **B** shows the predicted hairpin RNA produced from this construct as in Figure 10B.

Figure 47 shows a comparison showing the predicted transcripts produced by the constructs pU6.AD1&2-A/UU (**A**), pU6.AD1&2-A/UUA (**B**) and pU6.AD1&2-A/UUACAA (**C**). Predicted structures are shown as in Figure 10B.

15

Figure 48 shows maps of the plasmid pU6.ACTB-A/UUA. **A** shows a map of the hairpin DNA transcriptional unit as in Figure 10A; in this instance a “stem” sequence, derived from the first seven nucleotides of the ADAR 1-A target has been incorporated into the construct. Without being bound by any theory or mode

20 of action, it is believed that this sequence is too short to target ADAR 1 mRNA, but can act by maintaining the structure of the bubble sequence in the construct. **B** shows the predicted hairpin RNA produced from this construct as in Figure 10B.

Figure 49 shows maps of the plasmid pU6.AD1-A&ACTB-A/UU. **A** shows a map of the hairpin DNA transcriptional unit as in Figure 10A. **B** shows the predicted hairpin RNA produced from this construct as in Figure 10B.

25

Figure 50 shows maps of the plasmid pU6.AD1-A&ACTB-A/UUA. **A** shows a map of the hairpin DNA transcriptional unit as in Figure 10A. **B** shows the predicted hairpin RNA produced from this construct as in Figure 10B.

Figure 51 shows maps of the plasmid pU6.AD1-A&ACTB-A/UUAG. **A** shows a map of the hairpin DNA transcriptional unit as in Figure 10A. **B** shows the predicted hairpin RNA produced from this construct as in Figure 10B.

30



Figure 52 shows maps of the plasmid pU6.AD1-A&ACTB-A/UUACAA. **A** shows a map of the hairpin DNA transcriptional unit as in Figure 10A. **B** shows the predicted hairpin RNA produced from this construct as in Figure 10B.

Figure 53 shows maps of the plasmid pU6.ACTB-A&AD1-A/UUA. **A** shows a map of the hairpin DNA transcriptional unit as in Figure 10A. **B** shows the predicted hairpin RNA produced from this construct as in Figure 10B.

Figure 54 shows a comparison showing the encoded transcripts produced by the constructs pU6.ACTB-A/UUA (**A**), pU6.AD1-A&ACTB-A/UU (**B**), pU6.AD1-A&ACTB-A/UUA (**C**), pU6.AD1-A&ACTB-A/UUAG (**D**), pU6.AD1-A&ACTB-A/UUACAA (**E**), pU6.ACTB-A&AD1-A/UUA (**F**) as in Figure 10B.

Figure 55 shows the activity of double hairpin constructs targeting ADAR 1 and shows the enhanced activity of some bubble constructs compared to a single hairpin construct.

Figure 56 shows the activity of double hairpin constructs targeting ADAR 2.

Figure 57 shows the activity of double hairpin constructs targeting ADAR 1.

Figure 58 shows the activity of double hairpin constructs targeting  $\beta$  actin.

Figure 59 shows a map of pU6.GR-21 hp, which targets GFP and Rluc for inactivation. **A** shows a map of the hairpin DNA transcriptional unit as for Figure 10A. **B** shows the predicted hairpin RNA produced from this construct as in Figure 10B.

Figure 60 shows a map of the library construct pU6.GR-21-1-2N, which targets GFP and Rluc for inactivation. **A** shows a map of the hairpin DNA transcriptional unit as for Figure 10A. The position of randomised sequences within the construct is shown as a stippled arrow below the map. **B** shows the predicted hairpin RNA produced from this construct as in Figure 10B, in this instance N represents any ribonucleotide (ie A,C,U or G).

Figure 61 shows a map of the library construct pU6.GR-21-4-2N, which targets GFP and Rluc for inactivation. **A** shows a map of the hairpin DNA transcriptional unit as for Figure 10A. **B** shows the predicted hairpin RNA produced from this construct as in Figure 10B.

Figure 62 shows a map of the library construct pU6.GR-21-1&4-2N, which targets GFP and Rluc for inactivation. **A** shows a map of the hairpin DNA transcriptional unit as for Figure 10A. **B** shows the predicted hairpin RNA produced from this construct as in Figure 10B.

5        Figure 63 shows maps and sequences of the library construct series pU6.GR-22-1-4N and pU6.GR-22-4-4N, both target GFP and Rluc for inactivation. **A** shows a map of the hairpin DNA transcriptional unit of pU6.GR-22-1-4N as for Figure 10A. **B** shows the predicted hairpin RNA produced from this construct as in Figure 10B; in this instance D represents the ribonucleotides A, G or U; V  
10        represents the ribonucleotides A, C or G; and H represents the ribonucleotides A, C or U. **C** shows a map of the hairpin DNA transcriptional unit of pU6.GR-22-4-4N as for Figure 60A. **D** shows the predicted hairpin RNA produced from this construct as in Figure 10B; in this instance H represents the ribonucleotides A, C or U; B represents the ribonucleotides C, G or U and D represents the  
15        ribonucleotides A, G or U.

Figure 64 shows maps and sequences of the library construct pU6.GR-22-1-NAAN and pU6.GR-22-4-NAAN, both target GFP and Rluc for inactivation. **A** shows a map of the hairpin DNA transcriptional unit of pU6.GR-22-1-NAAN as for Figure 10A. **B** shows the predicted hairpin RNA produced from this construct as in  
20        Figure 10B; in this instance N represents any ribonucleotide. **C** shows a map of the hairpin DNA transcriptional unit of pU6.GR-22-4-NAAN as for Figure 60A. **D** shows the predicted hairpin RNA produced from this construct as in Figure 10B; in this instance in this instance N represents any ribonucleotide.

Figure 65 shows a map of the library construct pU6.GR-21-1&4-4N, which  
25        targets GFP and Rluc for inactivation. **A** shows a map of the hairpin DNA transcriptional unit as for Figure 63. **B** shows the predicted hairpin RNA produced from this construct as in Figures 63 and 64.

Figure 66 shows selected examples of 3 phasing constructs, namely pU6.GR-17 hp (**A**), pU6.GR-21 hp(**B**) and pU6.GR-26 hp (**C**). In these examples  
30        the grey bar represents a small region of the human U6 promoter; the open arrow represents the EGFP-A effector sequences which range from 17 to 26 nts; the black arrows represent the *Rluc* targeting sequences, which are constant in these constructs.



Figure 67 shows the predicted transcripts produced by pU6.GR-17 hp (**A**), pU6.GR-18 hp(**B**), pU6.GR-19 hp (**C**), pU6.GR-20 hp (**D**), pU6.GR-21 hp(**E**), pU6.GR-22 hp (**F**), pU6.GR-23 hp (**G**), pU6.GR-24 hp(**H**), pU6.GR-25 hp (**I**) and pU6.GR-26 hp (**J**). The predicted transcripts are shown as in Figure 2C, except  
 5 the variable length GFP targeting sequences are shown in bold.

Figure 68 shows the relative activity of the phasing constructs against *Rluc* (n=5;  $\pm$  SD). Note the constructs pU6.GR21 hp and pU6.GR-22 hp show the highest activity.

Figure 69 Defining constructs with higher activity by screening 2N libraries.  
 10 **A** shows primary screening of the activity of 22 clones isolated from the pU6.GR-21-1-2N library against *Rluc* (n=3;  $\pm$  SD). **B** rescreening of clones from **A** showing highest activity. Clone pU6.GR-21-1-2n-18 hp showed higher activity than the control pU6.GR-21 hp.

Figure 70 shows a diagrammatic representation of the multi-target strategy.  
 15 **A** shows a diagrammatic representation of a construct targeting 3 genes (targ. 1, targ. 2 and targ. 3 in this example). The construct contains a promoter (either pol II, pol III or any other type of promoter) and terminator (either pol II or pol III terminator or any sequence that can generate a 3' end of the transcript): It also contains a transcribed effector sequences in sense (targ. 1, targ. 2 and targ. 3)  
 20 and antisense (3.grat, 2.grat and 1.grat) orientation (arrows); loop sequences (box) and bubbles shown as black circles. **B** a primary transcript is produced as shown in Figure 70A, consisting of sense and antisense effector sequences, separated by bubbles, with loop sequences separated by a loop. **C** The transcript then forms a hpRNA structure, presumably spontaneously. **D** The hp RNA  
 25 transcript is then processed by Dicer to produce three different effector si RNAs. In this example the effectors can target 3 different RNAs (horizontal bars) and cleave them (vertical bars).

Figure 71 shows construction of the plasmid pU6.GF-3. This plasmid contains 2 transcriptional units on a single plasmid, one designed to inactivate  
 30 Akt1, the second to inactivate Akt2. **A** shows a map of the plasmid pU6.GL as in Figure 2, the positions of Sma I and Kpn I restriction sites are also shown. The predicted hairpin RNA produced from this construct as in Figure 2C. **B** shows a map of the entire plasmid pU6.GG-4 (Figure 37), the position of Hinc II and Kpn I

restriction sites is shown. **C** shows a map of a region of the construct pU6.GF-3 which will be prepared by cloning the U6 transcriptional unit from pU6.GL as a Sma I / Hind III fragment into Hinc II / Kpn I restricted pU6.GG-4. The map shows the region of pU6.GF-3 containing the two U6 transcriptional units. The resultant  
 5 plasmid is predicted to produce two hairpin RNAs, one targeting Akt2, as shown in Figure 37B, the second targeting Akt1 as in Figure 71B.

Figure 72 shows a map of the construct pU6.HCVx3 hp. **A** shows a map of the hairpin DNA transcriptional unit as in Figure 10A. **B** shows the predicted hairpin RNA produced from this construct as in Figure 10B.

10 Figure 73 shows maps of regions of two plasmids, namely pU6.GR22-sense (**A**) and pU6.GR22-antisense (**B**). The predicted transcripts produced from these constructs in vivo are shown below the respective maps. The transcripts are predicted to anneal as shown in **C** to produce a double stranded RNA designed to inactivate both EGFP and hRluc mRNAs.

15 Figure 74 shows partial maps of two DNA fragments, namely T7 GR22-sense template rc (**A**) and T7 GR22-antisense rc (**B**). The predicted transcripts produced from these constructs in vitro are shown below the respective maps. The transcripts are predicted to anneal as shown in **C** to produce a double stranded RNA designed to inactivate both EGFP and hRluc mRNAs.

## 20 EXAMPLES

### 1. Test constructs

DNA constructs were prepared which were targeted to inactivate a number of genes, principally the Renilla luciferase gene because of the availability of simple rapid assays (see below). The base plasmid for all constructs was  
 25 pU6.cass shown in Figure 1. The cloning procedures used to prepare all constructs are well known to those skilled in the art. To prepare pU6.cass human genomic DNA was PCR amplified with Pfu polymerase using the primers.

U6FR1

GAATTCAAGGTCGGGCAGGAAGAGGG



U6T5H3

AAGCTTAGATCTCGTCTCACGGTGTTTCGTCCTTTCCACAAG

The resulting fragment was A-tailed using Taq polymerase and cloned into the vector pZero Blunt (pZB) using the manufacturer's protocols (Invitrogen). The human U6 promoter region was excised from this plasmid as an Eco RI / Hind III fragment and cloned into the vector pBluescript II SK+ (Stratagene), using the restriction sites introduced into the fragment by the above oligonucleotides. The resulting plasmid pU6.cass (Fig. 1) differed slightly from the predicted sequence because the particular clone chosen for subsequent manipulation had a two base pair (GA) deletion in the U6 fragment. The fragment actually cloned was an EcoRI / Hind III fragment, where the Eco RI site came from the pZB vector. pU6.cass thus had a 10 bp insertion at the 5' end of the human U6 gene. The vector was designed to allow cloning of hairpin DNA inserts as Bsm BI / Hind III fragments, in such a fashion that hairpin RNA would be expressed from the insert.

The plasmid pU6.ACTB-A hp (Figure 2) was prepared using annealing of four oligonucleotides, namely:

ACTB-A-hp-U6-5

ACCGTGTGCACCGGCACAGACATTCAAGAGA

ACTB-A-hp-U6-6

GCAATGATCTTGATCTTCA

ACTB-A-hp-H1-3

GCAATGATCTTGATCTTCATTTTTTGGAAA

ACTB-A-hp-H1-4

AGCTTTTCCAAAAATGAAGATCAAGATCATTGCTCTCTTGAA

The partially complementary oligonucleotide pairs, ACTB-A-hp-U6-5 and ACTB-A-hp-U6-6 and ACTB-A-hp-H1-3 and ACTB-A-hp-H1-4 were annealed, and the annealed pairs themselves subsequently annealed to form a double-stranded DNA structure compatible with cloning into BsmB 1 / Hind III digested pU6.cass. The annealed oligonucleotides were phosphorylated with T4 polynucleotide kinase using the manufacturer's (Promega) protocol and then cloned into the cut vector which had been dephosphorylated using Shrimp Alkaline Phosphatase (SAP) using

the manufacturer's (Promega) protocol. This plasmid was expected to express a hairpin RNA, with transcription initiating in the human U6 promoter and terminating at the poly T tract in the 3' region of the annealed sequences as shown in Figure 2C.

## 5    2.    Long-range PCR method

The general strategy of the long-range PCR method is shown in Figure 3. The steps of the method are as follows:

- A.    Step 1: Long-range PCR (LPCR) primers are used to extend and amplify circular or linear templates. DNA templates are shown as two lines, denoting double stranded DNA, although single stranded DNA could be used as a template. The LPCR primers are shown as bent lines above and below the templates; thin regions represent 3' fixing parts of primers, thick lines represent 5' effector parts of primers.
- B.    Step 2: Amplify DNA molecule. PCR amplification of either of the templates in A will result in the production of linear DNA molecules, where the effector parts of the two LPCR oligonucleotides, denoted as thick lines, are incorporated into both ends of the linear DNA molecule.
- C.    Step 3: Circularized DNA molecule. The linear DNA can be readily recircularised using T4 DNA ligase or a similar enzyme. Note 5' phosphorylation of at least one end of the DNA molecule is required to achieve this. This can be done by either synthesising 5' phosphorylated oligonucleotides, or treating the linear DNA molecule with an enzyme such as T4 polynucleotide kinase; the former method is simplest.

### 2.1    Insertion of a restriction site into a plasmid

An Asc I restriction site was introduced into a plasmid as shown in Figure 4. The addition of additional restriction sites to pre-existing DNA molecules is a widely used technique and in this instance the site was used for further manipulations.

The forward and reverse primers used in this reaction were:

30    TATAGGCGCGCCAGAGAGCAATGATCTTGATCTTCATTT

and



CTTGAAGCAATGATCTTGATCTTCACGGT

The substrate plasmid was amplified and ligated, and bacterial colonies were obtained and analysed as described above. In this fashion an ASC I restriction site was introduced in a single step.

5 The procedure is shown in Figure 4 as follows:

A circular plasmid template is shown at the top, the two lines denote the positions at which the forward and reverse primers can anneal to the template at the point of sequence insertion. In this instance one primer contains only a 3' fixing part, the other primer contains a 3' fixing part as well as a 5' effector part. The double stranded sequence of the plasmid surrounding the point of insertion is shown below this. Above this, the sequence of the forward primer is shown, the 3' fixing part is shown directly above the sequence, the primer binding site is indicated by the arrow. The sequence of the 5' effector region, which in this instance contains an Asc I restriction site, is indicated by the inclined letters. The sequence of the reverse primer is shown below this and its primer binding site is also indicated by an arrow.

## 2.2 Long-Range PCR Strategy for Generating Hairpin DNA Constructs in U6 Expression Cassette

This example describes the optimised approach for generating hairpin DNA constructs using long range PCR as outlined in Figure 5. The approach involves the use of two primers to generate a full copy of the expression cassette. The primers each contain approximately half of the hairpin and loop sequence, but no overlap in sequence. One primer is anchored in the U6 promoter region, the other in the pol III termination sequence and the primers are phosphorylated. The substrate used for amplification was a hairpin DNA construct (pU6.ACTB-A hp) containing both the human U6 promoter and a pol III terminator sequence; this template plasmid was prepared using conventional oligonucleotide cloning strategy similar to that described above. Following long-range amplification the PCR product is re-circularised and resultant colonies screened and a plasmid with the appropriate insert obtained.

The reverse and forward primers are designed to contain a 3' U6 fixing part and a 3' terminator fixing part, respectively. The 5' sequences of each primer

contain approximately half of the hairpin and loop sequences, in this instance 30 nucleotides homologous to a region of the murine GLUT4 gene separated by a 9 nucleotide loop.

The general design of the primers are shown below. U6 and terminator  
5 fixing parts are shown in bold.

The reverse primer is:

5' (NNN)loop(a/s) (NNN)hairpin(a/s) **GGTGTTTCGTCCTTTCCACA** 3'

The forward primer is:

5 '(NNN)loop(s) (NNN)hairpin(a/s)

10 **TTTTTGGAAAAGCTTATCGATACCGTC**3'

In this example the sequences of the reverse and forward primers were:

G U6-A

CTCTTGAACGCTCTCTCTCCAACCTCCGTTTCTCATCCGGTGTTT  
CGTCCTTTCCACA

15 G term-A

ACGCTCTCTCTCCAACCTCCGTTTCTCATCCTTTTTTGGAAAAGCT  
TATCGATACCGTC

#### Long-range PCR

To produce the linear amplification product, PCR reactions are assembled  
20 as follows:

1 µl template	10 ng pU6.ACTB-A hp
5 µl 10 x buffer	10 x buffer (Stratagene) <sup>a</sup> or Pfu Ultra <sup>TM</sup> Buffer (Stratagene)
2 µl 10mM dNTPs	10mM each dNTP
1 µl U6 primer	10 µM
1 µl term primer	10 µM
40 µl DDW	



1  $\mu$ l *Pfu* Turbo<sup>b</sup> or *Pfu* Ultra<sup>TM</sup>

Stratgene 2.5 U/ $\mu$ l<sup>b</sup>

50  $\mu$ l

<sup>a</sup> 10 x cloned *Pfu* DNA polymerase reaction buffer (Stratagene). 200 mM Tris-HCl (pH8.8), 20 mM Mg SO<sub>4</sub>, 100mM KCl, 100mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, 1% Triton X-100, 1 mg/ml BSA (nuclease free).

<sup>b</sup> *Pfu* is added last, preferably just prior to running reaction to minimise  
5 primer degradation.

Reactions are undertaken using a "touchdown" protocol as follows:

Initial denaturation

95°C 2 mins

Touch-down PCR reaction consists of 30 cycles as follows:

10 95°C 30 secs

60°C/55°C 1 min Decrease by 1°C for first 5 cycles

74°C 5 mins

Final cycle

74°C 10 mins

15 Hold reaction at 4°C

#### Optimising Reactions

These reaction conditions are robust. If necessary individual reactions can be optimised by:

- Altering touch down and annealing conditions, e.g., use temperature  
20 ranges of 65°C/60°C, 60°C/55°C and 55°C/50°C.

- Adding MgCl<sub>2</sub>, e.g an extra 0.5 mM MgCl<sub>2</sub> can dramatically effect PCR yields.

#### Ligation and transformation

PCR products are circularised using T4 DNA ligase, using a quick ligation  
25 kit according to the manufacturer's (New England Biolabs) instructions.

For Quick Ligation:

10 $\mu$ l buffer	2 x Quick Ligation Buffer
10 $\mu$ l DNA	Approximately 100ng DNAI
<u>1 <math>\mu</math>l</u> ligase	Quick T4 DNA ligase
21 $\mu$ l	

Incubate for 5 mins at room temperature.

Bacteria are then transformed using standard protocols and transformed cells selected on ampicillin, since the pU6.EGFP-A hp construct encodes ampicillin resistance.

- 5 Transformed colonies were analysed using a standard "colony cracking" procedure, in which plasmids in individual colonies were amplified using M13 Forward and Reverse primers. The resultant reactions were analysed using agarose gel electrophoresis. In this instance plasmids containing the correct insert gave a larger product, since the GLUT4 hairpin was longer than the hairpin  
10 sequence in the substrate plasmid. In this example 8 colonies were analysed by colony cracking and 6 gave the correct size band. Plasmids from 3 colonies were sequenced and one gave the correct product, which was designated pU6.GA.

Both covalent closed circular or linearised templates can be used to construct hairpin plasmids in this fashion. Background levels are lower when linear  
15 templates are used. For U6 constructs the preferred template is pU6.GA hp cut with Bsm BI, which linearises within the loop region of the construct. Treatment with shrimp alkaline phosphatase (SAP) further reduces background.

### 2.3 Increasing the length of an inverted repeat in a plasmid

The length of an inverted repeat within a plasmid was increased as shown  
20 in Figure 6 as follows:

The relative positions and sequences of the forward and reverse primers are indicated as in Figure 4. In this instance the forward and reverse primers are identical. The primer binding site is designed to hybridise to either arm of a hairpin DNA construct designed to target EGFP, whilst the 5' effector sequence contains  
25 further sequences homologous to EGFP. The length of hairpin DNA constructs can be sequentially increased using this strategy.



## 2.4 Insertion of an intron into a cloned sequence

A mouse Ige3 intron was inserted into a cloned sequence of the EGFP gene.

The reverse and forward primers were designed to contain a 3' fixing part homologous to sequential sequences located in the EGFP gene. The 5' effector sequences of each primer contained approximately half of the sequence of intron 3 from the mouse IgE3 gene.

The forward and reverse primers used in this reaction were:

GAGAACATGGTTAACTGGTTAAGTCATGTCGTCCCACAGGAGCGCACCATCT  
10 TCTTCAAGGA

and

TGAACATGAGAAGGGCTGGCCACTCTCCACCTCCTGTACTCACCTGGACGTA  
GCCTTCGGGCATGG

The substrate plasmid was amplified and ligated, and bacterial colonies were obtained and analysed as described above. In this fashion a functional intron (intron 3 from the mouse IgE gene) was inserted into the coding sequences of the EGFP gene in a single step.

This procedure is shown in Figure 7 as follows:

The relative positions and sequences of the forward and reverse primers are indicated as in Figure 4. In this instance the forward and reverse primer binding sites bind to coding sequences of EGFP. The forward and reverse 5' effector sequences for each primer encode approximately half of intron 3 of the mouse IgE 3 gene.

## 3. Preparation of hairpin constructs

Most constructs described in this application were prepared using the long range PCR strategy described above. The plasmid pU6.cass lin (Figure 8) may be used as a precursor construct to generate many of the constructs described below. This construct was prepared using a precursor construct pU6.GA which for this purpose is essentially identical to the plasmid pU6.ACTB-A hp (Figure 2), except its hairpin sequences target another gene. pU6.GA contains identical U6  
30

promoter and pol III terminator sequences to pU6.ACTB-A hp, however the new insert sequences inserted a Bsm BI restriction site which allowed linearisation of the vector prior to long range PCR amplification.

To prepare pU6.cass lin, Bsm BI linearised pU6.GA was amplified using the following primers:

U6mcs

TCTTGGACGTGGGTGTTTCGTCCTTTC

termmcs

TCTTGGAATGCTTTTTTGGAAAAGCTTATCG

A clone of the predicted sequence was isolated, this contains a polylinker containing three unique restriction sites (BmgB I, Bgl II and Bsm I) which can be used to linearise the vector prior to long range PCR amplification to reduce background (Figure 8A). To generate constructs using this plasmid, the plasmid (Figure 8B) was linearised with Bgl II prior to amplification.

The constructs used in these experiments are described in Table 1. Conventional single hp DNA constructs were used as controls. Double hairpin constructs were prepared and their activity was compared to the control constructs. The control constructs targeted a single gene, the test constructs ("double hairpin" constructs) targeted two genes, using one sequence at the "base" of the hairpin sequence (furthest from the loop), and a second sequence near the loop of the hairpin structure (the "top" of the hairpin). This terminology can extend to triple, quadruple, etc hairpins with 3, 4, etc duplex sequences. The activity of constructs where sequences targeting the *Renilla* luciferase gene were located at the base or the top of a double hairpin RNA, was compared with the activity of a single construct targeting only *Renilla* luciferase. Using this method, the ability of a construct to target two genes can be reliably inferred. This can optionally be confirmed by determining the activity of a single construct against both target genes.

**Table 1: Control and "double hairpin" constructs used in these experiments.**

Construct designation	Target <sup>a</sup>	"Bubble" sequence
Single hp constructs		



Construct designation	Target <sup>a</sup>	"Bubble" sequence
pU6.ACTB-A hp	ACTB-A site (negative control construct)	na
pU6.Rluc hp	<i>Renilla</i> luciferase (positive control construct)	na
<b>Double hp constructs</b>		
pU6.Rluc/ACTB TTA	ACTB-A site and <i>Renilla</i> luciferase	5'-UUA-3' 3'-GUU-5'
pU6.Rluc/ACTB TTAG	ACTB-A site and <i>Renilla</i> luciferase	5'-UUAG-3' 3'-check-5'
pU6.ACTB/Rluc TTA	ACTB-A site and <i>Renilla</i> luciferase	5'-UUA-3' 3'-GUU-5'
pU6.ACTB/Rluc TTAG	ACTB-A site and <i>Renilla</i> luciferase	5'-UUAG-3' 3'-check-5'
pU6.ACTB/AD1 hp	ACTB-A site and ADAR 1 site (negative control construct)	

<sup>a</sup> mRNA targeted for inactivation

-ACTB-A corresponds to positions 1047-1065 of Genbank accession NM\_001101.

5 -Rluc site corresponds to positions 1543-1561 of Genbank accession U47298.

- ADAR 1 site corresponds to positions 1477 to 1497 of GenBank sequence NM\_001111.

The test constructs were prepared as follows.

#### 10 pU6.Rluc hp

This construct was designed to target *Renilla* luciferase mRNA, present in HeLa cells stably transformed with a construct designed to express *Renilla* luciferase. The construct was prepared using the long range PCR strategy described above using Bgl II linearised pU6.cass lin as a substrate; this was  
15 amplified with Pfu Turbo polymerase (Stratagene) using the primers:

U6lucb

ACACAAAGTAGGAGTAGTGAAAGGCCGGTGTTTCGTCCTTTC

termIucb

AGGTAGGAGTAGTGAAAGGCCTTTTTTTGGAAAAGCTTATCG

A map of this construct is shown in Figure 9A and the sequence and predicted structure of the RNA produced by the construct is shown in Figure 9B.

#### **pU6.Rluc/ACTB TTA**

- 5 This construct tested whether a construct carrying a UUA bubble sequence was capable of inactivating two mRNAs, namely a *Renilla* luciferase transgene and  $\beta$  actin. The construct was prepared using the plasmid pU6.cass lin (Fig 8) as a substrate by amplifying with the two primers:

U6lucACTB-TTA

- 10 ACACAAAGCAATGATCTTGATCTTCATAAGTAGGAGTAGTGAAAGGCCGGTG  
TTTCGTCCTTTC

termluc-ACTB-TTG

AGGCAATGATCTTGATCTTCATTGGTAGGAGTAGTGAAAGGCCTTTTTTTGGAA  
AAGCTTATCG

- 15 A map of this construct is shown in Figure 10A and the sequence and predicted structure of the RNA produced by the construct is shown in Figure 10B.

#### **pU6.Rluc/ACTB TTAG hp**

- This construct tested whether a construct carrying a UUAG bubble sequence could inactivate two mRNAs, namely a *Renilla* luciferase transgene and  
20  $\beta$  actin. The construct was prepared by annealing the following nucleotides:

Rluc/ACTB-1

ACCGGCCTTTCACTACTCCTACTTAGTGAAGATCAAGATCATTGC

Rluc/ACTB-2

TTGATCTTCACTAAGTAGGAGTAGTGAAAGGC

- 25 Rluc/ACTB-3

TTTGTGTAGGCAATGATCTTGATCTTCAT

Rluc/ACTB-4

GATCATTGCCTACACAAAGCAATGATC



Rluc/ACTB-5

TGAGTAGGAGTAGTGAAAGGCCTTTTTTGGAAA

Rluc/ACTB-6

AGCTTTTCCAAAAAAGGCCTTTCCTACTCCTACTCAATGAAGATCAA

5 To prepare this construct an oligo assembly strategy was used. Each oligonucleotide was resuspended at 1ug/ml in water and 1ul of each was added together, to create a final volume of 100ul, containing 0.5 x strength Buffer M (Roche; 10 x Buffer M is 100 mM tris HCl (pH 7.5), 100 mM MgCl<sub>2</sub>, 500 mM NaCl, 10 mM DTE). The mixture was heated to 95°C, then oligonucleotides annealed by  
10 cooling to 30°C at 1°C per minute; these manipulations were performed in a Corbett Palm-Cycler PCR machine (Corbett Research). 20ul of annealed oligonucleotides were then treated with T4 polynucleotide kinase according to the manufacturer's (Promega) protocol. The annealed oligonucleotides were then purified using a Qiagen PCR purification column, according to the manufacturer's  
15 (Qiagen) protocol. 2 ul of eluted oligonucleotides (from 28 ul of eluted material) were then ligated to approximately 100 ng of BsmB I / Hind III Shrimp Alkaline Phosphatase (SAP: Promega) treated pU6.cass prepared, using procedures well known to those familiar with the art, Colonies containing the appropriate sequences were then isolated, and sequence of the construct was confirmed  
20 using well known sequencing protocols.

A map of this construct is shown in Figure 11A and the sequence and predicted structure of the RNA produced by the construct is shown in Figure 11B.

#### **pU6.ACTB/Rluc TTA**

This construct tests whether a construct carrying a UUA bubble sequence  
25 inactivates two mRNAs, namely  $\beta$  actin and a *Renilla* luciferase transgene. The construct is prepared using the plasmid pU6.cass lin as a substrate by amplifying with the two primers:

U6ACTB-luc-TTA

ACACAAAGTAGGAGTAGTGAAAGGCCTAAGCAATGATCTTGATCTTCACGGT

30 GTTTCGTCCTTTC

termACTB-luc-TTG

AGGTAGGAGTAGTGAAAGGCCTTGGCAATGATCTTGATCTTCATTTTTTGGAA  
AAGCTTATCG

A map of this construct is shown in Figure 12A and the sequence and  
predicted structure of the predicted RNA produced by the construct is shown in  
5 Figure 12B.

#### **pU6.ACTB/Rluc TTAG**

This construct tests whether a construct carrying a UUAG bubble sequence  
is capable of inactivating two mRNAs, namely  $\beta$  actin and a *Renilla* luciferase  
transgene. The construct is prepared using the plasmid pU6.cass lin as a  
10 substrate by amplifying with the two primers:

U6ACTB-luc-TTAG

ACACAAAGTAGGAGTAGTGAAAGGCCCTAAGCAATGATCTTGATCTTCAGGT  
GTTTCGTCCTTTC

termACTB-luc-TTGA

15 AGGTAGGAGTAGTGAAAGGCCTTGAGCAATGATCTTGATCTTCATTTTTTGGAA  
AAAGCTTATCG

A map of this construct is shown in Figure 13A and the sequence and  
predicted structure of the RNA produced by the construct is shown in Figure 13B.

#### **4. Constructs targeting three genes**

20 Four constructs were prepared targeting *Renilla* luciferase and a variety of  
other genes. Three constructs contain *Renilla* luciferase-targeting sequences at  
three different positions, respectively, within the hairpin RNA, namely the base,  
middle and top of the hairpin RNAs and contain the UUAG bubble sequence. The  
constructs are outlined in Table 2. A fifth construct acted as a negative control.

25 **Table 2: Hairpin constructs targeting three genes**



Construct	Target <sup>a</sup>	Bubble Sequence
pU6.Rluc/ACTB/AD1 hp	<i>Renilla</i> luciferase $\beta$ actin (ACTB-A) ADAR1	5'-UUAG-3' 3'-AGUU-5'
pU6.ACTB/Rluc/AD1 hp	$\beta$ actin (ACTB-A) <i>Renilla</i> luciferase ADAR1	5'-UUAG-3' 3'-AGUU-5'
pU6.ACTB/AD1/Rluc hp	$\beta$ actin (ACTB-A) ADAR1 <i>Renilla</i> luciferase	5'-UUAG-3' 3'-AGUU-5'
pU6.ACTB/AD1/GFP hp	<i>Renilla</i> luciferase $\beta$ actin (ACTB-A) EGFP	5'-UUAG-3' 3'-AGUU-5'
pU6.ACTB/AD1/GFP hp	$\beta$ actin (ACTB-A) ADAR1 EGFP	5'-UUAG-3' 3'-AGUU-5'

<sup>a</sup> mRNA targeted for inactivation

-EGFP target corresponds to positions 924-942 of pEGFPN1-MCS (Invitrogen).

5 The constructs were prepared mainly using the long range PCR strategy described above.

#### **pU6.Rluc/ACTB/AD1**

This construct tested whether a construct carrying sequences targeting a *Renilla* luciferase transgene in the base of the predicted hairpin RNA inactivated *Renilla* luciferase. The construct was prepared using linearised plasmid pU6.cass lin as a substrate by amplifying with the two primers:

U6LBA

ACAAATGAACAGGTGGTTTCAGTCCTAAGCAATGATCTTGATCTTCACTAAGT

AGGAGTAGTGAAAGGCCGGTGTTCGTCCTTTC

termLBA

GTAGTGAACAGGTGGTTTCAGTCTTGAGCAATGATCTTGATCTTCATTGAGTA  
GGAGTAGTGAAAGGCCCTTTTTTGGAAAAGCTTATCG

- 5           A map of this construct is shown in Figure 15A and the sequence and predicted structure of the predicted RNA produced by the construct is shown in Figure 15B.

**pU6.ACTB/Rluc/AD1 hp**

- This construct tested whether a construct carrying sequences targeting a  
10   *Renilla* luciferase transgene in the middle of the predicted hairpin RNA inactivated *Renilla* luciferase. The construct was prepared using linearised plasmid pU6.cass lin as a substrate by amplifying with the two primers:

U6BLA

- CACAAATGAACAGGTGGTTTCAGTCCTAAGTAGGAGTAGTGAAAGGCCCTAA  
15   GCAATGATCTTGATCTTCACCGGTGTTCGTCCTTTC

termBLA

TAGTGAACAGGTGGTTTCAGTCTTGAGTAGGAGTAGTGAAAGGCCCTTGAGCA  
ATGATCTTGATCTTCATTTTTTGGAAAAGCTTATCG

- A map of this construct is shown in Figure 16A and the sequence and  
20   predicted structure of the RNA produced by the construct is shown in Figure 16B.

**pU6.ACTB/AD1/Rluc hp**

- This construct tested whether a construct carrying sequences targeting a  
*Renilla* luciferase transgene at the top of the predicted hairpin RNA inactivated  
*Renilla* luciferase. The construct was prepared using the plasmid pU6.cass lin as a  
25   substrate by amplifying with the two primers:

U6BAL

CACAAAGTAGGAGTAGTGAAAGGCCCTAATGAACAGGTGGTTTCAGTCCTAA  
GCAATGATCTTGATCTTCACCGGTGTTCGTCCTTTC

termBAL



TAGGTAGGAGTAGTGAAAGGCCTTGATGAACAGGTGGTTTCAGTCTTGAGCA  
ATGATCTTGATCTTCATTTTTTTGGAAAAGCTTATCG

A map of this construct is shown in Figure 17A and the sequence and predicted structure of the RNA produced by the construct is shown in Figure 17B.

## 5 pU6.ACTB/AD1/GFP hp

This construct acted as a negative control for the three previous constructs. The construct was prepared using linearised plasmid pU6.cass lin as a substrate by amplifying with the two primers

U6BAG

10 CACAAAGATGAACTTCAGGGTCAGCCTAATGAACAGGTGGTTTCAGTCCTAA  
GCAATGATCTTGATCTTCACGGTGTTCGTCCTTTC

termBAG

TAGGATGAACTTCAGGGTCAGCTTGATGAACAGGTGGTTTCAGTCTTGAGCA  
ATGATCTTGATCTTCATTTTTTTGGAAAAGCTTATCG

15 A map of this construct is shown in Figure 18A and the sequence and predicted structure of the RNA produced by the construct is shown in Figure 18B.

## 5. Constructs targeting four genes

To test constructs targeting four separate genes, five constructs may be prepared targeting *Renilla* luciferase and a variety of other genes. The four  
20 constructs each contain a sequence targeting *Renilla* luciferase at one of four possible positions within the predicted hairpin RNA, namely the base, next to the base, next to the top and top of the hairpin RNAs. The hairpin RNAs further contain the UUAG bubble sequence separating the various components. The constructs are outlined in Table 3.

25 **Table 3: Hairpin constructs targeting four genes**

Construct	Target <sup>a</sup>	Bubble Sequence
pU6.Rluc/ACTB/AD1/GFP hp	<i>Renilla</i> luciferase	5'-UUAG-3'
	$\beta$ actin (ACTB-A)	3'-AGUU-5'
	ADAR1	

Construct	Target <sup>a</sup>	Bubble Sequence
	EGFP	
pU6.ACTB/Rluc/AD1/GFP hp	$\beta$ actin (ACTB-A) <i>Renilla</i> luciferase ADAR1 EGFP	5'-UUAG-3' 3'-AGUU-5'
pU6.ACTB/AD1/Rluc/GFP hp	$\beta$ actin (ACTB-A) ADAR1 <i>Renilla</i> luciferase EGFP	5'-UUAG-3' 3'-AGUU-5'
pU6.ACTB/AD1/GFP/Rluc hp	$\beta$ actin (ACTB-A) ADAR1 EGFP <i>Renilla</i> luciferase	5'-UUAG-3' 3'-AGUU-5'
pU6.ACTB/AD1/GFP/HER2 hp	$\beta$ actin (ACTB-A) ADAR1 EGFP HER-2	5'-UUAG-3' 3'-AGUU-5'

<sup>a</sup> mRNA targeted for inactivation

-HER2 target corresponds to positions 223-241 of Genbank accession HUMHER2A.

- 5 The constructs may be prepared using the long range PCR strategy described above.

#### **pU6.Rluc/ACTB/AD1/GFP hp**

This construct tests whether a construct carrying sequences targeting a *Renilla* luciferase transgene in the base of the predicted hairpin RNA inactivates *Renilla* luciferase. The construct is prepared using the plasmid pU6.Rluc/ACTB/AD1 hp as a substrate by amplifying with the two primers:

10



U6AGG4

GTTTCATCAAGCTGACCCTGAAGTTCATCCTACACAAAGATGAACTTCA  
GGGTCAGCCTAATGAACAGGTGGTTTCAGTCCTAA

ABL4

5 AGGTGGTTTCAGTCTTGAGCAATGATCTTGATCTTCATTGAGTAGGAGT  
AGTGAAAGGCCTTTTTTTGGAAAAGCTTATCG

A map of the construct is shown in Figure 19A and the sequence and predicted structure of the RNA produced by the construct is shown in Figure 19B.

#### **pU6.ACTB/Rluc/AD1/GFP hp**

10 This construct tests whether a construct carrying sequences targeting a *Renilla* luciferase transgene in the second position from the base of the predicted hairpin RNA inactivates *Renilla* luciferase. The construct is prepared using the plasmid pU6.ACTB/Rluc/AD1 hp as a substrate by amplifying with the two primers:

U6AGG4

15 GTTCATCAAGCTGACCCTGAAGTTCATCCTACACAAAGATGAACTTCA  
GGGTCAGCCTAATGAACAGGTGGTTTCAGTCCTAA

termALB4

AGGTGGTTTCAGTCTTGAGTAGGAGTAGTGAAAGGCCTTGAGCAATGA  
TCTTGATCTTCATTTTTTTGGAAAAGCTTATCG

20 A map of the construct is shown in Figure 20A and the sequence and potential structure of the RNA produced by the construct is shown in Figure 20B.

#### **pU6.ACTB/AD1/Rluc/GFP hp**

25 This construct tests whether a construct carrying sequences targeting a *Renilla* luciferase transgene in the third position from the base of the predicted hairpin RNA inactivates *Renilla* luciferase. The construct is prepared using the plasmid pU6.ACTB/AD1/Rluc hp as a substrate by amplifying with the two primers:

U6LGG4

CTACTCAAGCTGACCCTGAAGTTCATCCTACACAAAGATGAACTTCAG  
GGTCAGCCTAAGTAGGAGTAGTGAAAGGCCCTAA

30 termLAB4

GAGTAGTGAAAGGCCTTGATGAACAGGTGGTTTCAGTCTTGAGCAATG  
ATCTTGATCTTCATTTTTTTGGAAAAGCTTATCG

A map of the construct is shown in Figure 21A and the sequence and potential structure of the predicted RNA produced by the construct is shown in  
5 Figure 21B.

**pU6.ACTB/AD1/GFP/Rluc hp**

This construct tested whether a construct carrying sequences targeting a *Renilla* luciferase transgene adjacent to the loop of the predicted hairpin RNA inactivated *Renilla* luciferase. The construct was prepared by annealing the  
10 following oligonucleotides:

BAGR1

ACCGTGAAGATCAAGATCATTGCTTAGGACTGAAACCA

BAGR2

ATGAACAGGTGGTTTCAGTCCTAAGCAATGATCTTGATCTTCA

15 BAGR3

CCTGTTCATTAGGCTGACCCTGAAGTTCATCTTAG

BAGR4

TGAAAGGCCCTAAGATGAACTTCAGGGTCAGCCTA

BAGR5

20 GGCCTTTCAC TACTCCTACTTTGTGTAGGTAGGAGTAGTGAAAGGCC

BAGR6

TCATCTCAAGGCCTTTCAC TACTCCTACCTACACAAAGTAGGAGTAG

BAGR7

TTGAGATGAACTTCAGGGTCAGCTTGATGAACAGGTGGTTTCAGTC

25 BAGR8

CACCTGTTCATCAAGCTGACCCTGAAGT

BAGR9

TTGAGCAATGATCTTGATCTTCATTTTTTTGGAAA



**BAGR10**

AGCTTTTCCAAAAAATGAAGATCAAGATCATTGCTCAAGACTGAAAC

The oligonucleotides were annealed together, treated with T4 PNK according to the manufacturer's (Promega) protocol and cloning the resultant  
5 mixture into BsmB I / Hind III cleaved pU6.cass that had been treated with SAP as described above.

A map of the construct is shown in Figure 22A and the sequence and predicted structure of the RNA produced by the construct is shown in Figure 22B.

**pU6.ACTB/AD1/GFP/HER2 hp**

10 This construct acts as a negative control for the four previous constructs. The construct is prepared using the plasmid pU6.ACTB/AD1/GFP hp as a substrate by amplifying with the two primers:

U6GHH4

CATCTCAAGTGTGCACCGGCACAGACACTACACAAATGTCTGTGCCGG  
15 TGCACACCTAAGATGAACTTCAGGGTCAGCCTAA

termGAB4

AACTTCAGGGTCAGCTTGATGAACAGGTGGTTTCAGTCTTGAGCAATG  
ATCTTGATCTTCATTTTTTGGAAAAGCTTATCG

A map of the construct is shown in Figure 23A and the sequence and  
20 predicted structure of the RNA produced by the construct is shown in Figure 23B.

**6. Constructs targeting five genes**

To test constructs targeting five separate genes, six constructs may be prepared targeting *Renilla* luciferase and a variety of other genes. Each of the five constructs contains a sequence targeting *Renilla* luciferase at one of five possible  
25 positions within the predicted hairpin RNA, namely the base, all positions from next to the base to next to the top and the top of the hairpin RNAs. The hairpin RNAs further contain the UUAG bubble sequence separating the various components. The constructs are outlined in Table 4.

**Table 4: Hairpin constructs targeting five genes**

Construct	Target <sup>a</sup>	Bubble Sequence
-----------	---------------------	-----------------

Construct	Target <sup>a</sup>	Bubble Sequence
pU6.Rluc/ACTB/AD1/GFP/HER2 hp	<i>Renilla</i> luciferase $\beta$ actin (ACTB-A) ADAR1 EGFP HER2	5'-UUAG-3' 3'-AGUU-5'
pU6.ACTB/Rluc/AD1/GFP/HER2 hp	$\beta$ actin (ACTB-A) <i>Renilla</i> luciferase ADAR1 EGFP HER2	5'-UUAG-3' 3'-AGUU-5'
pU6.ACTB/AD1/Rluc/GFP/HER2 hp	$\beta$ actin (ACTB-A) ADAR1 <i>Renilla</i> luciferase EGFP HER2	5'-UUAG-3' 3'-AGUU-5'
pU6.ACTB/AD1/GFP/Rluc/HER2 hp	$\beta$ actin (ACTB-A) ADAR1 EGFP <i>Renilla</i> luciferase HER2	5'-UUAG-3' 3'-AGUU-5'
pU6.ACTB/AD1/GFP/HER2/Rluc hp	$\beta$ actin (ACTB-A) ADAR1 EGFP HER2 <i>Renilla</i> luciferase	5'-UUAG-3' 3'-AGUU-5'
pU6.ACTB/AD1/GFP/HER2/LAM hp	$\beta$ actin (ACTB-A) ADAR1 EGFP	5'-UUAG-3' 3'-AGUU-5'



Construct	Target <sup>a</sup>	Bubble Sequence
	HER2  Lamin A/C	

<sup>a</sup> mRNA targeted for inactivation

-LAM target corresponds to positions 820-838 of Genbank accession NM\_005572.

5 The constructs may be prepared using the long range PCR strategy described above.

#### **pU6.Rluc/ACTB/AD1/GFP/HER2 hp**

This construct tests whether a construct carrying sequences targeting a *Renilla* luciferase transgene in the base of the predicted hairpin RNA inactivates *Renilla* luciferase. The construct is prepared using the plasmid pU6.Rluc/ACTB/AD1/GFP hp as a substrate by amplifying with the two primers:

U6GHH5

TCAAGTGTGCACCGGCACAGACACTACACAAATGTCTGTGCCGGTGC  
ACACCTAAGATGAACTTCAGGGTCAGCCTAA

15 termGABL5

GATGAACTTCAGGGTCAGCTTGATGAACAGGTGGTTTCAGTCTTGAGC  
AATGATCTTGATCTTCATTGAGTAGGAGTAGTGAAAGGCCTTTTTTGGAAAAG  
CTTATCG

A map of the construct is shown in Figure 24A and the sequence and  
20 predicted structure of the RNA produced by the construct is shown in Figure 24B.

#### **pU6.ACTB/Rluc/AD1/GFP/HER2 hp**

This construct tests whether a construct carrying sequences targeting a *Renilla* luciferase transgene in position two, one position up the base of the predicted hairpin RNA inactivates *Renilla* luciferase. The construct is prepared  
25 using the plasmid pU6.ACTB/Rluc/AD1/GFP hp as a substrate by amplifying with the two primers:

U6GHH5

TCAAGTGTGCACCGGCACAGACACTACACAAATGTCTGTGCCGGTGC  
ACACCTAAGATGAACTTCAGGGTCAGCCTAA

termGALB5

GATGAACTTCAGGGTCAGCTTGATGAACAGGTGGTTTCAGTCTTGAGT  
5 AGGAGTAGTGAAAGGCCTTGAGCAATGATCTTGATCTTCATTTTTTTGGAAAAG  
CTTATCG

A map of the construct is shown in Figure 25A and the sequence and predicted structure of the RNA produced by the construct is shown in Figure 25B.

#### **pU6.ACTB/AD1/Rluc/GFP/HER2 hp**

10 This construct tests whether a construct carrying sequences targeting a *Renilla* luciferase transgene in position three, in the middle of the predicted hairpin RNA, inactivates *Renilla* luciferase. The construct is prepared using the plasmid pU6.ACTB/AD1/Rluc/GFP hp as a substrate by amplifying with the two primers:

U6GHH5

15 TCAAGTGTGCACCGGCACAGACACTACACAAATGTCTGTGCCGGTGC  
ACACCTAAGATGAACTTCAGGGTCAGCCTAA

termGLAB5

GATGAACTTCAGGGTCAGCTTGAGTAGGAGTAGTGAAAGGCCTTGATG  
AACAGGTGGTTTCAGTCTTGAGCAATGATCTTGATCTTCATTTTTTTGGAAAAG  
20 CTTATCG

A map of the construct is shown in Figure 26A and the sequence and predicted structure of the predicted RNA produced by the construct is shown in Figure 26B.

#### **pU6.ACTB/AD1/GFP/Rluc/HER2 hp**

25 This construct tests whether a construct carrying sequences targeting a *Renilla* luciferase transgene in position four, one back from the loop sequence of the predicted hairpin RNA, inactivates *Renilla* luciferase. The construct is prepared using the plasmid pU6.ACTB/AD1/GFP/Rluc hp as a substrate by amplifying with the two primers:

30 U6LHH5

TCAAGTGTGCACCGGCACAGACACTACACAAATGTCTGTGCCGGTGC



ACACCTAAGTAGGAGTAGTGAAAGGCCCTAA

termLGAB5

GTAGGAGTAGTGAAAGGCCCTTGAGATGAACTTCAGGGTCAGCTTGATG  
AACAGGTGGTTTCAGTCTTGAGCAATGATCTTGATCTTCATTTTTTGGAAAAG  
5 CTTATCG

A map of the construct is shown in Figure 27A and the sequence and predicted structure of the predicted RNA produced by the construct is shown in Figure 27B.

### **pU6.ACTB/AD1/GFP/HER2/Rluc hp**

10 This construct tested whether a construct carrying sequences targeting a *Renilla* luciferase transgene in position five, adjacent to the loop sequence of the predicted hairpin RNA, inactivated *Renilla* luciferase. The construct was prepared by annealing the following oligonucleotides:

BAGR1 ACCGTGAAGATCAAGATCATTGCTTAGGACTGAAACCA  
15 BAGR2 ATGAACAGGTGGTTTCAGTCCTAAGCAATGATCTTGATCTTCA  
BAGR3 CCTGTTCATTAGGCTGACCCTGAAGTTCATCTTAG  
BAGHR4 GGTGCACACCTAAGATGAACTTCAGGGTCAGCCTA  
BAGHR5  
GTGTGCACCGGCACAGACATTAGGGCCTTTCACTACTCCTACTTTGT  
20 BAGHR6  
CCTACCTACACAAAGTAGGAGTAGTGAAAGGCCCTAATGTCTGTGCC  
BAGHR7  
GTAGGTAGGAGTAGTGAAAGGCCCTTGATGTCTGTGCCGGTGCACAC  
BAGHR8  
25 TCATCTCAAGTGTGCACCGGCACAGACATCAAGGCCTTTCACTACT  
BAGR7  
TTGAGATGAACTTCAGGGTCAGCTTGATGAACAGGTGGTTTCAGTC  
BAGHR10 CACCTGTTCATCAAGCTGACCCTGAAGT  
BAGR9 TTGAGCAATGATCTTGATCTTCATTTTTTGGAAA

**BAGR10**

AGCTTTTCCAAAAAATGAAGATCAAGATCATTGCTCAAGACTGAAAC

The oligonucleotides were annealed together, treated with T4 PNK according to the manufacturer's (Promega) protocol and cloning the resultant  
5 mixture into BsmB I / Hind III cleaved pU6.cass that had been treated with SAP as described above.

A map of the construct is shown in Figure 28A and the sequence and predicted structure of the RNA produced by the construct is shown in Figure 28B.

**pU6.ACTB/AD1/GFP/HER2/Lam hp**

10 This construct acts as a control for the five previous constructs. The construct is prepared using the plasmid pU6.ACTB/AD1/GFP/HER2 hp as a substrate by amplifying with the two primers:

U6HMM5

TCAACTGGACTTCCAGAAGAACAACACTACACAAATGTTCTTCTGGAAGTC  
15 CAGCTAATGTCTGTGCCGGTGCACACCTAA

termHGAB5

TGTCTGTGCCGGTGCACACTTGAGATGAACTTCAGGGTCAGCTTGATG  
AACAGGTGGTTTCAGTCTTGAGCAATGATCTTGATCTTCATTTTTTGGAAAAG  
CTTATCG

20 A map of the construct is shown in Figure 29A and the sequence of the predicted RNA produced by the construct is shown in Figure 29B.

**7. Testing the activity of constructs**

To test the activity of constructs targeting Renilla luciferase, plasmids were prepared using Qiagen columns according to the manufacturer's protocol. Plasmid  
25 DNAs were then transfected into HeLa cells that had been previously stably transformed with the construct. pHRLSV40 (Promega). This was done by co-transfection of pHRLSV40 with a selectable marker plasmid encoding hygromycin resistance; techniques to obtain such stably transformed cells are well known to those familiar with the art.

30 3,000 cells (as determined by haemocytometer count) were plated into each well of a 96 well tissue culture plates (Costar) and incubated overnight in



100 ul of DMEM media (Gibco) supplemented with heat inactivated 10% FBS (Gibco). To transfect cells each well was treated as follows:

-0.2 ul or 0.3 ul LT1 transfection reagent (Mirus Corp.) was added to 25 ul serum free media (DMEM) and incubated for 10 mins at room temperature.

5        -100 ng of DNA was added to this mixture and complex formation allowed to proceed for a further 10 mins at room temperature. The entire mixture was then added to a well of transgenic HeLa cells.

- Cells were incubated at 37°C overnight then media removed and 100 ul fresh DMEM 10% FBS added and incubation continued.

10        To determine *Renilla* luciferase activity, media was removed and fresh media containing EnduRen was added according to the manufacturer's (Promega) protocol; cells were then incubated for 5 hrs. *Renilla* luciferase activity was determined using a Veritas Microplate Luminometer according to the manufacturer's (Turner Biosystems) protocols. These values were then corrected  
15 for relative cell numbers which were determined using CellTiter-Glo reagent according to the manufacturer's (Promega) protocols using a Veritas Microplate Luminometer according to the manufacturer's (Turner Biosystems) protocols.

In this fashion the relative activity of individual constructs could be easily and accurately determined, moreover these activities were then corrected using  
20 appropriate negative controls, typically pU6.cass, to determine the relative activities of constructs.

Figure 30 shows the activity of double hairpin constructs targeting *Renilla* luciferase. These data demonstrate that sequences at the base or top of a double hairpin construct both significantly reduce *Renilla* luciferase activity, constructs  
25 were most active when the Rluc sequences were present in the base of the predicted transcript, but significant activity was retained in constructs where Rluc targeting sequences were present in the top of the predicted transcript, adjacent to the loop. This indicates that such a double hairpin construct can produce two active siRNAs and it follows necessarily that constructs may be designed to either  
30 inactivate two genes, or inactivate a single gene more effectively via the additive effect of producing two separate siRNAs targeting separate regions of an individual mRNAs.

Figure 31 shows the activity of triple hairpin constructs targeting *Renilla* luciferase. These data demonstrate that sequences at the base, middle or top of a triple hairpin construct significantly reduce *Renilla* luciferase activity. This indicates that such a triple hairpin construct can produce three active siRNAs and it follows  
 5 necessarily that constructs may be designed to inactivate three genes. Moreover such constructs might be used to inactivate a single gene more effectively via the additive effect of producing three separate siRNAs targeting separate regions of an individual mRNAs.

Figure 32 shows the activity of constructs 4x and 5x constructs targeting  
 10 *Renilla* luciferase. These data demonstrated that sequences at the top of a 4x or 5x construct significantly reduced *Renilla* luciferase activity. This indicates that such constructs can produce four or five active siRNAs and it follows necessarily that constructs may be designed to inactivate four or five genes. Moreover such constructs may be used to inactivate a single gene more effectively via the  
 15 additive effect of producing four or five separate siRNAs targeting separate regions of an individual mRNAs.

## 8. Inactivating two genes with a single construct

To demonstrate that the above strategy can be used to inactivate two endogenous genes a single construct was prepared targeting the Akt1 (site a) and  
 20 Akt2 (sites a and b) genes. This construct, pU6.GF-2, was designed to inactivate two genes, Akt1 and Akt2; sequences were designed based on the data of Jiang ZY, Zhou QL, Coleman KA, Chouinard M, Boese Q, Czech MP (2003). Insulin signalling through Akt/protein kinase B analyzed by small interfering RNA-mediated gene silencing. Proc Natl Acad Sci U S A. 100(13):7569-74. pU6.GF-2  
 25 was prepared using the long range PCR strategy described above using Bgl II linearised pU6.cass lin as a substrate; this was amplified with Pfu Turbo polymerase (Stratagene) using the primers:

G U6F-2

CACAAAGAGGCGCTCGTGGTCCTGGCTAACAGCTTCTCGTGGTCCTGGCGG  
 30 TGTTTCGTCCTTTC

and

G termF-2



TAGGAGGCGCTCGTGGTCCTGGTTGACAGCTTCTCGTGGTCCTGGTTTTTTG  
GAAAAGCTTATCG

A map of the construct is shown in Figure 33A and the sequence of the predicted RNA produced by the construct is shown in Figure 33B.

5 To assay the activity of this construct C2C12 cells were transfected with the plasmid using Lipofectamine 2000 according to the manufacturer's (Invitrogen) protocols. After 48 hrs total proteins were isolated and Akt1 and Akt2 protein levels were determined using Western blots; blots were also probed with a control antibody to ensure even loading. Procedures for these experiments are well  
10 known to those familiar with the art.

Figure 34 shows that the levels of both Akt1 and Akt2 were reduced in cells transfected with pU6.GF-2.

#### 9. Increasing the activity of a construct by targeting two regions of a single gene

15 To demonstrate this approach can be used to increase the activity of constructs the plasmid pU6.GG-4 was prepared. This construct targets the Akt2 gene, target site selection was based on the data of Jiang et al (2003) cited above. Two sites ("a" and "b") within the Akt2 gene were targeted and compared to the activity of the two single hp constructs targeting each sites, these single hp  
20 constructs were named pU6.GG-2 and pU6.GG-3.

The construct pU6.GG-2 was prepared using the long range PCR strategy described above using Bgl II linearised pU6.cass lin as a substrate; this was amplified with Pfu Turbo polymerase (Stratagene) using the primers:

G U6-G2

25 CACAAAGGTGCCCTTGCCGAGGAGTCGGTGTTTCGTCCTTTC

and

G term-G2

TAGGAGGCGCTCGTGGTCCTGGTTTTTTTGAAAAGCTTATCG

A map of the construct is shown in Figure 35A and the sequence of the  
30 predicted RNA produced by the construct is shown in Figure 35B.

The construct pU6.GG-3 was prepared using the long range PCR strategy described above using Bgl II linearised pU6.cass lin as a substrate; this was amplified with Pfu Turbo polymerase (Stratagene) using the primers:

GU6-G3

5 CACAAAGAGGCGCTCGTGGTCCTGGCGGTGTTTCGTCCTTTC

and

G term-G3

TAGGGTGCCCTTGCCGAGGAGTTTTTTGGAAAAGCTTATCG

A map of the construct is shown in Figure 36A and the sequence of the predicted RNA produced by the construct is shown in Figure 36B.

The construct pU6.GG-4 was prepared using the long range PCR strategy as described above using Bgl II linearised pU6.cass lin as a substrate; this was amplified with Pfu Turbo polymerase (Stratagene) using the primers:

G U6-G4

15 CACAAAGAGGCGCTCGTGGTCCTGGCTAAGGTGCCCTTGCCGAGGAGTCGG  
TGTTTCGTCCTTTC

and

G term-G4

TAGGAGGCGCTCGTGGTCCTGGTTGAGGTGCCCTTGCCGAGGAGTTTTTTG  
20 GAAAAGCTTATCG

A map of the construct is shown in Figure 37A and the sequence of the predicted RNA produced by the construct is shown in Figure 37B.

To assay the activity of these constructs C2C12 myoblasts were transfected with the constructs and Akt2 protein levels were determined using quantitative Western blots as described above.

The results of these experiments are shown in Figure 38 which demonstrates that pU6.GG-4 shows increased activity compared to either of the constructs. pU6.GG-2 or pU6.GG-3.

## 10. Double hairpin constructs targeting ADAR and $\beta$ actin



## 10.1 Test constructs

In this example DNA constructs were prepared which were targeted to inactivating the ADAR 1 and ADAR 2 genes (these are also sometimes known as ADARA and ADARB respectively).

- 5 Two plasmids, pU6.ACTB-A hp (Figure 2) and pU6.ACTB-A48 hp (Figure 39) were used. These constructs were designed to inactivate  $\beta$  actin mRNA and were used as controls in the experiments described below, in addition pU6.ACTB-A hp was used as a precursor to generate many of the constructs designed below.

10 A similar strategy to that described above for pU6.ACTB-Ahp was used to prepare the construct pU6.ACTB-A48 hp. In this instance eight oligonucleotides were annealed, namely

ACTB48-9	ACCGTGAAGATCAAGATCATTGCTCCTCCTGA
ACTB48-10	CAATGATCTTGATCTTCA
ACTB48-3	GCGCAAGTACTCCGTGTGGTTCAAGAGA
15 ACTB48-4	CCACACGGAGTACTTGCGCTCAGGAGGAG
ACTB48-5	CCACACGGAGTACTTGCGCTCAGGAGGAGCA
ACTB48-6	TGAGCGCAAGTACTCCGTGTGGTCTCTTGAA
ACTB48-11	AATGATCTTG ATCTTCATTTTTGGAAA
ACTB48-12	AGCTTTTCCAAAAATGAAGATCAAGATCATTGCTCCTCC

- 20 Four partially complementary pairs of oligonucleotides (ACTB48-9 and ACTB48-10, ACTB48-3 and ACTB48-4, ACTB48-5 and ACTB48-6, and ACTB48-11 and ACTB48-12) were annealed, and annealed pairs were themselves annealed through two further cycles of annealing to produce a double-stranded DNA structure compatible with cloning into BsmB 1 / Hind III digested pU6.cass as  
 25 shown diagrammatically in Figure 39. The annealed oligonucleotides were cloned into pU6.cass as described above. This plasmid was expected to express a 48 nt hairpin RNA, with transcription initiating in the human U6 promoter and terminating at the poly T tract in the 3' region of the annealed sequences.

The constructs used in these experiments are described in Table 5.  
 30 Conventional single hp DNA constructs were used as controls. Double hairpin

constructs were prepared and their activity was compared to the control constructs. The control constructs targeted a single gene, the test constructs ("double hairpin" constructs) targeted two genes, one gene targeted by the base of the hairpin sequence, the second by sequences near the loop of the hairpin structure.

**Table 5: Control and "double hairpin constructs used in these experiments.**

Construct designation	Target <sup>a</sup>	"Bubble" sequence
<b>Single hp constructs</b>		
pU6.AD1-A	ADAR 1 site A	na
pU6.AD2-C	ADAR 2 site C	na
pU6.AD2-A	ADAR 2 site A	na
pU6.AD1/2-B	ADAR 1 site <b>B</b> & ADAR 2 site <b>B</b> (single 19 nt hairpin)	na
<b>Double hp constructs</b>		
pU6.AD1&2-A/UU	ADAR 1 site <b>A</b> and ADAR 2 site <b>A</b> (19 nt hairpin targeting each target)	5'-UU-3' 3'-UU-5'
pU6.AD1&2-A/UUA	ADAR 1 site <b>A</b> and ADAR 2 site <b>A</b> (19 nt hairpin targeting each target)	5'-UUA-3' 3'-GUU-5'
pU6.AD1&2-A/UUACAA	ADAR 1 site <b>A</b> and ADAR 2 site <b>A</b> (19 nt hairpin targeting each target)	5'-UUACAA-3' 3'-GUUGUU-5'

<sup>a</sup> mRNA targeted for inactivation

- ADAR 1 site **A** corresponds to positions 1477 to 1497 of GenBank sequence NM\_001111.

10 - ADAR 2 site **C** corresponds to positions 22 to 42 of GenBank sequence HSU82121.

- ADAR 2 site **A** corresponds to positions 2134 to 2154 of GenBank sequence HSU82121.

- ADAR 1 site **A** and ADAR 2 site **A** are completely different sequences.

15 - ADAR1 site **B** and ADAR 2 site **B** are identical sequences present in both the ADAR 1 and ADAR 2 genes ADAR1 site **B** corresponds to positions 2906 to 2927 of GenBank sequence NM\_001111. ADAR2 site **B** corresponds to positions 1174 to 1192 of GenBank sequence HSU82121.



The test constructs were prepared as follows.

### **pU6.AD1-A**

This construct was designed to target ADAR 1 mRNA for inactivation at the ADAR 1 **A** site and acted as a control for the double hairpin constructs which all targeted ADAR1 mRNA at the **A** site with sequences located at the base of the hairpin. The construct was prepared using the long range PCR strategy described above. The plasmid pU6.ACTB-A hp was used as a substrate, this was amplified using Pfu Turbo polymerase (Stratagene) with the primers:

*pU6 ADAR-A Fwd*

10 AGAGATGAACAGGTGGTTTCAGTCTTTTTGGAAAAGCTTATCGATACC

*pU6 ADAR-A Rev*

TGAATGAACAGGTGGTTTCAGTCGGTGTTCGTCCTTTCCACAAG

A map of this construct is shown in Figure 40.

### **pU6.AD2-C**

15 This construct was designed to target ADAR 1 mRNA for inactivation at the ADAR 2 **C** site and acted as a control for the double hairpin constructs which all targeted ADAR2 mRNA at a different site. The construct was prepared using the long range PCR strategy described above. The plasmid pU6.ACTB-A hp was used as a substrate, this was amplified using Pfu Turbo polymerase (Stratagene) with  
20 the primers:

*pU6 ADARB1-A Fwd*

AGAGAGGCTGTGAACAGACGCGCCTTTTTGGAAAAGCTTATCGATACC

*pU6 ADARB1-A Rev*

TGAAGGCTGTGAACAGACGCGCCGGTGTTCGTCCTTTCCACAAG

25 A map of this construct is shown in Figure 41.

### **pU6.AD2-A**

This construct was designed to target ADAR 2 mRNA for inactivation at the ADAR 2 **A** site, and acted as a control for the double hairpin constructs which all targeted ADAR 2 mRNA at the **A** site with sequences located near the loop of the

hairpin structure. The construct was prepared using the long range PCR strategy described above. The plasmid pU6.ACTB-A hp was used as a substrate, this was amplified using Pfu Turbo polymerase (Stratagene) with the primers:

*pU6 ADARB1-C Fwd*

5        3AGAGAAGTGCTGCTGGAACATCATGCTTTTTGGAAAAGCTTATCGATAC  
CG

*pU6 ADARB1-C Rev*

3TGAAAGTGCTGCTGGAACATCATGCGGTGTTTCGTCCTTTCCACAAG

A map of this construct is shown in Figure 42.

#### 10    **pU6.AD1/2-B**

This construct was designed to target both ADAR 1 and ADAR 2 mRNA for inactivation at the ADAR 1 **B** site and the ADAR 2 **B** site. Both ADAR 1 mRNA and ADAR 2 mRNA contain this site, both mRNAs were therefore potentially inactivated by a single hairpin element within the construct. This construct acted  
15 as a control for the double hairpin constructs which all targeted ADAR 1 and/or ADAR 2 mRNAs at different sites. The construct was prepared using the long range PCR strategy described above. The plasmid pU6.ACTB-A hp was used as a substrate, this was amplified using Pfu Turbo polymerase (Stratagene) using the primers:

20        *pU6 ADAR1/2-B Fwd*

AGAGATTATTTCTGCATGGCAGTCATTTTTGGAAAAGCTTATCGATACCG

*pU6 ADAR1/2-B Rev*

3TGAATTATTTCTGCATGGCAGTCGGTGTTTCGTCCTTTCCACAAG

A map of this construct is shown in Figure 43.

25

#### **pU6.AD1&2-A/UU**

This double hairpin construct was designed to inactivate ADAR 1 mRNA at the ADAR 1 **A** site with sequences at the base of the hairpin DNA construct, and ADAR 2 mRNA at the ADAR 2 **A** site with sequences near the loop of the double



hairpin structure. The two structural elements were separated by a two nucleotide “bubble” sequence UU (Figure 44). The construct was prepared using the long range PCR strategy described above. The plasmid pU6.AD1-A was used as a substrate, this was amplified using Pfu Turbo polymerase (Stratagene) using the

5 primers:

*pU6 ADAR 1/2-AA Fwd*

AGAGAGGCTGTGAACAGACGCGCCTTTGAACAGGTGGTTTCAGTCTTT  
TTGGAAAAGC

*pU6 ADAR 1/2-AA Rev*

10 TGAAGGCTGTGAACAGACGCGCCAATGAACAGGTGGTTTCAGTCGGT  
GTTTCGT

A map of this construct is shown in Figure 44.

#### **pU6.AD1&2-A/UUA**

This double hairpin construct was designed to inactivate ADAR 1 mRNA at

15 the ADAR 1 **A** site with sequences at the base of the hairpin DNA construct, and  
ADAR 2 mRNA at the ADAR 2 **A** site with sequences near the loop of the double  
hairpin structure. The two structural elements were separated by a three  
nucleotide “bubble” sequence UUA (Figure 45). The construct was prepared using  
the long range PCR strategy described above. The plasmid pU6.AD1-A was used

20 as a substrate, this was amplified using Pfu Turbo polymerase (Stratagene) using  
the primers:

*pU6ADAR1/2-AA (+1) F*

AGAGAGGCTGTGAACAGACGCGCCTTGTGAACAGGTGGTTTCAGTCT  
TTTTGGAAAAGC

25 *pU6ADAR1/2- AA(+1)R*

TGAAGGCTGTGAACAGACGCGCCTAATGAACAGGTGGTTTCAGTCGG  
TGTTTCGT

A map of this construct is shown in Figure 45.

#### **pU6.AD1&2-A/UUACAA**

This double hairpin construct was designed to inactivate ADAR 1 mRNA at the ADAR 1 **A** site with sequences at the base of the hairpin DNA construct, and ADAR 2 mRNA at the ADAR 2 **A** site with sequences near the loop of the double hairpin structure. The two structural elements were separated by a six nucleotide  
 5 “bubble” sequence UUACAA (Figure 46). The construct was prepared using the long range PCR strategy described above. The plasmid pU6.AD1-A was used as a substrate, this was amplified using Pfx Turbo polymerase (Invitrogen) using the primers:

*pU6ADAR1/2-AA ButF*

10 AGAGAGGCTGTGAACAGACGCGCCTTGTAATGAACAGGTGGTTTCAG  
 TCTTTTTGGAAAAGC

*pU6ADAR1/2-AA ButR*

TGAAGGCTGTGAACAGACGCGCCTTGTAATGAACAGGTGGTTTCAGTC  
 GGTGTTTCG

15 A map of this construct is shown in Figure 46.

## 10.2 Control constructs

The two hairpin DNA constructs, pU6.ACTB-A hp (Figure 2) and pU6.ACTB-A48 hp (Figure 39) were used as controls for non-specific effects of expressing hairpin RNAs. The construct pU6.ACTB-A48 hp was the most  
 20 appropriate control since it expresses a hairpin RNA of very similar size to that expressed by the double hairpin constructs. The ACTB-A sequence targeted by pU6.ACTB-A hp, corresponds to positions 1045-1065 of GenBank sequence NM\_001101. The ACTB-A sequence targeted by pU6.ACTB-A48 hp, corresponds to positions 1045-1094 of GenBank sequence NM\_001101. As an additional  
 25 control the effects of an siRNA targeting the ADAR 1 **B** and ADAR 2 **B** sites was tested using RNA transcribed from T7 promoters. The siRNA was termed siAD1/2-B and was prepared using the oligonucleotides:

*ADAR1/2-B T7 S*

AATGACTGCCATGCAGAAATACCTGTCTC

30 *ADAR1/2-B T7 AS*



AATATTTCTGCATGGCAGTCACCTGTCTC

As an additional control the effects of an siRNA targeting the ACTB-A site was tested using RNA transcribed from T7 promoters. The siRNA was termed siACTB-A and the DNA encoding this siRNA was prepared using the 5 oligonucleotides:

ACTB-A T7 S

AATGAAGATCAAGATCATTGCCCTGTCTC

ACTB-A T7 AS

AAGCAATGATCTTGATCTTCACCTGTCTC

### 10 10.3 Double hairpin constructs targeting $\beta$ actin and ADAR1

Five further constructs, targeting both  $\beta$  actin and ADAR 1 were prepared as outlined in the Table 6 illustrating other embodiments of the invention.

**Table 6: Double hairpin constructs**

Construct	Target <sup>a</sup>	Bubble Sequence
pU6.AD1-A&ACTB-A/UU	ADAR1 site A $\beta$ actin (ACTB-A)	5'-UU-3' 3'-UU-5'
pU6.AD1-A&ACTB-A/UUA	ADAR1 site A $\beta$ actin (ACTB-A)	5'-UUA-3' 3'-GUU-5'
pU6.AD1-A&ACTB-A/UUAG	ADAR1 site A $\beta$ actin (ACTB-A)	5'-UUAG-3' 3'-AGUU-5'
pU6.AD1-A&ACTB-A/UUACAA	ADAR1 site A $\beta$ actin (ACTB-A)	5'-UUACAA-3' 3'-UUAGUU-5'
pU6.ACTB-A&AD1-A/UUA	$\beta$ actin (ACTB-A) ADAR1 site A	5'-UUA-3' 3'-GUU-5'

<sup>a</sup> ACTB-A site corresponds to positions 1045-1065 of NM\_001101.

15 The constructs were prepared using the long range PCR strategy described above.

#### **pU6.ACTB-A/UUA**

This construct was designed to test whether a UUA bubble sequence will 20 enhance the activity of a single hairpin DNA construct having the sequence of

ACTB-A ( $\beta$  actin). The construct is prepared using the plasmid pU6.ACTB-A hp as a substrate by amplifying with the two primers:

ACTADdelR

CTGAAATCTCTTGAATTTTCAGTCTAAGCAATGATCTTGATCTTCACGGT

5 G

ACTADdelF

TCTTGGCAATGATCTTGATCTTCATTTTTGGAAAAGCTTATCGATACCG

TC

A map of this construct is shown in Figure 48.

#### 10 pU6.AD1-A&ACTB-A/UU

This construct was designed to test whether a construct carrying a UU bubble sequence was capable of inactivating two mRNAs, namely ADAR 1 and  $\beta$  actin. The construct was prepared using the plasmid pU6.AD1&2-A/UU as a substrate by amplifying with the two primers:

15 AAR

TCATTGCTCTCTTGAAGCAATGATCTTGATCTTCAAATGAACAGGTGGT  
TTCAGTCGGTG

AAF

TCTTGATCTTCATTTGAACAGGTGGTTTCAGTCTTTTTGGAAAAGCTTA

20 TCGATACCGTC

A map of this construct is shown in Figure 49.

#### pU6.AD1-A&ACTB-A/UUA

This construct was designed to test whether a construct carrying a UUA bubble sequence was capable of inactivating two mRNAs, namely ADAR 1 and  $\beta$  actin. The construct was prepared using the plasmid pU6.AD1&2-A/UU as a substrate by amplifying with the two primers:

AA+1R

TCATTGCTCTCTTGAAGCAATGATCTTGATCTTCATAATGAACAGGTGG  
TTTCAGTCGGTG



AA+1F

TCTTGATCTTCATTGTGAACAGGTGGTTTCAGTCTTTTTGGAAAAGCTT  
ATCGATACCGTC

A map of this construct is shown in Figure 50.

## 5 **pU6.AD1-A&ACTB-A/UUAG**

This construct was designed to test whether a construct carrying a UUAG bubble sequence was capable of inactivating two mRNAs, namely ADAR 1 and  $\beta$  actin. The construct was prepared using the plasmid pU6.AD1&2-A/UU as a substrate by amplifying with the two primers:

10 AA+2R

CATTGCTCTCTTGAAGCAATGATCTTGATCTTCACTAATGAACAGGTGG  
TTTCAGTCGGTG

AA+2F

ATCTTGATCTTCATTGATGAACAGGTGGTTTCAGTCTTTTTGGAAAAGC  
15 TTATCGATACCGTC

A map of this construct is shown in Figure 51.

## **pU6.AD1-A&ACTB-A/UUACAA**

This construct was designed to test whether a construct carrying a UUACAA bubble sequence was capable of inactivating two mRNAs, namely  
20 ADAR 1 and  $\beta$  actin. The construct was prepared using the plasmid pU6.AD1&2-A/UU as a substrate by amplifying with the two primers:

AABR

CATTGCTCTCTTGAAGCAATGATCTTGATCTTCATTGTAATGAACAGGT  
GGTTTCAGTCGGTG

25 AABF

ATCTTGATCTTCATTGTAATGAACAGGTGGTTTCAGTCTTTTTGGAAAA  
GCTTATCGATACCGTC

A map of this construct is shown in Figure 52.

## **pU6.ACTB-A&AD1-A/UUA**

This construct was designed to test whether a construct carrying a UUA bubble sequence was capable of inactivating two mRNAs, namely  $\beta$  actin and ADAR 1. The construct differed from the construct pU6.AD1-A&ACTB-A/UUA in that the relative positions of the AD1-A and ACTB-A differed. The construct was prepared using the plasmid pU6.ACTB-A hp as a substrate by amplifying with the two primers:

ACTADR

TGTTTCATCTCTTGAATGAACAGGTGGTTTCAGTCTAAGCAATGATCTTG  
ATCTTCACGGTG

10 ACTADF

GGTGGTTTCAGTCTTGGCAATGATCTTGATCTTCATTTTTGGAAAAGCT  
TATCGATACCGTC

A map of this construct is shown in Figure 53. Figure 54 shows the predicted structure of hairpin RNAs produced by the double hairpin constructs targeting ADAR 1 and  $\beta$  actin.

#### 10.4 Tissue culture

HeLa cells were grown and maintained in tissue culture using known procedures. To transfect HeLa cells, 200,000 cells were plated in each well of a 6 well tissue culture plate. After overnight incubation cells were transfected with either siRNAs or plasmid DNAs. siRNAs were transfected using Oligofectamine according to manufacturer's (Invitrogen) protocol. Plasmid DNAs were transfected into cells using PolyFect according to manufacturer's (Qiagen) protocol. Cells were incubated for 48 hrs following transfection and total RNAs were isolated for analysis of ADAR1, ADAR 2 and/or  $\beta$  actin mRNA levels.

#### 25 10.5 RNA preparation and analysis using Quantitative Real Time PCR and Northern blot assays

Total RNAs were prepared using QIAGEN RNeasy mini columns according to the manufacturer's protocol. To remove DNase contamination samples were treated with DNase according to the manufacturer's (Qiagen) protocol. Poly A<sup>+</sup> RNA was prepared using DYNAL Dynabeads® mRNA DIRECT™ Micro Kit according to the manufacturer's (DYNAL) protocol. Levels of ADAR 1 and ADAR



2 mRNAs were determined using Quantitative Real Time PCR assays. Three duplicate assays were performed for each RNA sample using SYBR green incorporation to determine relative mRNA levels. The reactions and analyses were performed using procedures widely known to those skilled in the art.

5 Quantitative Northern blot analyses were used to determine levels of  $\beta$  actin mRNA, and thereby quantify  $\beta$  actin inactivation. Northern blots of total RNAs isolated from cells were probed with a fragment specific to the 3' UTR of  $\beta$  actin mRNA, prepared using PCR of total HeLa cell RNA, and the degree of hybridization quantified using a phosphoimager. To correct for unequal loading,  
10 Northern filters were stripped then reprobed with a PCR fragment corresponding to human GAPDH and the degree of hybridization also quantified using a phosphoimager.  $\beta$  actin mRNA levels in individual RNA samples were then normalized to GAPDH levels and the relative levels of  $\beta$  actin between experimental treatments were determined. The methodologies and procedures  
15 used for these analyses are widely known to those skilled in the art.

#### **10.6 Double hairpin constructs can simultaneously inactivate two genes and can show enhanced activity**

In Figure 55, the graph shows the relative ADAR 1 mRNA levels in cells transfected with various DNA constructs and siRNAs. All data were normalized to  
20 ADAR 1 mRNA levels determined in cells transfected with pU6.ACTB-A48 hp, since this construct produced a hairpin RNA most similar to the double hp constructs. White bars represent ADAR 1 mRNA levels in HeLa cells and in HeLa cells transfected with various non-specific controls. The constructs pU6.ACTB-A hp and pU6.AD2-C had relatively minor effects on ADAR 1 mRNA levels. The  
25 construct pU6.AD2-A (the stippled box) which targeted ADAR 2 reduced ADAR 1 mRNA levels; this result might be artefactual but could reflect genuine reductions in ADAR 1 mRNA, since 17/21 nucleotides of the ADAR 2-A site are shared in the ADAR 1 sequence. The horizontally stippled bars represent relative ADAR 1 mRNA levels in HeLa cells transfected with siRNA controls. ACTB-A siRNA had a  
30 moderate, non-specific effect on ADAR 1 mRNA levels, whilst siAD1/2-B dramatically reduced ADAR 1 mRNA. The grey bars represent relative ADAR 1 mRNA levels in HeLa cells transfected with the DNA constructs pU6.AD1-A and pU6.AD1/2-B. Both constructs target ADAR 1 mRNA for degradation, and both



reduced ADAR 1 mRNA levels markedly. The black bars represent relative ADAR 1 mRNA levels in HeLa cells transfected with the double hairpin DNA constructs, pU6.AD1&2/UU, pU6.AD1&2/UUACAA and pU6.AD1&2/UUA. Both pU6.AD1&2/UUACAA and pU6.AD1&2/UUA markedly reduced ADAR 1 mRNA levels. Most significantly the construct pU6.AD1&2/UUA shows increased activity compared to the control pU6.AD1-A. The construct pU6.AD1&2/UU showed no activity against ADAR 1 mRNA. These data indicated that the inclusion of a small bubble sequence in a hairpin DNA construct enhanced the activity of a DNA construct, either in the context of a single construct or a double hairpin construct.

In Figure 56, the graph shows the relative ADAR 2 mRNA levels in cells transfected with various DNA constructs and siRNAs. All data were normalized to ADAR 2 mRNA levels determined in cells transfected with pU6.ACTB-A48 hp, since this construct produced a hairpin RNA most similar to the double hp constructs. White bars represent ADAR 2 mRNA levels in HeLa cells and in HeLa cells transfected with various non-specific controls. The constructs pU6.ACTB-A hp and pU6.AD1-A have relatively minor effects on ADAR 2 mRNA levels. The horizontally stippled bars represent relative ADAR 1 mRNA levels in HeLa cells transfected with siRNA controls. ACTB-A siRNA had a moderate, non-specific effect on ADAR 1 mRNA levels, whilst siAD1/2-B dramatically reduced ADAR 1 mRNA. The grey bars represent relative ADAR 2 mRNA levels in HeLa cells transfected with the DNA constructs pU6.AD2-C, pU6.AD2-A and pU6.AD1/2-B. The construct pU6.AD2-C has no effect on ADAR 2 mRNA levels, whilst pU6.AD2-A and pU6.ACT1/2-B reduced ADAR 2 mRNA to a moderate degree. The black bars represent relative ADAR 1 mRNA levels in HeLa cells transfected with the double hairpin DNA constructs. The construct pU6.AD1&2/UU showed no activity against ADAR 2 mRNA, as was the case with ADAR 1 mRNA. Both the constructs pU6.AD1&2/UUACAA and pU6.AD1&2/UUA moderately reduced ADAR 2 mRNA levels to a similar degree to that seen for pU6.AD2-A and pU6.AD1/2-B. These data indicated that a short hairpin sequence adjacent to the loop sequence can inactivate a second gene in the context of at least two of the bubble sequences we tested.

Figure 57 shows the relative levels of ADAR1 mRNA in cells transfected with various DNA constructs. All data were normalized to cells transfected with



pU6.ACTB-A hp which was used as a non-specific control in this experiment. The grey bar shows that construct pU6.AD1-A had a moderate effect on ADAR 1 mRNA levels, similar to that seen in Figure 55. The constructs pU6.AD1-A&ACTB-A/UU, pU6.AD1-A&ACTB-A/UUA, pU6.AD1-A&ACTB-A/UUAG, pU6.AD1-A&ACTB-A/UU ACAA and pU6.ACTB-A&AD1/UUA all resulted in reductions in ADAR 1 mRNA levels, the construct pU6AD1-A&ACTB-A/UUAG showed the highest activity. These data demonstrated that ADAR 1 sequences in the context of a double hairpin can inactivate ADAR1 mRNA.

Figure 58 shows the relative levels of  $\beta$  actin mRNA in cells transfected with various DNA constructs, as determined by quantitative Northern blot analyses. In this instance all data are normalized to the construct pU6.AD1&2-A/UUA. Various non-specific controls (pU6.Ad1-A, pU6.AD1&2-A/UU, pU6.AD1&2-A/UUA and pU6.AD1&2-A/UUACAA) showed essentially no effect on  $\beta$  actin mRNA levels. Cells transfected with the construct pU6.ACTB-A hp showed an approximately 30% reduction in  $\beta$  actin mRNA levels. Cells transfected with the constructs pU6.AD1-A&ACTB-A/UU, pU6.AD1-A&ACTB-A/UUA, pU6.AD1-A&ACTB-A/UUAG, pU6AD1-A&ACTB-A/UUACAA and pU6.ACTB-A&AD1/UUA all showed reductions in the levels of  $\beta$  actin mRNA, the construct pU6.AD1-A&ACTB-A/UUAG showed the highest activity. These data demonstrated that  $\beta$  actin sequences in the context of a double hairpin can inactivate  $\beta$  actin mRNA. These data combined with the results shown in Figure 57 demonstrate that a double hairpin construct can simultaneously inactivate two genes.

#### **11. Increasing the activity of double hairpin constructs by screening random libraries of "bubble" sequences**

To define sequences that may increase the activity of double and higher order hairpin constructs, a series of libraries are prepared containing randomised sequences in regions of the hp RNAs that might be predicted to be sites for Dicer processing.

The base construct for these experiments is the construct pU6.GR-21. This was prepared using the oligonucleotide annealing strategy described above, using the primers:

LGR-1      ACCGCTGACCCTGAAGTTCATCCTGGCCTTTC

	LGR-2	GGAGTAGTGAAAGGCCAGGATGAACTTCAGGGTCAG
	LGR-3	ACTACTCCTACTTTGTGTAGGT
	LGR-4	ACTACTCCTACCTACACAAAGTA
	LGR-5	AGGAGTAGTGAAAGGCCAGGATGAACTTC
5	LGR-6	CTGACCCTGAAGTTCATCCTGGCCTTTC
	LGR-7	AGGGTCAGCTTTTTTTGGAAA
	LGR-8	AGCTTTTCCAAAAAAG

A map of the construct is shown in Figure 59A and the sequence of the predicted RNA produced by the construct is shown in Figure 59B.

10 The library constructs described below all contain identical sequences targeting *Renilla* luciferase at the top position of the double hairpin construct. By comparing the activity of individual clones from the library against *Renilla* luciferase as described above to the activity of pU6.GR-21 sequences of bubbles showing enhanced activity might be determined. Based on such data, generalised  
15 design rules to enhance the activity of double, and higher order, hairpin constructs may be developed.

#### **pU6.GR-21-1-2N**

This construct series was prepared using the oligonucleotide assembly strategy described above. Libraries were prepared using the oligonucleotides:

20	LGR-1-2N	ACCGCTGACCCTGAAGTTCATCCNNGCCTTTC
	LGR-2-2N	GGAGTAGTGAAAGGCNNGGATGAACTTCAGGGTCAG
	LGR-3	ACTACTCCTACTTTCAGTAGGT
	LGR-4	ACTACTCCTACCTACACAAAGTA
	LGR-5	AGGAGTAGTGAAAGGCCAGGATGAACTTC
25	LGR-6	CTGACCCTGAAGTTCATCCTGGCCTTTC
	LGR-7	AGGGTCAGCTTTTTTTGGAAA
	LGR-8	AGCTTTTCCAAAAAAG



In this instance **N** denotes any nucleotide. A map of such constructs is shown in Figure 60A and the sequence of the predicted RNA produced by the construct is shown in Figure 60B.

#### **pU6.GR-21-4-2N**

5 This construct series was prepared using the oligonucleotide assembly strategy described above. Libraries were prepared using the oligonucleotides:

LGR-1	ACCGCTGACCCTGAAGTTCATCCTGGCCTTTC
LGR-2	GGAGTAGTGAAAGGCNNGGATGAACTTCAGGGTCAG
LGR-3	ACTACTCCTACTTTGTGTAGGT
10 LGR-4	ACTACTCCTACCTACACAAAGTA
LGR-5-2N	AGGAGTAGTGAAAGGCCANNATGAACTTC
LGR-6-2N	CTGACCCTGAAGTTCATNNTGGCCTTTC
LGR-7	AGGGTCAGCTTTTTTTGGAAA
LGR-8	AGCTTTTCCAAAAAAG

15 In this instance **N** denotes any nucleotide. A map of such constructs is shown in Figure 61A and the sequence of the predicted RNA produced by the construct is shown in Figure 61B.

#### **pU6.GR-21-1&4-2N**

20 This construct series may be prepared using the oligonucleotide assembly strategy described above. Libraries may be prepared using the oligonucleotides:

LGR-1-2N	ACCGCTGACCCTGAAGTTCATCCNNGCCTTTC
LGR-2-2N	GGAGTAGTGAAAGGCNNGGATGAACTTCAGGGTCAG
LGR-3	ACTACTCCTACTTTGTGTAGGT
LGR-4	ACTACTCCTACCTACACAAAGTA
25 LGR-5-2N	AGGAGTAGTGAAAGGCCANNATGAACTTC
LGR-6-2N	CTGACCCTGAAGTTCATNNTGGCCTTTC
LGR-7	AGGGTCAGCTTTTTTTGGAAA
LGR-8	AGCTTTTCCAAAAAAG

In this instance **N** denotes any nucleotide. A map of such constructs is shown in Figure 62A and the sequence of the predicted RNA produced by the construct is shown in Figure 62B.

### **pU6.GR22-1-4N**

- 5 This construct series may be prepared using the oligonucleotide assembly strategy described above. In this instance random oligonucleotides are not used, rather three nucleotides which are incapable of base pairing in the predicted hpRNA are incorporated synthetically. To generate the constructs, the oligonucleotides GR5-22, GR6-22, GR7 and GR8 are annealed together with:

10	GR22-1-4N-1	ACCGCTGACCCTGAAGT
	GR22-1-4N-2	AGTGAAAGGDDDBHAGATGAACTTCAGGGTCAG
	GR22-1-4N-3	TCATCTDVHHCCTTTCACTACTCCTACTTTGTG
	GR22-1-4N-4	CTCCTACCTACACAAAGTAGGAGT

- 15 In this instance, D denotes A,G or T; B denotes C,G or T; H denotes A,C or T and V denotes A,C or G. A map of such constructs is shown in Figure 63A and the predicted sequence and structure of hpRNAs produced from such constructs is shown in Figure 63B.

### **pU6.GR22-1-4N**

- 20 This construct series may be prepared using the oligonucleotide assembly strategy described above. In this instance random oligonucleotides are not used, rather three nucleotides which are incapable of base pairing in the predicted hpRNA are incorporated synthetically. To generate the constructs, the oligonucleotides GR1, GR2-22, GR3-22, GR4, GR7 and GR8 are annealed  
25 together with:

	GR22-4-4N-5	TAGGTAGGAGTAGTGAAAGGDDDBHAGATGAA
	GR22-4-4N-6	ACCCTGAAGTTCATCTDVHHCCTTTCACTA

- 30 In this instance, D denotes A,G or T; B denotes C,G or T; H denotes A,C or T and V denotes A,C or G. A map of such constructs is shown in Figure 63C and the predicted sequence and structure of hpRNAs produced from such constructs is shown in Figure 63D.

### **PU6.GR22-1-NAAN**



This construct series may be prepared using the oligonucleotide assembly strategy described above. In this instance random oligonucleotides may be incorporated to screen for sequences that may augment the optimal AA sequence identified previously. To generate the constructs, the oligonucleotides GR22-1-4N-1, GR2-1-4N-4, GR5-22, GR6-22, GR7 and GR8 are annealed together with:

GR22-1-NAAN-2 AGTGAAAGGNTTNAGATGAACTTCAGGGTCAG

GR22-1-NAAN-3 TCATCTNAANCCTTTCACTACTCCTACTTTGTG

In this instance N denotes any nucleotide. A map of such constructs is shown in Figure 64A and the predicted sequence and structure of hpRNAs produced from such constructs is shown in Figure 64B.

#### **PU6.GR22-4-NAAN**

This construct series may be prepared using the oligonucleotide assembly strategy described above. In this instance random oligonucleotides may be incorporated to screen for sequences that might potentially augment the optimal AA sequence defined previously.

To generate the constructs, the oligonucleotides GR1, GR2-22, GR3-22, GR4, GR7 and GR8 are annealed together with:

GR22-4-NAAN-5 TAGGTAGGAGTAGTGAAAGGNAANAGATGAA

GR22-4-NAAN-6 ACCCTGAAGTTCATCTNTTNCCTTTCACTA

In this instance N denotes any nucleotide. A map of such constructs is shown in Figure 64C and the predicted sequence and structure of hpRNAs produced from such constructs is shown in Figure 64D.

#### **pU6.GR21-1&4-4N**

This construct series may be prepared using the long range PCR strategy described above. In this instance random oligonucleotides are not used, rather three nucleotides which are incapable of conventional base pairing in the predicted hp RNA are incorporated. The oligonucleotides suitable for use in these experiments are:

LU6GR-21-4N

CACAAAGTAGGAGTAGTGAAAGGDDBHGATGAACTTCAGGGTCAGCG  
GTGTTTCGTCCTTTC

and

5 LtermGR-21-4N

TAGGTAGGAGTAGTGAAAGGCCBHHBTGAACTTCAGGGTCAGCTTTTT  
TGGAAAAGCTTATCG

In this instance, D denotes A,G or T; B denotes C,G or T, H denotes A,C or  
T and V denotes A,C or G. A map of such constructs is shown in Figure 65A and  
10 the sequence of the predicted RNA produced by the construct is shown in Figure  
65B.

## 12. Phasing constructs

Based on the model whereby Dicer processes from the base of an  
15 expressed hpRNA, the actual distance (in nucleotides) between dicer cuts  
becomes a critical factor in designing multi-constructs to obtain maximum activity,  
since this "phasing" of Dicer processing will be critical in precisely defining the  
sequence of effector siRNAs produced from a hpRNA. To determine the optimal  
phasing a series of constructs were prepared which were designed to express  
20 variable lengths of EFGP effector sequences at the base of a double hairpin  
construct and constant sequences at the top, targeting *R/luc*.

The constructs were prepared using the oligonucleotide assembly strategy  
and cloned into *BsmBI* / *Hind* III digested pU6.cass as described above. The  
constructs and oligonucleotides used to prepare the constructs were:

25

### pU.GR-17 hp

	GR1	ACCGCTGACCCTGAAGTTC
	GR2-17	GAAAGGCCAGAACTTCAGGGTCAG
	GR3-17	TGGCCTTTCACTACTCCTACTTTGTG
30	GR4	CTCCTACCTACACAAAGTAGGAGTAGT
	GR5-17	TAGGTAGGAGTAGTGAAAGGCCAGAA
	GR6-17	ACCCTGAAGTTCTGGCCTTTCACT



GR7 CTTCAGGGTCAGCTTTTTTGGAAA  
GR8 AGCTTTTCCAAAAAAGCTG

**pU.GR-18 hp**

5 GR1, GR4, GR7, GR8 and:

GR2-18 GAAAGGCCATGAACTTCAGGGTCAG  
GR3-18 ATGGCCTTTCACTACTCCTACTTTGTG  
GR5-18-2 TAGGTAGGAGTAGTGAAAGGCCATGAA  
GR6-18-2 ACCCTGAAGTTCATGGCCTTTCACTA

10

**pU6.GR-19 hp**

GR1, GR4, GR7, GR8 and:

GR2-19 GAAAGGCCAATGAACTTCAGGGTCAG  
GR3-19 ATTGGCCTTTCACTACTCCTACTTTGTG  
15 GR5-19 TAGGTAGGAGTAGTGAAAGGCCAGTGAA  
GR6-19 ACCCTGAAGTTCACTGGCCTTTCACTA

**pU6.GR-20 hp**

GR1, GR4, GR7, GR8 and:

20 GR2-20 GAAAGGCCAGATGAACTTCAGGGTCAG  
GR3-20 ATCTGGCCTTTCACTACTCCTACTTTGTG  
GR5-20 TAGGTAGGAGTAGTGAAAGGCCAGATGAA  
GR6-20 ACCCTGAAGTTCATCTGGCCTTTCACTA

25

**pU6.GR-21 hp**

GR1, GR4, GR7, GR8 and:

GR2-21 GAAAGGCCAGGATGAACTTCAGGGTCAG  
GR3-21 ATCCTGGCCTTTCACTACTCCTACTTTGTG  
GR5-21 TAGGTAGGAGTAGTGAAAGGCCAGGATGAA  
30 GR6-21 ACCCTGAAGTTCATCCTGGCCTTTCACTA

**pU6.GR-22 hp**

GR1, GR4, GR7, GR8 and:

GR2-22 GAAAGGCCAGAGATGAACTTCAGGGTCAG

GR3-22 ATCTCTGGCCTTTCACTACTCCTACTTTGTG  
 GR5-22 TAGGTAGGAGTAGTGAAAGGCCAGAGATGAA  
 GR6-22 ACCCTGAAGTTCATCTGCTGGCCTTTCACTA

5 **pU6.GR-23 hp**

GR1, GR4, GR7, GR8 and:

GR2-23 GAAAGGCCAGCAGATGAACTTCAGGGTCAG  
 GR3-23 ATCTGCTGGCCTTTCACTACTCCTACTTTGTG  
 GR5-23 TAGGTAGGAGTAGTGAAAGGCCAGCAGATGAA  
 10 GR6-23 ACCCTGAAGTTCATCTGCTGGCCTTTCACTA

**pU6.GR-24 hp**

GR1, GR4, GR7, GR8 and:

GR2-24 GAAAGGCCAGGCAGATGAACTTCAGGGTCAG  
 15 GR3-24 ATCTGCCTGGCCTTTCACTACTCCTACTTTGTG  
 GR5-24 TAGGTAGGAGTAGTGAAAGGCCAGGCAGATGAA  
 GR6-24 ACCCTGAAGTTCATCTGCCTGGCCTTTCACTA

**pU6.GR-25 hp**

20 GR1, GR4, GR7, GR8 and:

GR2-25 GAAAGGCCAGTGCAGATGAACTTCAGGGTCAG  
 GR3-25 ATCTGCACTGGCCTTTCACTACTCCTACTTTGTG  
 GR5-25 TAGGTAGGAGTAGTGAAAGGCCAGTGCAGATGAA  
 GR6-25 ACCCTGAAGTTCATCTGCACTGGCCTTTCACTA

25

**pU6.GR-26 hp**

GR1, GR4, GR7, GR8 and:

GR2-26 GAAAGGCCAGGTGCAGATGAACTTCAGGGTCAG  
 GR3-26 ATCTGCACCTGGCCTTTCACTACTCCTACTTTGTG  
 30 GR5-26 TAGGTAGGAGTAGTGAAAGGCCAGGTGCAGATGAA  
 GR6-26 ACCCTGAAGTTCATCTGCACCTGGCCTTTCACTA

Examples of phasing constructs are shown in Figure 66. The sequence and predicted structure of the hpRNAs produced by these constructs are shown in Figure 67.



These constructs were transformed into transgenic *Rluc*-expressing HeLa cells and *Rluc* activity determined as described above. Results of these experiments are shown in Figure 68. Note that the constructs pU6.GR-21 hp show the greatest activity. Phasing of 21, or preferably 22 nt is therefore optimal for multiple hpRNAs.

### 13. Screening 2N libraries

Plasmid DNAs from randomly picked clones from the pU6.GR-21-1-2N and pU6.GR-21-4-2N libraries were prepared and screened for activity against *Rluc* in transgenic HeLa cells as described above.

A total of 22 clones from the pU6.GR-21-4-2N library were screened in this fashion. None of these clones showed increased activity (Data not shown).

A total of 38 clones from the pU6.GR-21-1-2N library were screened in this fashion. Data from 22 clones are shown in Figure 69A. In this experiment the activity of these clones was compared to a control pU6.ACTB *Rluc* TTA, however the activity of this clone was considered to be unusually high in this particular experiment. Consequently, the activity of the three best clones was retested, results are shown in Figure 69B. The data demonstrate that the clone pU6.GR-21-1-2N-18 showed enhanced activity compared to the most appropriate control, pU6.GR-21 hp and these data are confirmed in Figure 69B.

Upon sequencing it was shown that pU6.GR-21-1-2N-18 had the sequence AA between positions 21 and 22 of the predicted hpRNA.

### 14. Inactivation of multiple genes using constructs containing multiple transcriptional units

An alternative approach to inactivating multiple genes, is to express multiple transcripts from a single construct. An example of such a construct is shown in Figure 71.

This construct pU6.GF-3 (Figure 71D) may be prepared from two precursors, pU6.GL (Figure 71A) and pU6 GG-4 (Figure 33 and Figure 71C). pU6.GL targets murine Akt1 at the same region of Akt1 as the double construct pU6.GF-2 shown in Figure 33. pU6.GL is made using the long range PCR strategy described above; Bgl II, SAP-treated pU6.cass lin is amplified using the primers:

U6 GL CACAAACAGCTTCTCGTGGTCCTGGCGGTGTTTCGTCCTTTC

term GL TAGCAGCTTCTCGTGGTCCTGGTTTTTTGGAAAAGCTTATCG

A map of a portion of pU6.GL is shown in 71A, the positions of Sma I and Kpn I cloning sites in the plasmid are also shown. The predicted transcript  
 5 produced from this plasmid is shown in Fig. 71 B. pU6.GF-3 may be prepared by cloning the U6 transcriptional unit from pU6.GL as a Sma I / Kpn I fragment into Hinc II / Kpn I digested pU6.GG-4 to produce pU6.GF-3. pU6.GF-3 will contain two U6 transcriptional units as shown in Figure 71D, and is designed to express two separate hairpin RNAs, one targeting Akt1, the other targeting Akt2. The activity of  
 10 this construct may be determined as described above (Example 8).

### 15. Constructs targeting HCV

One disease state that may be treated with the multiple target interfering RNA nucleic acid constructs of the present invention is hepatitis C virus (HCV) infection. Based on statistics compiled from the Centers for Disease Control and  
 15 Prevention, almost 2% of the American population (nearly 4 million people) is currently infected with HCV. Initially, the majority of the individuals infected with HCV exhibit no symptoms; however, greater than 80% will develop chronic and progressive liver disease eventually leading to cirrhosis or hepatocellular carcinomas. HCV is the leading indication for liver transplantation within the  
 20 United States and results in the death of 8,000 to 10,000 Americans every year. On a global level, the World Health Organization estimates that there are more than 170 million affected individuals, with infection rates as high as 10-30% of the general population in some countries.

HCV is a positive-sense single stranded enveloped RNA virus belonging to  
 25 the Flaviviridae family. The infectious cycle of HCV typically begins with the entry of the viral particle into the cell by receptor-mediated binding and internalization. After uncoating in the cytoplasm, the positive strand of RNA that comprises the genome can interact directly with the host cell translational machinery. Lacking 5' cap methylation, the RNA forms an extensive secondary structure in the 5' untranslated Region (UTR) that serves as an internal ribosomal entry site (IRES)  
 30 and permits the direct binding of the 40S subunit as the initiating step of the translation process.



The HCV genome, approximately 9600 nucleotides in length, encodes a single long open reading frame termed the polyprotein. Viral proteins are produced as linked precursors from the polyprotein which is subsequently cleaved into mature products by a wide variety of viral and cellular enzymes. Encoded  
5 amongst the genes are the structural proteins, including the core and envelope glycoproteins, so named because they are integral structural components in progeny virions. Non-structural proteins, which provide indispensable functions such as the RNA dependent RNA polymerase, are also produced. The viral replication machinery is established within the cytoplasm of infected cells that  
10 transcribe the positive-sense RNA into a negative strand intermediate. Thus, the HCV genomic RNA serves as both a template for its own replication and as a messenger RNA for translation of the virally encoded proteins. The negative strand is transcribed back into a positive strand of RNA, thereby amplifying the number of positive strand copies within the cell. At this stage, the positive strand  
15 can interact with the host cell translational machinery once again or, if there have been enough structural proteins accumulated, be packaged into virions. Following egress from the cell, the virus repeats its infectious cycle.

Although many of the individual steps of HCV replication are understood, until recently there was no tissue culture system that propagated the viral life  
20 cycle, making studies of the virus difficult. However, an in vitro replicon system has been developed (see, e.g., US Pat. Nos. 5,585,258; 6,472,180; and 6,127,116 to Rice, et al.). A replicon is an autonomously replicating portion of HCV genomic RNA containing a marker gene for selection and verification of replication. HCV-RNA constructs are transfected into cell lines that are amenable to support  
25 continuous propagation. Following the steps of the infectious cycle, the RNA is translated by the cellular machinery and produces the appropriate viral proteins required for replication of the genome are produced, as is the selectable marker. Full-length and sub-genomic replicons have been generated and shown to be functional, although only the non-structural proteins are obligate. The  
30 autonomously replicating properties of the RNA remain independent of expression of the structural genes. Even when present in replicons expressing the full length HCV genome, the core and envelope proteins fail to effectively package the genome into infectious particles, resulting in the loss of a model system to study



the packaging, egress and re-entry steps of the virus. Regardless, the replicon is able to recreate a portion of the biology and mechanisms utilized by HCV.

**Development of an AAV-2 expression vector for in vivo delivery of interfering RNA according to the present invention**

5 Before the delivery of interfering RNA nucleic acid constructs according to the present invention by infectious particles is tested, the appropriate expression plasmid is constructed and validated. AAV-2 vectors which have been gutted of rep and cap provide the backbone (hereinafter referred to as the rAAV vector) for the viral interfering RNA nucleic acid construct. This vector has been extensively  
10 employed in AAV studies and the requirements for efficient packaging are well understood. The U6 and H1 promoters may be used for the expression of interfering RNA according to the present invention, though there have been reports of vastly different levels of inhibition of an identical interfering RNA driven independently by each promoter. However, vector construction is such that  
15 promoters can be easily swapped if such variation is seen.

As with virtually any viral delivery system, the rAAV vector must meet certain size criteria in order to be packaged efficiently. In general, an rAAV vector must be 4300-4900 nucleotides in length (McCarty, et al. Gene Ther. 8: 1248-1254 (2001)). When the rAAV vector falls below the limit, a 'stuffer' fragment must  
20 be added (Muzyczka, et al. Curr. Top. Microbiol. Immunol. 158: 970129 (1992)). In the AAV vector embodiment described here, one or more selectable marker genes may be engineered into the rAAV interfering RNA nucleic acid construct in order to assess the transfection efficiency of the rAAV interfering RNA nucleic acid construct as well as allow for quantification of transduction efficiency of target cells  
25 by the rAAV interfering RNA nucleic acid construct delivered via infectious particles.

The initial test expression construct drives expression of interfering RNAs designed from sequences with demonstrated ability to inhibit luciferase activity from a reporter construct (see, Elbashir, et al. Embo. J. 20(23): 6877-6888  
30 (2001)). A commercially available expression plasmid that encodes for the production of luciferase functions as the reporter to verify the ability of the various interfering RNAs to downregulate the target sequences.



Although the interfering RNAs against luciferase have been previously validated, the efficacy of rAAV-delivered interfering RNAs is assessed in vitro prior to testing the construct in vivo. The test and reporter constructs are transfected into permissive cells utilizing standard techniques. An rAAV expression construct  
5 in which the luciferase-specific RNAi agent has been replaced by an unrelated RNA sequence is utilized as a negative control in the experiments. The relative percentage of transfection efficiency is estimated directly by assessing the levels of the selective marker using fluorescence microscopy. For assessing inhibitory activity of each different RNAi agent, luciferase activity is measured utilizing  
10 standard commercial kits. Alternatively, quantitative real time PCR analysis (Q-PCR) is run on RNA that is harvested and purified from parallel experimental plates. Activity decreases greater than about 70%, relative to the activity recovered in lysates from cells treated with the unrelated RNA species, are an indication that the RNAi agent is functional.

15 Subsequent experiments are performed in order to assess the effects of interfering RNAs on a luciferase reporter system that is transfected into the livers of mice, similar to the work of McCaffrey et al. in *Nature*, 418: 38-39 (2002). Nucleic acids delivered to mice by hydrodynamic transfection methods (high pressure tail vein injection) primarily localized to the livers. Much like the principle  
20 which governs co-transfection in cell culture, simultaneous injection of multiple plasmids from a mixture often permits the penetrance of all of the expression constructs into the same cell. Thus, even though the tail vein injection procedures are well documented to only transfect 5-40% of the hepatocytes within the liver (McCaffrey, et al. *Nature Biotech.* 21(6): 639-644 (2003)), co-injection permits  
25 delivery of the reporter system and the expression construct into the same cells.

The rAAV nucleic acid construct bearing the interfering RNA targeted against luciferase is co-injected with the reporter construct that encodes for the luciferase gene. In animals receiving the negative control, an expression construct bearing an unrelated RNA is co-injected with the reporter construct.  
30 After seven days, the mice are sacrificed and the livers harvested. Luciferase activity is measured on lysates generated from a portion of the liver. Remaining portions of the liver are utilized for Q-PCR measurements as well as histological analysis to determine marker protein expression for normalization of the data.



Alternative methods to assess transfection efficiency may include ELISA measurements of serum from mice that have been co-injected with a third marker plasmid for a secreted protein such as human  $\alpha$ 1-antitrypsin (hAAT) (Yant, et al. Nature Genetics. 25: 35-41 (2000), see also McCaffrey, et al. Nature Biotech. 5 21(6): 639-644 (2003)).

Once it is established that the nucleic acid construct is functional in both in vitro cell culture systems as well as in vivo mouse models by utilizing co-transfection of the naked DNA plasmids, testing is initiated on the rAAV expression construct packaged into infectious particles. The infectious particles 10 are produced from a commercially available AAV helper-free system that requires the co-transfection of three separate expression constructs containing 1) the rAAV nucleic acid construct expressing the interfering RNA against luciferase (flanked by the AAV ITRs); 2) the construct encoding the AAV rep and cap genes; and 3) an expression construct comprising the helper adenovirus genes required for the 15 production of high titer virus. Following standard purification procedures, the viral particles are ready for use in experiments.

Before mice can be infused with the rAAV particles, a reporter system is established in the mouse livers. Hydrodynamic transfection is employed to deliver the luciferase reporter construct as well as an expression plasmid for hAAT to 20 control for differences in transfection efficiencies from animal to animal. The mice are permitted to recover for several days in order to establish sufficient levels of reporter activity. After luciferase reporter activity has been established in the livers, AAV particles are infused into normal C57B1/6 mice either through portal vein or tail vein injection. AAV particles bearing the expression construct of an 25 unrelated RNA are used as a negative control. Initially, the mice are infused with relatively high doses ( $2 \times 10^{12}$  vector genomes (vg)) which are reduced in follow-up experiments performed to generate dose-response curves. After seven to ten days, the mice are sacrificed, the livers harvested and samples of serum collected. The relative levels of hepatic luciferase activity and RNA are determined from the 30 isolated livers utilizing the luciferase assay and QPCR procedures previously described. Additionally, the efficiency of transduction is assessed by measurement of the marker protein in serial slices of the hepatic tissues.

It has been estimated that hydrodynamic transfection procedures may



result in the transfection of 5-40% of hepatocytes. Transduction of liver cells by AAV-2 delivery procedures have been shown to result in 5-10% transduction efficiencies. Although AAV may preferentially transduce the same pool of hepatocytes that were transfected by the initial tail vein injection procedure, it is possible that the subsets of cells that each technique affects are non-overlapping. If the former occurs, a reduction in luciferase activity relative to mice transduced with an unrelated interfering RNA is seen. If the latter occurs, then no decrease in luciferase activity is seen.

### **Modifications to enhance efficiency of AAV transduction of liver tissues**

Although it has been demonstrated that AAV-based vectors can deliver desired sequences to hepatocytes, the relative level of transduction that occurs within those tissues has been rather poor. For current clinical hemophilia studies which employ AAV-2 to deliver and express blood factor IX, this is not a significant issue. For treatment of hemophilia, it is critical only to replenish levels of secreted protein to therapeutic levels. Such replenishment may occur from a small number of transduced cells able to express significant levels of the desired protein. However, because the mechanism of interfering RNA action is intracellular and the effect is not transmitted directly from cell to cell, the transduction efficiency must be increased in order for AAV expressing interfering RNAs to be utilized as a therapeutic.

McCarty et al. were able to generate a self complementary AAV vector (scAAV) that has both a plus and a minus strand of the same expression cassette within its capsid (Gene Ther. 8: 1248-1254 (2001)). This was achieved by mutating the 5' ITR and leaving the 3' ITR intact. By mutating or deleting the terminal resolution site other non-essential AAV sequences, thus eliminating possible recombination by wild type AAV and this construct, a DNA template is created where replication starts at the 3' ITR. Once the replication machinery reaches the 5' ITR, no resolution takes place and replication continues to the 3' ITR. The resulting product has both a plus and complementary minus strand, yet is efficiently packaged. Employing the scAAV vectors, transduction of liver cells was increased to 30% of the total hepatocytes (Fu, et al. Molec Therapy. doi: 10.1016/j.ymthe.2003.08.021:1-7 (2003)). When delivered intercosternally, more than 50% of the Purkinje cells in the cerebellum were transduced by the scAAV

particles. Thomas et al. showed that self-complementary vectors could produce 50-fold higher luciferase transgene expression levels in mouse livers than their corresponding single-stranded AAV counterparts when infused into mouse livers at equivalent doses (Thomas, et al., J. Virol. (in press)). Though dropping slightly, the relative difference of expression between the vectors persisted at 20-fold nearly one year after injection.

Other modifications of AAV-delivery systems also have been used to dramatically enhance transduction efficiencies, including the production of pseudotyped viral particles by packaging rAAV-2 vector genomes with the Cap protein from other serotypes. Because they have been among the best characterized of all of the serotypes, the Cap proteins from AAV-1 through AAV-6 are used most commonly to pseudotype the AAV-2 vectors. Even with the advantages gained by these employing pseudotyping strategies, the threshold of transduction efficiency of hepatocytes may be increased only to 15% of the total population. However, dozens of other serotypes of AAV have been isolated and identified, but have not been characterized to any appreciable degree. For example, one of these is AAV-8, which was isolated originally from the heart tissue of a rhesus monkey. In an effort to determine effects novel cap proteins on transduction, pseudotyped virus in which the single stranded AAV-2 genome was pseudotyped with AAV-8 cap was created. The vectors carried the LacZ gene to assess the relative efficiency of transduction of mouse livers after infusion with increasing doses of infectious particles. A summary of the results (Thomas, et al. (2004)) is shown below in Table 1:

<b>Table 1: AAV-2/2 and AAV-2/8 Dose Responses- (%beta-gal positive hepatocytes)</b>					
	Dose (v.g./mouse)				
<b>Vector</b>	<b><math>5 \times 10^{10}</math></b>	<b><math>3 \times 10^{11}</math></b>	<b><math>1.8 \times 10^{12}</math></b>	<b><math>3.9 \times 10^{12}</math></b>	<b><math>7.2 \times 10^{12}</math></b>
<b>AAV-2 nls lac Z</b>	$0.6 \pm 0.4\%$	$3.0 \pm 0.5\%$	$8.1 \pm 1.0\%$	$8.9 \pm 1.0\%$	NA
<b>AAV-8 nls lac Z</b>	$8.1 \pm 1.8\%$	$14.9 \pm 3.4\%$	$65.8 \pm 9.1\%$	NA	$97.4 \pm 0.3\%$

As the dose of infused control AAV-2/2 particles is increased, there is a modest increase in transduction of hepatocytes; however, the upper threshold of transduction remains entrenched near the 10% limit. Surprisingly, pseudotyped



AAV-2/8 particles transduced 8% of hepatocytes at the lowest dose of particles administered; doses that were 30-80 fold less than their AAV-2/2 counterparts. Additionally, the dose-dependent increase in transduction efficiency for AAV-2/8 surpassed the transduction efficiency for AAV-2/2 to greater than 97% at the  
5 highest dose. Transduction efficiencies within this range enable to efficient delivery of interfering RNA to cells within tissues.

Similar modifications of AAV are engineered into the rAAV interfering RNA nucleic acid constructs. Following incorporation of these simple modifications, stocks of virus are generated for testing in the mouse model system. The  
10 following rAAV RNAi experimental virus stocks are tested: single-strand AAV-2/2; single-strand AAV-2/8; self-complementary AAV-2/2; and self-complementary AAV-2/8.

Corresponding viral particles that harbor rAAV vectors expressing unrelated RNA sequences are produced and used as negative controls. Large decreases in  
15 relative levels of luciferase activity correlate with increases in transduction efficiency.

### **Development of an AAV interfering RNA nucleic acid construct**

Construction of a nucleic acid construct according to the present invention includes two or more individual interfering RNAs under the influence of a single  
20 promoter. Initially, assessment of promoter strength of various promoter sequences is conducted in vectors containing the single, individual promoters, driving expression of the same interfering RNA with demonstrated functional inhibition of luciferase activity (Elbashir, et al. Nature. 411: 494-498 (2001a)). Since there is a wealth of data demonstrating the successful utilization of the U6  
25 promoter for the expression of interfering RNAs, it is used as the standard for assessing the relative strength of other promoters. The majority of the promoters that are tested are quite short, most in the range of 200-300 nucleotides in length. Long, overlapping oligonucleotides may be used to assemble the promoters and terminators de novo and are then cloned into multiple cloning sites that flank the  
30 sequence encoding the interfering RNA. The promoter is paired with the termination signal that occurs naturally downstream of the gene from which the promoter is taken.

The relative strength of each promoter is assessed in vitro by the decrease in activity of a co-transfected luciferase reporter. The test and reporter constructs are transfected into permissive cells utilizing standard techniques. Controls consist of a test promoter construct in which the sequence encoding the functional  
5 interfering RNA against luciferase is replaced by an unrelated RNA sequence. A third marker construct encoding for the secreted protein human  $\alpha$ 1-antitrypsin (hAAT) is co-transfected into the cells in order to assess for variations in transfection efficiencies. For assessing inhibitory activity of the interfering RNA, luciferase activity is measured utilizing standard commercial kits. The interfering  
10 RNA-mediated decrease in luciferase expression, normalized to hAAT levels, is an indirect measurement of promoter strength. Alternatively or in addition, quantitative real time PCR analysis (Q-PCR) on luciferase RNA levels is performed on RNA that is harvested and purified from parallel experimental plates.

#### **Testing of highly functional interfering RNA against HCV in vivo**

15 It must be verified that AAV particles delivered by the interfering RNA nucleic acid construct of the present invention inhibit the luciferase-HCV fusion reporter in vitro. Permissive tissue culture cells are transfected with one of the reporter constructs described supra. In addition, each co-transfection mixture is supplemented with a plasmid coding for hAAT. Following 48 hours of incubation,  
20 cells are dosed with infectious particles harboring the interfering RNA nucleic acid construct against HCV. AAV particles containing a triple promoter construct expressing three unrelated RNAs serve as the negative control. Measurement of luciferase activity is used to verify that the AAV-delivered interfering RNAs are highly functional.

25 Nucleic acids delivered to mice by hydrodynamic transfection methods (high pressure tail vein injection) localize primarily to the liver; thus, this technique is used to deliver the luciferase-HCV fusions to mouse livers. In order to assess the differences in transfection efficiency from animal to animal, a hAAT expression plasmid is included in the transfection mixture.

30 Infectious AAV particles containing constructs that express the interfering RNAs targeted against HCV sequences are delivered to normal C57B1/6 mice either by tail vein or hepatic portal vein injection. Infectious AAV particles expressing three unrelated RNAs serve as the negative control. Initially, a fairly



high dose of virus, e.g.  $2 \times 10^{12}$  vector genomes, is used, though subsequent experiments are performed to establish dose-response curves. After 48-72 hours, the mice are sacrificed, the livers harvested and samples of serum collected. Luciferase activity is used as a benchmark to assess efficacy of the AAV-delivered RNA agents. In addition to monitoring the levels of hAAT, serum levels of the liver enzymes alanine aminotransferase, aspartate aminotransferase, and tumor necrosis factor alpha are measured by ELISA to ensure general hepatic toxicity is not induced by the treatment.

#### 16. Constructs targeting three separate regions of HCV

Hepatitis C virus (HCV) is a small single stranded RNA virus that shows a high degree of sequence variation. The use of multiple constructs targeting HCV and other variable viruses, such as HIV, offers considerable advantages. Specifically, the use of multiple constructs may act to greatly reduce or eliminate the development of ddRNAi-resistant HCV strains. Moreover, as demonstrated by examples above, more active constructs may be obtained.

The construct pU6.HCVx3 hp (Figure 72) is designed to target 3 separate regions of the HCV genome, namely positions 130-151, 148-169 and 318-340 of Accession No. NC\_004102.

pU6.HCVx3 may be prepared using the oligonucleotide assembly strategy with the following oligonucleotides:

HCV-3x-1	ACCGGAGAGCCATAGTGGTCTGGAAA
HCV-3x-2	ACCGGTTCCGTTTCCAGACCACTATGGCTCTC
HCV-3x-3	CGGAACCGGTGAGTACACGAAAAGG
HCV-3x-4	GCACGGTCTACGAGACCTTTTCGTGTACTC
HCV-3x-5	TCTCGTAGACCGTGCAATTTGTGTA
HCV-3x-6	AGACCGTGCACTACACAAAT
HCV-3x-7	GTGCACGGTCTACGAGACCTCAAGGTG
HCV-3x-8	GGTGAGTACACCTTGAGGTCTCGT
HCV-3x-9	TACTCACCGGTTCCGCAAGCAGACCAC
HCV-3x-10	AGAGCCATAGTGGTCTGCTTGCGGAACC

HCV-3x-11            TATGGCTCTCCTTTTTTTGGAAA

HCV-3x-12            AGCTTTTCCAAAAAAGG

The activity of this construct against HCV may be determined using the assays described above.

## 5    17.    **Production of sense and antisense RNAs in vivo**

The interfering RNA of the present invention may be produced by two constructs *in vivo*. Figure 73 shows an example of this approach. Two ddRNAi constructs, pU6.GR22-sense (A) and pU6.GR22-antisense (B) may be prepared using the long range PCR strategy described above. pU6.GR22-sense is prepared

10    using the oligonucleotides:

U6 GR22-s

TGAGATGAACTTCAGGGTCAGCGGTGTTTCGTCCTTTC

term GR22-s

AGCCTTTCAC TACTCCTACTTTTTTTTGGAAAAGCTTATCG

15    pU6.GR22-antisense is prepared using the oligonucleotides

U6 GR22-as

CTGGCCTTTCAC TACTCCTACCTGGTGTTTCGTCCTTTC

term GR22-as

AGATGAACTTCAGGGTCAGCTTTTTTTGGAAAAGCTTATCG

20    These constructs are designed to produce RNAs that are the reverse complement of each other, they are predicted to (spontaneously) form double stranded RNA as shown in Figure 73C. thereby triggering degradation of EGFP and hRluc mRNAs. hRluc mRNA degradation can readily be assayed as described above. EGFP degradation can be readily assayed by monitoring  
25    reductions in expression of a EGFP in co-transfection experiments, methods for which are well known to those familiar with the art.

The constructs might be tested by co-transfecting the two plasmids into HeLa cells expressing hRluc and hRluc inactivation assayed as described above. Alternatively the two transcriptional units might be combined into a single construct  
30    as shown in Figure 71 and this construct assayed. Similar experiments may be



performed in HeLa cells to monitor for inactivation of a co-transfected EGFP expressing plasmid.

### 18. Production of sense and antisense RNAs in vitro

The interfering RNA of the present invention may be produced by two constructs *in vitro*. Figure 74 shows an example of this approach. In vitro transcribed RNA may be prepared from these fragments using a commercial kit (Ambion siRNA construction kit) according to the manufacturer's protocols. Transcripts from two DNA fragments, namely, T7 GR22-sense (A) and T7 GR22-antisense (B) may be prepared using the above kit. T7 GR22-sense is prepared using the oligonucleotide:

T7 GR22-s

GCTGACCCTGAAGTTCATCTCAAGCCTTTCACTACTCCTACTTCCTGTC  
TC

T7 GR22-antisense is prepared using the oligonucleotide:

15 T7 GR22-as

AAAGTAGGAGTAGTGAAAGGCCAGAGATGAACTTCAGGGTCAGCCTG  
TCTC

The two transcripts are predicted to anneal and following the appropriate RNase treatment they will produce the dsRNA shown in Figure 74C. The activity of the constructs may be determined as described above.

It will be understood that the invention disclosed and defined in this specification extends to all alternative combinations of two or more of the individual features mentioned or evident from the text or drawings. All of these different combinations constitute various alternative aspects of the invention.

## SEQUENCE LISTING

<110> Benitec Australia Limited

<120> DOUBLE-STRANDED NUCLEIC ACID

<130> M80692060

<150> 60/475827  
<151> 2003-06-03

<150> 60/553920  
<151> 2004-03-17

<150> 60/550504  
<151> 2004-03-05

<150> 2003906281  
<151> 2003-11-14

<150> 2004901258  
<151> 2004-03-10

<150> 2004902279  
<151> 2004-04-30

<150> 60/479616  
<151> 2003-06-17

<160> 308

<170> PatentIn version 3.2

<210> 1  
<211> 26  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 1  
gaattcaagg tcgggcagga agaggg

26

<210> 2  
<211> 42  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 2  
aagcttagat ctcgtctcac ggtgtttcgt cctttccaca ag

42

<210> 3  
<211> 31  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 3  
accgtgtgca ccggcacaga cattcaagag a

31



WO 2004/106517

PCT/AU2004/000759

<210> 4  
<211> 19  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 4  
gcaatgatct tgatcttca 19

<210> 5  
<211> 29  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 5  
gcaatgatct tgatcttcat ttttggaaa 29

<210> 6  
<211> 42  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 6  
agcttttcca aaaatgaaga tcaagatcat tgctctcttg aa 42

<210> 7  
<211> 29  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 7  
cttgaagcaa tgatcttgat cttcacggt 29

<210> 8  
<211> 20  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 8  
ggtgtttcgt cctttccaca 20

<210> 9  
<211> 27  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

WO 2004/106517

PCT/AU2004/000759

<400> 9  
 tttttggaaa agcttatcga taccgtc 27

<210> 10  
 <211> 58  
 <212> DNA  
 <213> Artificial

<220>  
 <223> oligonucleotide

<400> 10  
 ctcttgaacg ctctctctcc aacttccgtt tctcatccgg tgtttcgtcc tttccaca 58

<210> 11  
 <211> 58  
 <212> DNA  
 <213> Artificial

<220>  
 <223> oligonucleotide

<400> 11  
 acgctctctc tccaacttcc gtttctcatc ctttttggaa aagcttatcg ataccgtc 58

<210> 12  
 <211> 62  
 <212> DNA  
 <213> Artificial

<220>  
 <223> oligonucleotide

<400> 12  
 gagaacatgg ttaactgggt aagtcatgtc gtccacacagg agcgcaccat cttcttcaag 60  
 ga 62

<210> 13  
 <211> 66  
 <212> DNA  
 <213> Artificial

<220>  
 <223> oligonucleotide

<400> 13  
 tgaacatgag aagggtggtg cactctccac ctctgtact cacctggacg tagccttcgg 60  
 gcatgg 66

<210> 14  
 <211> 27  
 <212> DNA  
 <213> Artificial

<220>  
 <223> oligonucleotide

<400> 14  
 tcttggacgt ggggtgtttcg tcctttc 27



WO 2004/106517

PCT/AU2004/000759

<210> 15  
<211> 31  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 15  
tcttggaatg cttttttgga aaagcttatc g

31

<210> 16  
<211> 42  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 16  
acacaaagta ggagtagtga aaggccggtg tttcgtcctt tc

42

<210> 17  
<211> 41  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 17  
aggtaggagt agtgaaaggc cttttttgga aaagcttatc g

41

<210> 18  
<211> 64  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 18  
acacaaagca atgatcttga ttttcataag taggagtagt gaaaggccgg tgtttcgtcc  
tttc

60

64

<210> 19  
<211> 63  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 19  
aggcaatgat cttgatcttc attggtagga gtagtgaaag gccttttttg gaaaagctta  
tcg

60

63

<210> 20  
<211> 45  
<212> DNA

WO 2004/106517

PCT/AU2004/000759

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; oligonucleotide

&lt;400&gt; 20

accggccttt cactactcct acttagtgaa gatcaagatc attgc

45

&lt;210&gt; 21

&lt;211&gt; 32

&lt;212&gt; DNA

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; oligonucleotide

&lt;400&gt; 21

ttgatcttca ctaagtagga gtagtgaaag gc

32

&lt;210&gt; 22

&lt;211&gt; 29

&lt;212&gt; DNA

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; oligonucleotide

&lt;400&gt; 22

tttgtgtagg caatgatctt gatcttcat

29

&lt;210&gt; 23

&lt;211&gt; 27

&lt;212&gt; DNA

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; oligonucleotide

&lt;400&gt; 23

gatcattgcc tacacaaagc aatgatc

27

&lt;210&gt; 24

&lt;211&gt; 33

&lt;212&gt; DNA

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; oligonucleotide

&lt;400&gt; 24

tgagtaggag tagtgaaagg ctttttttgg aaa

33

&lt;210&gt; 25

&lt;211&gt; 48

&lt;212&gt; DNA

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; oligonucleotide

&lt;400&gt; 25

agcttttcca aaaaaggcct ttcactactc ctactcaatg aagatcaa

48



WO 2004/106517

PCT/AU2004/000759

<210> 26  
 <211> 65  
 <212> DNA  
 <213> Artificial

<220>  
 <223> oligonucleotide

<400> 26  
 acacaaagta ggagtagtga aaggcctaag caatgatctt gatcttcacg gtgtttcgtc 60  
 ctttc 65

<210> 27  
 <211> 63  
 <212> DNA  
 <213> Artificial

<220>  
 <223> oligonucleotide

<400> 27  
 aggtaggagt agtgaaaggc cttggcaatg atcttgatct tcattttttg gaaaagctta 60  
 tcg 63

<210> 28  
 <211> 65  
 <212> DNA  
 <213> Artificial

<220>  
 <223> oligonucleotide

<400> 28  
 acacaaagta ggagtagtga aaggccctaa gcaatgatct tgatcttcag gtgtttcgtc 60  
 ctttc 65

<210> 29  
 <211> 64  
 <212> DNA  
 <213> Artificial

<220>  
 <223> oligonucleotide

<400> 29  
 aggtaggagt agtgaaaggc cttgagcaat gatcttgatc ttcatttttt ggaaaagctt 60  
 atcg 64

<210> 30  
 <211> 86  
 <212> DNA  
 <213> Artificial

<220>  
 <223> oligonucleotide

<400> 30  
 acaaatgaac aggtggtttc agtcctaagc aatgatcttg atcttcacta agtaggagta 60

WO 2004/106517

PCT/AU2004/000759

gtgaaaggcc ggtgtttcgt cctttc

86

<210> 31  
<211> 89  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 31  
gtagtgaaca ggtggtttca gtcttgagca atgatcttga tcttcattga gtaggagtag 60

tgaaaggcct tttttggaaa agcttatcg 89

<210> 32  
<211> 89  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 32  
cacaaatgaa caggtggttt cagtcctaag taggagtagt gaaaggcct aagcaatgat 60

cttgatcttc accggtgttt cgtcctttc 89

<210> 33  
<211> 88  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 33  
tagtgaacag gtggtttcag tcttgagtag gagtagtgaa aggccttgag caatgatctt 60

gatcttcatt ttttggaaaa gcttatcg 88

<210> 34  
<211> 88  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 34  
cacaaagtag gagtagtgaa aggccctaata gaacaggtgg tttcagtcct aagcaatgat 60

cttgatcttc acggtgtttc gtcctttc 88

<210> 35  
<211> 88  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 35



WO 2004/106517

PCT/AU2004/000759

taggtaggag tagtgaaagg ccttgatgaa caggtgggtt cagtcttgag caatgatctt 60  
gatcttcatt ttttggaaaa gcttatcg 88

<210> 36  
<211> 88  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 36  
cacaaagatg aacttcaggg tcagcctaata gaacaggtgg tttcagtcct aagcaatgat 60  
cttgatcttc acggtgtttc gtcctttc 88

<210> 37  
<211> 88  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 37  
taggatgaac ttcaggggtca gcttgatgaa caggtgggtt cagtcttgag caatgatctt 60  
gatcttcatt ttttggaaaa gcttatcg 88

<210> 38  
<211> 83  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 38  
gttcatcaag ctgaccctga agttcatcct acacaaagat gaacttcagg gtcagcctaa 60  
tgaacaggtg gtttcagtcc taa 83

<210> 39  
<211> 80  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 39  
aggtgggttc agtcttgagc aatgatcttg atcttcattg agtaggagta gtgaaaggcc 60  
ttttttggaa aagcttatcg 80

<210> 40  
<211> 83  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

WO 2004/106517

PCT/AU2004/000759

<400> 40  
 gttcatcaag ctgaccctga agttcatcct acacaaagat gaacttcagg gtcagcctaa 60  
 tgaacaggtg gtttcagtcc taa 83

<210> 41  
 <211> 80  
 <212> DNA  
 <213> Artificial

<220>  
 <223> oligonucleotide

<400> 41  
 aggtggtttc agtcttgagt aggagtagtg aaaggccttg agcaatgatc ttgatcttca 60  
 ttttttggaa aagcttatcg 80

<210> 42  
 <211> 82  
 <212> DNA  
 <213> Artificial

<220>  
 <223> oligonucleotide

<400> 42  
 ctactcaagc tgaccctgaa gttcatccta cacaaagatg aacttcaggg tcagcctaag 60  
 taggagtagt gaaaggccct aa 82

<210> 43  
 <211> 81  
 <212> DNA  
 <213> Artificial

<220>  
 <223> oligonucleotide

<400> 43  
 gagtagtgaa aggccttgat gaacaggtgg tttcagtctt gagcaatgat cttgatcttc 60  
 attttttgga aaagcttatc g 81

<210> 44  
 <211> 38  
 <212> DNA  
 <213> Artificial

<220>  
 <223> oligonucleotide

<400> 44  
 accgtgaaga tcaagatcat tgcttaggac tgaaacca 38

<210> 45  
 <211> 43  
 <212> DNA  
 <213> Artificial

<220>  
 <223> oligonucleotide



WO 2004/106517

PCT/AU2004/000759

<400> 45  
atgaacaggt ggtttcagtc ctaagcaatg atcttgatct tca 43

<210> 46  
<211> 35  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 46  
cctgttcatt aggctgaccc tgaagttcat cttag 35

<210> 47  
<211> 35  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 47  
tgaaaggccc taagatgaac ttcaggggtca gccta 35

<210> 48  
<211> 47  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 48  
ggcctttcac tactcctact ttgtgtaggt aggagtagtg aaaggcc 47

<210> 49  
<211> 47  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 49  
tcattctcaag gcctttcact actcctacct acacaaagta ggagtag 47

<210> 50  
<211> 46  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 50  
ttgagatgaa cttcagggtc agcttgatga acaggtgggtt tcagtc 46

<210> 51  
<211> 28  
<212> DNA

WO 2004/106517

PCT/AU2004/000759

<213> Artificial

<220>  
<223> oligonucleotide

<400> 51  
cacctgttca tcaagctgac cctgaagt 28

<210> 52  
<211> 34  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 52  
ttgagcaatg atcttgatct tcatttttttg gaaa 34

<210> 53  
<211> 47  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 53  
agctttttcca aaaaatgaag atcaagatca ttgctcaaga ctgaaac 47

<210> 54  
<211> 82  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 54  
catctcaagt gtgcaccggc acagacacta cacaaatgtc tgtgccggtg cacacctaag 60  
atgaacttca gggtcagcct aa 82

<210> 55  
<211> 81  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 55  
aacttcaggg tcagcttgat gaacaggtgg tttcagtctt gagcaatgat cttgatcttc 60  
attttttgga aaagcttatc g 81

<210> 56  
<211> 78  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide



WO 2004/106517

PCT/AU2004/000759

<400> 56  
tcaagtgtgc accggcacag acactacaca aatgtctgtg ccggtgcaca cctaagatga 60  
acttcaggggt cagcctaa 78

<210> 57  
<211> 108  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 57  
gatgaacttc agggtcagct tgatgaacag gtggtttcag tcttgagcaa tgatcttgat 60  
cttcattgag taggagtagt gaaaggcctt ttttgaaaa gcttatcg 108

<210> 58  
<211> 78  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 58  
tcaagtgtgc accggcacag acactacaca aatgtctgtg ccggtgcaca cctaagatga 60  
acttcaggggt cagcctaa 78

<210> 59  
<211> 108  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 59  
gatgaacttc agggtcagct tgatgaacag gtggtttcag tcttgagtag gagtagtgaa 60  
aggccttgag caatgatctt gatcttcatt ttttgaaaa gcttatcg 108

<210> 60  
<211> 78  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 60  
tcaagtgtgc accggcacag acactacaca aatgtctgtg ccggtgcaca cctaagatga 60  
acttcaggggt cagcctaa 78

<210> 61  
<211> 108  
<212> DNA  
<213> Artificial

WO 2004/106517

PCT/AU2004/000759

&lt;220&gt;

&lt;223&gt; Primer sequence

&lt;400&gt; 61

gatgaacttc agggtcagct tgagtaggag tagtgaaagg ccttgatgaa caggtgggtt 60

cagtcttgag caatgatctt gatcttcatt ttttggaata gcttatcg 108

&lt;210&gt; 62

&lt;211&gt; 78

&lt;212&gt; DNA

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; oligonucleotide

&lt;400&gt; 62

tcaagtgtgc accggcacag acactacaca aatgtctgtg ccggtgcaca cctaagtagg 60

agtagtgaaa ggccctaa 78

&lt;210&gt; 63

&lt;211&gt; 108

&lt;212&gt; DNA

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; Primer sequence

&lt;400&gt; 63

gtaggagtag tgaaaggcct tgagatgaac ttcaggggtca gcttgatgaa caggtgggtt 60

cagtcttgag caatgatctt gatcttcatt ttttggaata gcttatcg 108

&lt;210&gt; 64

&lt;211&gt; 38

&lt;212&gt; DNA

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; oligonucleotide

&lt;400&gt; 64

accgtgaaga tcaagatcat tgcttaggac tgaaacca 38

&lt;210&gt; 65

&lt;211&gt; 43

&lt;212&gt; DNA

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; oligonucleotide

&lt;400&gt; 65

atgaacaggt ggtttcagtc ctaagcaatg atcttgatct tca 43

&lt;210&gt; 66

&lt;211&gt; 35

&lt;212&gt; DNA

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; oligonucleotide



WO 2004/106517

PCT/AU2004/000759

<400> 66  
cctgttcatt aggctgaccc tgaagttcat cttag 35

<210> 67  
<211> 35  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 67  
ggtgcacacc taagatgaac ttcagggtca gccta 35

<210> 68  
<211> 47  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 68  
gtgtgcaccg gcacagacat tagggccttt cactactcct actttgt 47

<210> 69  
<211> 47  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 69  
cctacctaca caaagtagga gtagtgaaag gccctaattgt ctgtgcc 47

<210> 70  
<211> 46  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 70  
gtaggttagga gtagtgaaag gccttgatgt ctgtgccggt gcacac 46

<210> 71  
<211> 46  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 71  
tcattctcaag tgtgcaccgg cacagacatc aaggcctttc actact 46

<210> 72  
<211> 46  
<212> DNA

WO 2004/106517

PCT/AU2004/000759

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; oligonucleotide

&lt;400&gt; 72

ttgagatgaa cttcagggtc agcttgatga acaggtgggtt tcagtc

46

&lt;210&gt; 73

&lt;211&gt; 28

&lt;212&gt; DNA

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; oligonucleotide

&lt;400&gt; 73

cacctgttca tcaagctgac cctgaagt

28

&lt;210&gt; 74

&lt;211&gt; 34

&lt;212&gt; DNA

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; oligonucleotide

&lt;400&gt; 74

ttgagcaatg atcttgatct tcattttttg gaaa

34

&lt;210&gt; 75

&lt;211&gt; 47

&lt;212&gt; DNA

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; oligonucleotide

&lt;400&gt; 75

agctttttcca aaaaatgaag atcaagatca ttgctcaaga ctgaaac

47

&lt;210&gt; 76

&lt;211&gt; 78

&lt;212&gt; DNA

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; oligonucleotide

&lt;400&gt; 76

tcaactggac ttccagaaga acactacaca aatgttcttc tggaagtcca gctaattgtct

60

gtgccggtgc acacctaa

78

&lt;210&gt; 77

&lt;211&gt; 108

&lt;212&gt; DNA

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; oligonucleotide

&lt;400&gt; 77



WO 2004/106517

PCT/AU2004/000759

tgtctgtgcc ggtgcacact tgagatgaac ttcaggggtca gcttgatgaa caggtgggtt 60  
 cagtcttgag caatgatctt gatcttcatt ttttggaaaa gcttatcg 108

<210> 78  
 <211> 65  
 <212> DNA  
 <213> Artificial

<220>  
 <223> oligonucleotide

<400> 78  
 cacaaagagg cgctcgtggt cctggctaac agcttctcgt ggtcctggcg gtgtttcgtc 60  
 ctttc 65

<210> 79  
 <211> 65  
 <212> DNA  
 <213> Artificial

<220>  
 <223> oligonucleotide

<400> 79  
 taggaggcgc tcgtggtcct ggttgacagc ttctcgtggt cctgggttttt tggaaaagct 60  
 tatcg 65

<210> 80  
 <211> 42  
 <212> DNA  
 <213> Artificial

<220>  
 <223> oligonucleotide

<400> 80  
 cacaaaggtg cccttgccga ggagtcggtg tttcgtcctt tc 42

<210> 81  
 <211> 42  
 <212> DNA  
 <213> Artificial

<220>  
 <223> oligonucleotide

<400> 81  
 taggaggcgc tcgtggtcct ggttttttgg aaaagcttat cg 42

<210> 82  
 <211> 42  
 <212> DNA  
 <213> Artificial

<220>  
 <223> oligonucleotide

<400> 82  
 cacaaagagg cgctcgtggt cctggcggtg tttcgtcctt tc 42

WO 2004/106517

PCT/AU2004/000759

<210> 83  
 <211> 41  
 <212> DNA  
 <213> Artificial

<220>  
 <223> oligonucleotide

<400> 83  
 taggggtgcc ttgccgagga gttttttgga aaagcttatc g 41

<210> 84  
 <211> 65  
 <212> DNA  
 <213> Artificial

<220>  
 <223> oligonucleotide

<400> 84  
 cacaaagagg cgctcgtggt cctggctaag gtgcccttgc cgaggagtcg gtgttttcgtc 60  
 ctttc 65

<210> 85  
 <211> 64  
 <212> DNA  
 <213> Artificial

<220>  
 <223> oligonucleotide

<400> 85  
 taggaggcgc tcgtggtcct ggttgagggtg cccttgccga ggagtttttt ggaaaagctt 60  
 atcg 64

<210> 86  
 <211> 32  
 <212> DNA  
 <213> Artificial

<220>  
 <223> oligonucleotide

<400> 86  
 accgtgaaga tcaagatcat tgctcctcct ga 32

<210> 87  
 <211> 18  
 <212> DNA  
 <213> Artificial

<220>  
 <223> oligonucleotide

<400> 87  
 caatgatctt gatcttca 18

<210> 88  
 <211> 28  
 <212> DNA



WO 2004/106517

PCT/AU2004/000759

<213> Artificial

<220>  
<223> oligonucleotide

<400> 88  
gcgcaagtac tccgtgtggt tcaagaga 28

<210> 89  
<211> 29  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 89  
ccacacggag tacttgcgct caggaggag 29

<210> 90  
<211> 31  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 90  
ccacacggag tacttgcgct caggaggagc a 31

<210> 91  
<211> 31  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 91  
tgagcgcaag tactccgtgt ggtctcttga a 31

<210> 92  
<211> 27  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 92  
aatgatcttg atcttcattt ttggaaa 27

<210> 93  
<211> 39  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 93  
agcttttcca aaaatgaaga tcaagatcat tgctcctcc 39

WO 2004/106517

PCT/AU2004/000759

<210> 94  
<211> 48  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 94  
agagatgaac aggtggtttc agtctttttg gaaaagctta tcgatacc

48

<210> 95  
<211> 45  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 95  
tgaatgaaca ggtggtttca gtcggtgttt cgtcctttcc acaag

45

<210> 96  
<211> 48  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 96  
agagaggctg tgaacagacg cgcctttttg gaaaagctta tcgatacc

48

<210> 97  
<211> 45  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 97  
tgaaggctgt gaacagacgc gccggtgttt cgtcctttcc acaag

45

<210> 98  
<211> 50  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 98  
agagaagtgc tgctggaact catgcttttt ggaaaagctt atcgataccg

50

<210> 99  
<211> 46  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide



WO 2004/106517

PCT/AU2004/000759

<400> 99  
tgaaagtgtct gctggaactc atgcggtgtt tcgtcctttc cacaag 46

<210> 100  
<211> 50  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 100  
agagattatt tctgcatggc agtcattttt ggaaaagctt atcgataccg 50

<210> 101  
<211> 45  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 101  
tgaattattt ctgcatggca gtcggtgttt cgtcctttcc acaag 45

<210> 102  
<211> 58  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 102  
agagaggctg tgaacagacg cgcctttgaa cagggtggtt cagtcttttt ggaaaagc 58

<210> 103  
<211> 54  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 103  
tgaaggctgt gaacagacgc gccaatgaac aggtgggttc agtcggtgtt tcgt 54

<210> 104  
<211> 59  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 104  
agagaggctg tgaacagacg cgccttgatga acagggtggtt tcagtctttt tggaaaagc 59

<210> 105  
<211> 55  
<212> DNA

WO 2004/106517

PCT/AU2004/000759

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; oligonucleotide

&lt;400&gt; 105

tgaaggctgt gaacagacgc gcctaatgaa caggtgggtt cagtcggtgt ttcgt 55

&lt;210&gt; 106

&lt;211&gt; 62

&lt;212&gt; DNA

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; oligonucleotide

&lt;400&gt; 106

agagaggctg tgaacagacg cgccttgtaa tgaacagggtg gtttcagtct ttttggaana 60

gc 62

&lt;210&gt; 107

&lt;211&gt; 57

&lt;212&gt; DNA

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; oligonucleotide

&lt;400&gt; 107

tgaaggctgt gaacagacgc gccttgtaat gaacagggtg tttcagtcgg tgtttcg 57

&lt;210&gt; 108

&lt;211&gt; 29

&lt;212&gt; DNA

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; oligonucleotide

&lt;400&gt; 108

aatgactgcc atgcagaaat acctgtctc 29

&lt;210&gt; 109

&lt;211&gt; 29

&lt;212&gt; DNA

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; oligonucleotide

&lt;400&gt; 109

aatatttctg catggcagtc acctgtctc 29

&lt;210&gt; 110

&lt;211&gt; 29

&lt;212&gt; DNA

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; oligonucleotide

&lt;400&gt; 110



WO 2004/106517

PCT/AU2004/000759

aatgaagatc aagatcattg ccctgtctc

29

<210> 111  
<211> 29  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 111  
aagcaatgat cttgatcttc acctgtctc

29

<210> 112  
<211> 50  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 112  
ctgaaatctc ttgaatttca gtctaagcaa tgatcttgat cttcacggtg

50

<210> 113  
<211> 51  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 113  
tcttggcaat gatcttgatc ttcatttttg gaaaagctta tcgataccgt c

51

<210> 114  
<211> 60  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 114  
tcattgctct cttgaagcaa tgatcttgat cttcaaata acagggtggtt tcagtcggtg

60

<210> 115  
<211> 60  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 115  
tcttgatctt catttgaaca ggtgggttca gtcttttttg aaaagcttat cgataccgtc

60

<210> 116  
<211> 61  
<212> DNA  
<213> Artificial

WO 2004/106517

PCT/AU2004/000759

<220>  
<223> oligonucleotide

<400> 116  
tcattgctct cttgaagcaa tgatcttgat cttcataatg aacaggtggt ttcagtcggt 60  
g 61

<210> 117  
<211> 61  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 117  
tcttgatctt cattgtgaac aggtgggttc agtctttttg gaaaagctta tcgataccgt 60  
c 61

<210> 118  
<211> 61  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 118  
cattgctctc ttgaagcaat gatcttgatc ttcactaatg aacaggtggt ttcagtcggt 60  
g 61

<210> 119  
<211> 63  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 119  
atcttgatct tcattgatga acaggtgggt tcagtctttt tggaaaagct tatcgatacc 60  
gtc 63

<210> 120  
<211> 63  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 120  
cattgctctc ttgaagcaat gatcttgatc ttcattgtaa tgaacaggtg gtttcagtcg 60  
gtg 63

<210> 121  
<211> 65  
<212> DNA



WO 2004/106517

PCT/AU2004/000759

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; oligonucleotide

&lt;400&gt; 121

atcttgatct tcattgtaat gaacagggtgg tttcagtctt ttggaaaag cttatcgata 60

ccgtc 65

&lt;210&gt; 122

&lt;211&gt; 61

&lt;212&gt; DNA

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; oligonucleotide

&lt;400&gt; 122

tggtcatctc ttgaatgaac aggtgggttc agtctaagca atgatcttga tcttcacggg 60

g 61

&lt;210&gt; 123

&lt;211&gt; 62

&lt;212&gt; DNA

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; oligonucleotide

&lt;400&gt; 123

gggtgggttca gtcttggcaa tgatcttgat cttcattttt ggaaaagctt atcgataccg 60

tc 62

&lt;210&gt; 124

&lt;211&gt; 32

&lt;212&gt; DNA

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; oligonucleotide

&lt;400&gt; 124

accgctgacc ctgaagttca tcctggcctt tc 32

&lt;210&gt; 125

&lt;211&gt; 36

&lt;212&gt; DNA

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; oligonucleotide

&lt;400&gt; 125

ggagtagtga aaggccagga tgaacttcag ggtagc 36

&lt;210&gt; 126

&lt;211&gt; 22

&lt;212&gt; DNA

&lt;213&gt; Artificial

WO 2004/106517

PCT/AU2004/000759

<220>  
<223> oligonucleotide  
  
<400> 126  
actactccta ctttgtgtag gt

22

<210> 127  
<211> 23  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide  
  
<400> 127  
actactccta cctacacaaa gta

23

<210> 128  
<211> 29  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide  
  
<400> 128  
aggagtagtg aaaggccagg atgaacttc

29

<210> 129  
<211> 28  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide  
  
<400> 129  
ctgaccctga agttcatcct ggcctttc

28

<210> 130  
<211> 20  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide  
  
<400> 130  
agggtcagct tttttggaaa

20

<210> 131  
<211> 16  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide  
  
<400> 131  
agcttttcca aaaaag

16

<210> 132



WO 2004/106517

PCT/AU2004/000759

<211> 32  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<220>  
<221> misc\_feature  
<222> (24)..(25)  
<223> n is a, c, g, or t

<400> 132  
accgctgacc ctgaagttca tccnngcctt tc

32

<210> 133  
<211> 36  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<220>  
<221> misc\_feature  
<222> (16)..(17)  
<223> n is a, c, g, or t

<400> 133  
ggagtagtga aaggcnngga tgaacttcag ggtcag

36

<210> 134  
<211> 22  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 134  
actactccta ctttcagtag gt

22

<210> 135  
<211> 23  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 135  
actactccta cctacacaaa gta

23

<210> 136  
<211> 29  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 136

WO 2004/106517

PCT/AU2004/000759

aggagtagtg aaaggccagg atgaacttc

29

<210> 137  
<211> 28  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 137  
ctgaccctga agttcatcct ggcctttc

28

<210> 138  
<211> 20  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 138  
agggtcagct tttttggaaa

20

<210> 139  
<211> 16  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 139  
agcttttcca aaaaag

16

<210> 140  
<211> 32  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 140  
accgctgacc ctgaagttca tcctggcctt tc

32

<210> 141  
<211> 36  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<220>  
<221> misc\_feature  
<222> (16)..(17)  
<223> n is a, c, g, or t

<400> 141  
ggagtagtga aaggcnngga tgaacttcag ggtagc

36



WO 2004/106517

PCT/AU2004/000759

<210> 142  
<211> 22  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 142  
actactccta ctttgtgtag gt

22

<210> 143  
<211> 23  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 143  
actactccta cctacacaaa gta

23

<210> 144  
<211> 29  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<220>  
<221> misc\_feature  
<222> (19)..(20)  
<223> n is a, c, g, or t

<400> 144  
aggagtagtg aaaggccann atgaacttc

29

<210> 145  
<211> 28  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<220>  
<221> misc\_feature  
<222> (18)..(19)  
<223> n is a, c, g, or t

<400> 145  
ctgaccctga agttcatnnt ggcctttc

28

<210> 146  
<211> 20  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

WO 2004/106517

PCT/AU2004/000759

<400> 146  
agggtcagct tttttggaaa

20

<210> 147  
<211> 16  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 147  
agcttttcca aaaaag

16

<210> 148  
<211> 32  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<220>  
<221> misc\_feature  
<222> (24)..(25)  
<223> n is a, c, g, or t

<400> 148  
accgctgacc ctgaagttca tccnngcctt tc

32

<210> 149  
<211> 36  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<220>  
<221> misc\_feature  
<222> (16)..(17)  
<223> n is a, c, g, or t

<400> 149  
ggagtagtga aaggcnngga tgaacttcag ggtag

36

<210> 150  
<211> 22  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 150  
actactccta ctttgtgtag gt

22

<210> 151  
<211> 23  
<212> DNA



WO 2004/106517

PCT/AU2004/000759

<213> Artificial

<220>  
<223> oligonucleotide

<400> 151  
actactccta cctacacaaa gta 23

<210> 152  
<211> 29  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<220>  
<221> misc\_feature  
<222> (19)..(20)  
<223> n is a, c, g, or t

<400> 152  
aggagtagtg aaaggccann atgaacttc 29

<210> 153  
<211> 28  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<220>  
<221> misc\_feature  
<222> (18)..(19)  
<223> n is a, c, g, or t

<400> 153  
ctgaccctga agttcatnnt ggcctttc 28

<210> 154  
<211> 20  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 154  
agggtcagct tttttggaaa 20

<210> 155  
<211> 16  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 155  
agcttttcca aaaaag 16

WO 2004/106517

PCT/AU2004/000759

<210> 156  
<211> 17  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 156  
accgctgacc ctgaagt

17

<210> 157  
<211> 32  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 157  
agtgaaggd dbhagatgaa cttcagggtc ag

32

<210> 158  
<211> 33  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 158  
tcattctdvhh cctttcacta ctcctacttt gtg

33

<210> 159  
<211> 24  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 159  
ctcctaccta cacaaagtag gagt

24

<210> 160  
<211> 31  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 160  
taggtaggag tagtgaaagg ddbhagatga a

31

<210> 161  
<211> 30  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide



WO 2004/106517

PCT/AU2004/000759

<400> 161  
accctgaagt tcatctdvhh cctttcacta

30

<210> 162  
<211> 32  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<220>  
<221> misc\_feature  
<222> (10)..(10)  
<223> n is a, c, g, or t

<220>  
<221> misc\_feature  
<222> (13)..(13)  
<223> n is a, c, g, or t

<400> 162  
agtgaaggn ttnagatgaa cttcagggtc ag

32

<210> 163  
<211> 33  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<220>  
<221> misc\_feature  
<222> (7)..(7)  
<223> n is a, c, g, or t

<220>  
<221> misc\_feature  
<222> (10)..(10)  
<223> n is a, c, g, or t

<400> 163  
tcatctnaan cctttcacta ctctacttt gtg

33

<210> 164  
<211> 31  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<220>  
<221> misc\_feature  
<222> (21)..(21)  
<223> n is a, c, g, or t

<220>  
<221> misc\_feature  
<222> (24)..(24)

WO 2004/106517

PCT/AU2004/000759

&lt;223&gt; n is a, c, g, or t

&lt;400&gt; 164

taggtaggag tagtgaaagg naanagatga a

31

&lt;210&gt; 165

&lt;211&gt; 30

&lt;212&gt; DNA

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; oligonucleotide

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (17)..(17)

&lt;223&gt; n is a, c, g, or t

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (20)..(20)

&lt;223&gt; n is a, c, g, or t

&lt;400&gt; 165

accctgaagt tcatctnttn cttttcacta

30

&lt;210&gt; 166

&lt;211&gt; 62

&lt;212&gt; DNA

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; oligonucleotide

&lt;400&gt; 166

cacaaagtag gagtagtgaa aggddbhgat gaacttcagg gtcagcgggtg tttcgtcctt

60

tc

62

&lt;210&gt; 167

&lt;211&gt; 63

&lt;212&gt; DNA

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; oligonucleotide

&lt;400&gt; 167

taggtaggag tagtgaaagg ccbhhbtgaa cttcagggtc agcttttttg gaaaagctta

60

tcg

63

&lt;210&gt; 168

&lt;211&gt; 19

&lt;212&gt; DNA

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; oligonucleotide

&lt;400&gt; 168

accgctgacc ctgaagtgc

19



WO 2004/106517

PCT/AU2004/000759

<210> 169  
<211> 24  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 169  
gaaaggccag aacttcaggg tcag

24

<210> 170  
<211> 26  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 170  
tggcctttca ctactcctac tttgtg

26

<210> 171  
<211> 27  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 171  
ctcctaccta caciaagtag gagtagt

27

<210> 172  
<211> 26  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 172  
taggtaggag tagtgaaagg ccagaa

26

<210> 173  
<211> 24  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 173  
accctgaagt tctggccttt cact

24

<210> 174  
<211> 24  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

WO 2004/106517

PCT/AU2004/000759

<400> 174  
cttcagggtc agcttttttg gaaa

24

<210> 175  
<211> 19  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 175  
agcttttcca aaaaagctg

19

<210> 176  
<211> 25  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 176  
gaaaggccat gaacttcagg gtcag

25

<210> 177  
<211> 27  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 177  
atggcctttc actactccta ctttgtg

27

<210> 178  
<211> 27  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 178  
taggtaggag tagtgaaagg ccatgaa

27

<210> 179  
<211> 26  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 179  
accctgaagt tcatggcctt tcacta

26

<210> 180  
<211> 26  
<212> DNA



WO 2004/106517

PCT/AU2004/000759

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; oligonucleotide

&lt;400&gt; 180

gaaaggccaa tgaacttcag ggtcag

26

&lt;210&gt; 181

&lt;211&gt; 28

&lt;212&gt; DNA

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; oligonucleotide

&lt;400&gt; 181

attggccttt cactactcct actttgtg

28

&lt;210&gt; 182

&lt;211&gt; 28

&lt;212&gt; DNA

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; oligonucleotide

&lt;400&gt; 182

taggtaggag tagtgaaagg ccagtgaa

28

&lt;210&gt; 183

&lt;211&gt; 27

&lt;212&gt; DNA

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; oligonucleotide

&lt;400&gt; 183

accctgaagt tcactggcct ttcacta

27

&lt;210&gt; 184

&lt;211&gt; 27

&lt;212&gt; DNA

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; oligonucleotide

&lt;400&gt; 184

gaaaggccag atgaacttca gggtcag

27

&lt;210&gt; 185

&lt;211&gt; 29

&lt;212&gt; DNA

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; oligonucleotide

&lt;400&gt; 185

atctggcctt tcactactcc tactttgtg

29

WO 2004/106517

PCT/AU2004/000759

<210> 186  
<211> 29  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 186  
taggtaggag tagtgaaagg ccagatgaa

29

<210> 187  
<211> 28  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 187  
accctgaagt tcatctggcc tttcacta

28

<210> 188  
<211> 28  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 188  
gaaaggccag gatgaacttc agggtcag

28

<210> 189  
<211> 30  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 189  
atcctggcct ttcactactc ctactttgtg

30

<210> 190  
<211> 30  
<212> DNA  
<213> Artificial

<220>  
<223> Primer sequence

<400> 190  
taggtaggag tagtgaaagg ccaggatgaa

30

<210> 191  
<211> 29  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide



WO 2004/106517

PCT/AU2004/000759

<400> 191  
accctgaagt tcatcctggc ctttcacta

29

<210> 192  
<211> 29  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 192  
gaaaggccag agatgaactt cagggtcag

29

<210> 193  
<211> 31  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 193  
atctctggcc tttcactact cctactttgt g

31

<210> 194  
<211> 31  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 194  
taggtaggag tagtgaaagg ccagagatga a

31

<210> 195  
<211> 31  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 195  
accctgaagt tcatctgctg gcctttcact a

31

<210> 196  
<211> 30  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 196  
gaaaggccag cagatgaact tcagggtcag

30

<210> 197  
<211> 32  
<212> DNA

WO 2004/106517

PCT/AU2004/000759

<213> Artificial  
<220>  
<223> oligonucleotide  
<400> 197  
atctgctggc ctttcactac tcctactttg tg 32

<210> 198  
<211> 32  
<212> DNA  
<213> Artificial  
<220>  
<223> oligonucleotide  
<400> 198  
taggtaggag tagtgaaagg ccagcagatg aa 32

<210> 199  
<211> 31  
<212> DNA  
<213> Artificial  
<220>  
<223> oligonucleotide  
<400> 199  
accctgaagt tcatctgctg gcctttcact a 31

<210> 200  
<211> 31  
<212> DNA  
<213> Artificial  
<220>  
<223> oligonucleotide  
<400> 200  
gaaaggccag gcagatgaac ttcagggtca g 31

<210> 201  
<211> 33  
<212> DNA  
<213> Artificial  
<220>  
<223> oligonucleotide  
<400> 201  
atctgcctgg cctttcacta ctctacttt gtg 33

<210> 202  
<211> 33  
<212> DNA  
<213> Artificial  
<220>  
<223> oligonucleotide  
<400> 202  
taggtaggag tagtgaaagg ccaggcagat gaa 33



WO 2004/106517

PCT/AU2004/000759

<210> 203  
<211> 32  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 203  
accctgaagt tcatctgcct ggcctttcac ta

32

<210> 204  
<211> 32  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 204  
gaaaggccag tgcagatgaa cttcagggtc ag

32

<210> 205  
<211> 34  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 205  
atctgcactg gcctttcact actcctactt tgtg

34

<210> 206  
<211> 34  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 206  
taggtaggag tagtgaaagg ccagtgcaga tgaa

34

<210> 207  
<211> 33  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 207  
accctgaagt tcatctgcac tggcctttca cta

33

<210> 208  
<211> 33  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

WO 2004/106517

PCT/AU2004/000759

<400> 208  
gaaaggccag gtgcagatga acttcagggt cag 33

<210> 209  
<211> 35  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 209  
atctgcacct ggcctttcac tactcctact ttgtg 35

<210> 210  
<211> 35  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 210  
taggtaggag tagtgaaagg ccagggtgcag atgaa 35

<210> 211  
<211> 34  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 211  
accctgaagt tcattctgcac ctggcctttc acta 34

<210> 212  
<211> 42  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 212  
caciaacagc ttctcgtggt cctggcggtg tttcgtcctt tc 42

<210> 213  
<211> 42  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 213  
tagcagcttc tcgtggtcct gggttttttg aaaagcttat cg 42

<210> 214  
<211> 26  
<212> DNA



WO 2004/106517

PCT/AU2004/000759

<213> Artificial  
<220>  
<223> oligonucleotide  
<400> 214  
accggagagc catagtgggc tggaaa 26

<210> 215  
<211> 32  
<212> DNA  
<213> Artificial  
<220>  
<223> oligonucleotide  
<400> 215  
accggttccg tttccagacc actatggctc tc 32

<210> 216  
<211> 25  
<212> DNA  
<213> Artificial  
<220>  
<223> oligonucleotide  
<400> 216  
cggaaccggt gactacacga aaagg 25

<210> 217  
<211> 30  
<212> DNA  
<213> Artificial  
<220>  
<223> oligonucleotide  
<400> 217  
gcacggtcta cgagaccttt tcgtgtactc 30

<210> 218  
<211> 24  
<212> DNA  
<213> Artificial  
<220>  
<223> oligonucleotide  
<400> 218  
tctcgtagac cgtgcatttg tgta 24

<210> 219  
<211> 20  
<212> DNA  
<213> Artificial  
<220>  
<223> oligonucleotide  
<400> 219  
agaccgtgca ctacacaaat 20

WO 2004/106517

PCT/AU2004/000759

<210> 220  
<211> 27  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 220  
gtgcacggtc tacgagacct caagggtg

27

<210> 221  
<211> 24  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 221  
ggtgagtaca ccttgagggtc tcgt

24

<210> 222  
<211> 27  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 222  
tactcaccgg ttccgcaagc agaccac

27

<210> 223  
<211> 28  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 223  
agagccatag tgggtctgctt gcggaacc

28

<210> 224  
<211> 22  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 224  
tatggctctc ctttttttgga aa

22

<210> 225  
<211> 17  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide



WO 2004/106517

PCT/AU2004/000759

<400> 225  
agctttttcca aaaaagg 17

<210> 226  
<211> 49  
<212> RNA  
<213> Artificial

<220>  
<223> Hairpin sequence

<400> 226  
ugaagaucaa gaucauugcu ucaagagagc aaugaucuug aucuucuu 49

<210> 227  
<211> 39  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 227  
tataggcgcg ccagagagca atgatcttga tcttcattt 39

<210> 228  
<211> 67  
<212> DNA  
<213> Artificial

<220>  
<223> Hairpin sequence

<400> 228  
aaacaccgtg aagatcaaga tcattgcttt caagagagag caatgatctt gatcttcatt 60  
tttgga 67

<210> 229  
<211> 30  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 229  
cttgaaagca atgatcttga tcttcacggt 30

<210> 230  
<211> 58  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 230  
acgctctctc tccaacttcc gtttctcatc ctttttgga aagcttatcg ataccgtc 58

<210> 231

WO 2004/106517

PCT/AU2004/000759

<211> 58  
<212> DNA  
<213> Artificial

<220>  
<223> Plasmid sequence

<400> 231  
atatatcttg tggaaaggac gaaacacctt tttggaaaag cttatcgata ccgtcgac 58

<210> 232  
<211> 58  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 232  
ctcttgaacg ctctctctcc aacttccgtt tctcatccgg tgtttcgtcc tttccaca 58

<210> 233  
<211> 49  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 233  
cagggcacgg gcagcttgcc ggtggtgcag atgaacttca gggtcagcc 49

<210> 234  
<211> 60  
<212> DNA  
<213> Artificial

<220>  
<223> Plasmid sequence

<400> 234  
accgctgacc ctgaagttca tcttcaagag agatgaactt cagggtcagc tttttggaaa 60

<210> 235  
<211> 49  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 235  
cagggcacgg gcagcttgcc ggtggtgcaa gatgaacttc agggtcagc 49

<210> 236  
<211> 62  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 236



WO 2004/106517

PCT/AU2004/000759

gagaacatgg ttaactgggtt aagtcatgtc gtcccacagg agcgacccat cttcttcaag 60

ga 62

<210> 237

<211> 55

<212> DNA

<213> Artificial

<220>

<223> Primer sequence

<400> 237

ccgccatgcc cgaaggctac gtccaggagc gcaccatctt cttcaaggac gacgg 55

<210> 238

<211> 66

<212> DNA

<213> Artificial

<220>

<223> Oligonucleotide

<400> 238

tgaacatgag aagggtggc cactctccac ctctgtact cacctggacg tagccttcgg 60

gcatgg 66

<210> 239

<211> 49

<212> RNA

<213> Artificial

<220>

<223> Hairpin sequence

<400> 239

ggccuuucac uacuccuacu uuguguaggu aggaguagug aaaggccuu 49

<210> 240

<211> 93

<212> RNA

<213> Artificial

<220>

<223> Hairpin sequence

<400> 240

ggccuuucac uacuccuacu uaugaagauc aagaucuuug cuuguuguag gcaaugaucu 60

ugaucuucuu ugguaggagu agugaaaggc cuu 93

<210> 241

<211> 95

<212> RNA

<213> Artificial

<220>

<223> Hairpin sequence

<400> 241

ggccuuucac uacuccuacu uagugaagau caagaucuuu gcuuguugua ggcaaugauc 60

WO 2004/106517

PCT/AU2004/000759

uugaucuuca uugaguagga guagugaaag gccuu 95

<210> 242  
 <211> 95  
 <212> RNA  
 <213> Artificial

<220>  
 <223> Hairpin sequence

<400> 242  
 gugaagauca agaucuugc uuaggccuuu cacuacuccu acuuuguugu agguaggagu 60

agugaaaggc cuuggcaug aucuugaucu ucauu 95

<210> 243  
 <211> 97  
 <212> RNA  
 <213> Artificial

<220>  
 <223> Hairpin sequence

<400> 243  
 gugaagauca agaucuugc uuaggccuu ucacuacucc uacuuuguug uagguaggag 60

uagugaaagg ccuugagcaa ugaucuugau cuucauu 97

<210> 244  
 <211> 96  
 <212> RNA  
 <213> Artificial

<220>  
 <223> Hairpin sequence

<400> 244  
 gugaagauca agaucuugc uuaggacuga aaccaccugu ucauuuguugu agugaacagg 60

ugguuucagu cuugagcaau gaucuugauc uucauu 96

<210> 245  
 <211> 142  
 <212> RNA  
 <213> Artificial

<220>  
 <223> Hairpin sequence

<400> 245  
 ggccuuucac uacuccuacu uagugaagau caagaucauu gcuuaggacu gaaaccaccu 60

guucauuugu uguagugaac aggugguuuc agucuugagc aaugaucuug aucuucuuug 120

aguaggagua guguuuggcc uu 142

<210> 246  
 <211> 143  
 <212> RNA  
 <213> Artificial

<220>  
 <223> Hairpin sequence



WO 2004/106517

PCT/AU2004/000759

<400> 246  
 gugaagauca agaucuugc uuagggccuu ucacuacucc uacuuaggac ugaaaccacc 60  
 uguucauuug uuguagugaa caggugguuu cagucuugag uaggaguagu gaaaggccuu 120  
 gagcaugau cuugaucuuc auu 143

<210> 247  
 <211> 143  
 <212> RNA  
 <213> Artificial

<220>  
 <223> Hairpin sequence

<400> 247  
 gugaagauca agaucuugc uuaggacuga aaccaccugu ucauuagggc cuuucacuac 60  
 uccuacuuug uuguagguag gaguagugaa aggccuugau gaacaggugg uuucagucuu 120  
 gagcaugau cuugaucuuc auu 143

<210> 248  
 <211> 143  
 <212> RNA  
 <213> Artificial

<220>  
 <223> Hairpin Sequence

<400> 248  
 gugaagauca agaucuugc uuaggacuga aaccaccugu ucauuaggcu gaccugaag 60  
 uucaucuuug uuguaggaug aacuucaggg ucagcuugau gaacaggugg uuucagucuu 120  
 gagcaugau cuugaucuuc auu 143

<210> 249  
 <211> 186  
 <212> RNA  
 <213> Artificial

<220>  
 <223> Hairpin sequence

<400> 249  
 ggccuucacu acuccuacuu agugaagau aagaucauug cuuaggacug aaaccaccug 60  
 uucauuaggc ugaccugaa guucauuuu guuguaggau gaacuucagg gucagcuuga 120  
 ugaacaggug guuucagucu ugagcauga ucuugaucuu cauugaguag gaguagugaa 180  
 ggccuu 186

<210> 250  
 <211> 188  
 <212> RNA  
 <213> Artificial

<220>  
 <223> Hairpin sequence

<400> 250

WO 2004/106517

PCT/AU2004/000759

gugaagauca agaucuugc uuagggccuu ucacuacucc uacuuaggac ugaaccacc 60  
 uguucauuag gcugacccug aagucaucu uuguguagga ugaacuucag ggucagcuug 120  
 augaacaggu gguuucaguc uugaguagga guagugaaag gccuugagca augaucuuga 180  
 ucuucauu 188

<210> 251  
 <211> 188  
 <212> RNA  
 <213> Artificial

<220>  
 <223> Hairpin sequence

<400> 251  
 gugaagauca agaucuugc uuaggacuga aaccaccugu ucauuagggc cuuucacuac 60  
 uccuacuuag gcugacccug aagucaucu uuguguagga ugaacuucag ggucagcuug 120  
 aguaggagua gugaaaggcc uugaugaaca ggugguuucag gucuugagca augaucuuga 180  
 ucuucauu 188

<210> 252  
 <211> 177  
 <212> RNA  
 <213> Artificial

<220>  
 <223> Hairpin sequence

<400> 252  
 gaucauugcu uaggacugaa accaccuguu cauuaggcug acccugaagu ucaucuagg 60  
 gccuuucacu acuccuacuu uguguaggua ggaguaguga aaggccuuga gaugaacuuc 120  
 agggucagcu ugaugaacag gugguuucag ucuugagcaa ugaucuugau cuucauu 177

<210> 253  
 <211> 188  
 <212> RNA  
 <213> Artificial

<220>  
 <223> Hairpin sequence

<400> 253  
 gugaagauca agaucuugc uuaggacuga aaccaccugu ucauuaggcu gaccugaag 60  
 uucaucuug gugugcaccg gcacagacau uuguguagug ucugugccgg ugcacacuug 120  
 agaugaacuu caggguacag uugaugaaca ggugguuucag gucuugagca augaucuuga 180  
 ucuucauu 188

<210> 254  
 <211> 233  
 <212> RNA  
 <213> Artificial

<220>  
 <223> Hairpin sequence



WO 2004/106517

PCT/AU2004/000759

<400> 254  
 ggccuuucac uacuccuacu uagugaagau caagaucauu gcuuaggacu gaaaccaccu 60  
 guucauuagg cugacccuga aguucaucuu aggugugcac cggcacagac auuuguguag 120  
 ugucugugcc ggugcacacu ugagaugaac uucaggguca gcuugaugaa caggugguuu 180  
 cagucuugag caaugaucuu gaucuucauu gaguaggagu agugaaaggc cuu 233

<210> 255  
 <211> 233  
 <212> RNA  
 <213> Artificial

<220>  
 <223> Hairpin sequence

<400> 255  
 ugaagaucaa gaucauugcu uagggccuuu cacuacuccu acuuaggacu gaaaccaccu 60  
 guucauuagg cugacccuga aguucaucuu aggugugcac cggcacagac auuuguguag 120  
 ugucugugcc ggugcacacu ugagaugaac uucaggguca gcuugaugaa caggugguuu 180  
 cagucuugag uaggaguagu gaaaggccuu gagcaaugau cuugaucuu auu 233

<210> 256  
 <211> 234  
 <212> RNA  
 <213> Artificial

<220>  
 <223> Hairpin sequence

<400> 256  
 gugaagaucaga aucauugc uuaggacuga aaccaccugu ucauuagggc cuuucacuac 60  
 uccuacuuag gcugaccug aaguucaucuu uaggugugca ccggcacaga cauuugugua 120  
 gugucugugc cggugcacac uugagaugaa cuucaggguc agcuugagua ggaguaguga 180  
 aaggccuuga ugaacaggug guuucagucu ugagcaauga ucuugaucuu cauu 234

<210> 257  
 <211> 234  
 <212> RNA  
 <213> Artificial

<220>  
 <223> Hairpin sequence

<400> 257  
 gugaagaucaga aucauugc uuaggacuga aaccaccugu ucauuaggcu gaccugaag 60  
 uucaucuuag ggccuuucac uacuccuacu uaggugugca ccggcacaga cauuugugua 120  
 gugucugugc cggugcacac uugaguagga guagugaaag gccuugagau gaacuucagg 180  
 gucagcuuga ugaacaggug guuucagucu ugagcaauga ucuugaucuu cauu 234

<210> 258  
 <211> 234  
 <212> RNA

WO 2004/106517

PCT/AU2004/000759

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; Hairpin sequence

&lt;400&gt; 258

gugaagauca agaucuuugc uuaggacuga aaccaccugu ucauuaggcu gaccugaag 60

uucaucuuag gugugcaccg gcacagacau uagggccuuu cacuacuccu acuuugugua 120

gguaggagua gugaaaggcc uugaugucug ugccggugca cacuugagau gaacuucagg 180

gucagcuuga ugaacaggug guuucagucu ugagcaauga ucuugaucuu cauu 234

&lt;210&gt; 259

&lt;211&gt; 234

&lt;212&gt; RNA

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; Hairpin sequence

&lt;400&gt; 259

gugaagauca agaucuuugc uuaggacuga aaccaccugu ucauuaggcu gaccugaag 60

uucaucuuag gugugcaccg gcacagacau uagcuggacu uccagaagaa cauuugugua 120

guguucuucu ggaaguccag uugaugucug ugccggugca cacuugagau gaacuucagg 180

gucagcuuga ugaacaggug guuucagucu ugagcaauga ucuugaucuu cauu 234

&lt;210&gt; 260

&lt;211&gt; 96

&lt;212&gt; RNA

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; Hairpin sequence

&lt;400&gt; 260

gccaggacca cgagaagcug uuagccagga ccacgagcgc cucuuugugu aggaggcgcu 60

cgugguccug guugacagcu ucucgugguc cugguu 96

&lt;210&gt; 261

&lt;211&gt; 48

&lt;212&gt; RNA

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; Hairpin sequence

&lt;400&gt; 261

acuccucggc aagggcaccu uuguguaggg ugcccuugcc gaggaguu 48

&lt;210&gt; 262

&lt;211&gt; 50

&lt;212&gt; RNA

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; Hairpin sequence

&lt;400&gt; 262



WO 2004/106517

PCT/AU2004/000759

gccaggacca cgagcgccuc uuuguguagg aggcgcucgu gguccugguu 50

<210> 263  
 <211> 95  
 <212> RNA  
 <213> Artificial

<220>  
 <223> Hairpin sequence

<400> 263  
 gacuccucgg caagggcacc uuagccagga ccacgagcgc cucuuugugu aggaggcgcu 60

cgugguccug guugaggugc ccuugccgag gaguu 95

<210> 264  
 <211> 106  
 <212> RNA  
 <213> Artificial

<220>  
 <223> Hairpin sequence

<400> 264  
 gugaagauca agaucuuugc uccuccugag cgcaaguacu ccgugugguu caagagacca 60

cacggaguac uugcgcucag gaggagcaau gaucuugauc uucauu 106

<210> 265  
 <211> 49  
 <212> RNA  
 <213> Artificial

<220>  
 <223> Hairpin sequence

<400> 265  
 gacugaaacc accuguucau ucaagagaug aacagguggu uucagucuu 49

<210> 266  
 <211> 51  
 <212> RNA  
 <213> Artificial

<220>  
 <223> Hairpin sequence

<400> 266  
 gcaugaguuc cagcagcacu uucaagagaa gugcugcugg aacucaugcu u 51

<210> 267  
 <211> 49  
 <212> RNA  
 <213> Artificial

<220>  
 <223> Hairpin sequence

<400> 267  
 ggcgcgucug uucacagccu ucaagagagg cugugaacag acgcgccuu 49

<210> 268

WO 2004/106517

PCT/AU2004/000759

<211> 50  
 <212> RNA  
 <213> Artificial

<220>  
 <223> Hairpin sequence

<400> 268  
 gacugccaug cagaaauaau ucaagagauu auuucugcau ggcagucauu 50

<210> 269  
 <211> 91  
 <212> RNA  
 <213> Artificial

<220>  
 <223> Hairpin sequence

<400> 269  
 gacugaaacc accuguucau uggcgcgucu guucacagcc uucaagagag gcugugaaca 60  
 gacgcgccuu ugaacaggug guuucagucu u 91

<210> 270  
 <211> 93  
 <212> RNA  
 <213> Artificial

<220>  
 <223> Hairpin sequence

<400> 270  
 gacugaaacc accuguucau uaggcgcguc uguucacagc cuucaagaga ggcugugaac 60  
 agacgcgccu ugugaacagg ugguuucagu cuu 93

<210> 271  
 <211> 99  
 <212> RNA  
 <213> Artificial

<220>  
 <223> Hairpin sequence

<400> 271  
 gacugaaacc accuguucau uacaaggcgc gucuguucac agccuucaag agaggcugug 60  
 aacagacgcg ccuuguaaug aacagguggu uucagucuu 99

<210> 272  
 <211> 70  
 <212> RNA  
 <213> Artificial

<220>  
 <223> Hairpin sequence

<400> 272  
 ugaagaucaa gaucauugcu uagacugaau ucaagagauu ucagucuugg caaugaucuu 60  
 gaucuucauu 70

<210> 273



WO 2004/106517

PCT/AU2004/000759

<211> 91  
 <212> RNA  
 <213> Artificial

<220>  
 <223> Hairpin sequence

<400> 273  
 gacugaaacc accuguucau uugaagauca agaucuugc uucaagagag caaugaucuu 60  
 gaucuucuu ugaacaggug guuucaguc u 91

<210> 274  
 <211> 92  
 <212> RNA  
 <213> Artificial

<220>  
 <223> Hairpin sequence

<400> 274  
 gacugaaacc accuguucau uaugaagauca aagaucuuug cuucaagaga gcaaugaucu 60  
 ugaucuucau ugaacaggu gguuucaguc uu 92

<210> 275  
 <211> 95  
 <212> RNA  
 <213> Artificial

<220>  
 <223> Hairpin sequence

<400> 275  
 gacugaaacc accuguucau uagugaagau caagaucuu gcuucaagag agcaaugauc 60  
 ugaucuuca uaugaagaaca ggugguuca gucuu 95

<210> 276  
 <211> 99  
 <212> RNA  
 <213> Artificial

<220>  
 <223> Hairpin sequence

<400> 276  
 gacugaaacc accuguucau uacaugaag aucaagauca uugcuucaag agagcaauga 60  
 ucuugaucuu cauuguugug aacagguggu uucagucuu 99

<210> 277  
 <211> 94  
 <212> RNA  
 <213> Artificial

<220>  
 <223> Hairpin sequence

<400> 277  
 gugaagauca agaucuugc uuagacugaa accaccuguu cauucaagag augaacaggu 60  
 gguuucaguc uuggcaauga ucuugaucuu cauu 94

WO 2004/106517

PCT/AU2004/000759

<210> 278  
<211> 91  
<212> RNA  
<213> Artificial

<220>  
<223> Hairpin sequence

<400> 278  
gcugacccug aagucaucc uggccuuca cuacuccuac uuuguguagg uaggaguagu 60  
gaaaggccag gaugaacuuc agggucagcu u 91

<210> 279  
<211> 91  
<212> RNA  
<213> Artificial

<220>  
<223> Hairpin sequence

<220>  
<221> misc\_feature  
<222> (21)..(22)  
<223> n is a, c, g, or u

<400> 279  
gcugacccug aagucaucc nngccuuca cuacuccuac uuuguguagg uaggaguagu 60  
gaaaggccag gaugaacuuc agggucagcu u 91

<210> 280  
<211> 91  
<212> RNA  
<213> Artificial

<220>  
<223> Hairpin sequence

<220>  
<221> misc\_feature  
<222> (70)..(71)  
<223> n is a, c, g, or u

<400> 280  
gcugacccug aagucaucc uggccuuca cuacuccuac uuuguguagg uaggaguagu 60  
gaaaggccan naugaacuuc agggucagcu u 91

<210> 281  
<211> 91  
<212> RNA  
<213> Artificial

<220>  
<223> Hairpin sequence

<220>  
<221> misc\_feature  
<222> (21)..(22)  
<223> n is a, c, g, or u



WO 2004/106517

PCT/AU2004/000759

<220>  
 <221> misc\_feature  
 <222> (70)..(71)  
 <223> n is a, c, g, or u

<400> 281  
 gcugaccug aagucaucc nngccuuca cuacuccuac uuuguguagg uaggaguagu 60  
 gaaaggccan naugaacuuc agggucagcu u 91

<210> 282  
 <211> 93  
 <212> RNA  
 <213> Artificial

<220>  
 <223> Hairpin sequence

<400> 282  
 gcugaccug aagucaucu dvhhccuuuc acuacuccua cuuuguguag guaggaguag 60  
 ugaaaggcca gagaugaacu ucagggucag cuu 93

<210> 283  
 <211> 93  
 <212> RNA  
 <213> Artificial

<220>  
 <223> Hairpin sequence

<400> 283  
 gcugaccug aagucaucu cuggccuuuc acuacuccua cuuuguguag guaggaguag 60  
 ugaaaggddb hagaugaacu ucagggucag cuu 93

<210> 284  
 <211> 93  
 <212> RNA  
 <213> Artificial

<220>  
 <223> Hairpin sequence

<220>  
 <221> misc\_feature  
 <222> (21)..(21)  
 <223> n is a, c, g, or u

<220>  
 <221> misc\_feature  
 <222> (24)..(24)  
 <223> n is a, c, g, or u

<400> 284  
 gcugaccug aagucaucu naanccuuuc acuacuccua cuuuguguag guaggaguag 60  
 ugaaaggcca gagaugaacu ucagggucag cuu 93

<210> 285  
 <211> 94  
 <212> RNA

WO 2004/106517

PCT/AU2004/000759

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; Hairpin sequence

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (68)..(68)

&lt;223&gt; n is a, c, g, or u

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (71)..(71)

&lt;223&gt; n is a, c, g, or u

&lt;400&gt; 285

gcugaccug aagucaucu cuggccuuc acuacuccua cuuuguguag guaggaguag 60

ugaaagghaa ngagaugaac uucaggguca gcuu 94

&lt;210&gt; 286

&lt;211&gt; 93

&lt;212&gt; RNA

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; Hairpin sequence

&lt;400&gt; 286

gcugaccug aagucaucd vhhccuuca cuacuccuac uuuguguaga aguaggagua 60

gugaaaggbh hbgaugaacu ucagggucag cuu 93

&lt;210&gt; 287

&lt;211&gt; 83

&lt;212&gt; RNA

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; Hairpin sequence

&lt;400&gt; 287

gcugaccug aaguucuggc cuuucacuac uccuacuuug uguagguagg aguagugaaa 60

ggccagaacu ucagggucag cuu 83

&lt;210&gt; 288

&lt;211&gt; 85

&lt;212&gt; RNA

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; Hairpin sequence

&lt;400&gt; 288

gcugaccug aagucaugg ccuuucacua cuccuacuuu guguagguag gaguagugaa 60

aggccaugaa cuucaggguc agcuu 85

&lt;210&gt; 289

&lt;211&gt; 87

&lt;212&gt; RNA

&lt;213&gt; Artificial



WO 2004/106517

PCT/AU2004/000759

<220>  
 <223> Hairpin sequence  
 <400> 289  
 gcugacccug aaguucauug gccuuucacu acuccuacuu uguguaggua ggaguaguga 60  
 aaggccagug aacuucaggg ucagcuu 87

<210> 290  
 <211> 89  
 <212> RNA  
 <213> Artificial

<220>  
 <223> Hairpin sequence  
 <400> 290  
 gcugacccug aaguucaucu ggccuuucac uacuccuacu uuuguaggu aggaguagug 60  
 aaaggccaga ugaacuucag ggucagcuu 89

<210> 291  
 <211> 91  
 <212> RNA  
 <213> Artificial

<220>  
 <223> Hairpin sequence  
 <400> 291  
 gcugacccug aaguucaucc uggccuuuca cuacuccuac uuuguaggu uaggaguagu 60  
 gaaaggccag gaugaacuuc agggucagcu u 91

<210> 292  
 <211> 93  
 <212> RNA  
 <213> Artificial

<220>  
 <223> Hairpin sequence  
 <400> 292  
 gcugacccug aaguucaucu cuggccuuuc acuacuccua cuuuguaggu guaggaguag 60  
 ugaaaggcca gagaugaacu ucaggguag cuu 93

<210> 293  
 <211> 95  
 <212> RNA  
 <213> Artificial

<220>  
 <223> Hairpin sequence  
 <400> 293  
 gcugacccug aaguucaucu gcuggccuuu cacuacuccu acuuuguaggu gguaggagua 60  
 gugaaaggcc agcagaugaa cuucagggu agcuu 95

<210> 294  
 <211> 97

WO 2004/106517

PCT/AU2004/000759

<212> RNA  
 <213> Artificial

<220>  
 <223> Hairpin sequence

<400> 294  
 gcugaccug aagucaucu gccuggccu ucacuacucc uacuuugugu agguaggagu 60  
 agugaaaggc caggcagaug aacuucaggg ucagcuu 97

<210> 295  
 <211> 99  
 <212> RNA  
 <213> Artificial

<220>  
 <223> Hairpin sequence

<400> 295  
 gcugaccug aagucaucu gcacuggccu uucacuacuc cuacuuugug uagguaggag 60  
 uagugaaagg ccagugcaga ugaacuucag ggucagcuu 99

<210> 296  
 <211> 101  
 <212> RNA  
 <213> Artificial

<220>  
 <223> Hairpin sequence

<400> 296  
 gcugaccug aagucaucu gcaccuggcc uuucacuacu ccuacuuugu guagguagga 60  
 guagugaaag gccaggugca gaugaacuuc agggucagcu u 101

<210> 297  
 <211> 50  
 <212> RNA  
 <213> Artificial

<220>  
 <223> Hairpin sequence

<400> 297  
 gccaggacca cgagaagcug uuuguguagc agcuucucgu gguccugguu 50

<210> 298  
 <211> 139  
 <212> RNA  
 <213> Artificial

<220>  
 <223> Hairpin sequence

<400> 298  
 ggagagccau aguggucugg aaacggaacc ggugaguaca cgaaaagguc ucguagaccg 60  
 ugcauuugug uagugcacgg ucuacgagac cucaaggugu acucaccggu uccgcaagca 120  
 gaccacuaug gcucuccuu 139



WO 2004/106517

PCT/AU2004/000759

<210> 299  
<211> 38  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 299  
tgagatgaac ttcaggggtca gcggtgtttc gtcctttc

38

<210> 300  
<211> 41  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 300  
agcctttcac tactcctact tttttttgga aaagcttatc g

41

<210> 301  
<211> 39  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 301  
ctggcctttc actactccta cctggtgttt cgtcctttc

39

<210> 302  
<211> 40  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 302  
agatgaactt cagggtcagc ttttttggaa aagcttatcg

40

<210> 303  
<211> 49  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

<400> 303  
gctgaccctg aagttcatct caagcctttc actactccta cttcctgtc

49

<210> 304  
<211> 51  
<212> DNA  
<213> Artificial

<220>  
<223> oligonucleotide

WO 2004/106517

PCT/AU2004/000759

<400> 304  
aaagtaggag tagtgaaagg ccagagatga acttcaggggt cagcctgtct c 51

<210> 305  
<211> 43  
<212> RNA  
<213> Artificial

<220>  
<223> Sense sequence

<400> 305  
gcugaccug aagucaucu caagccuuc acuacuccua cuu 43

<210> 306  
<211> 46  
<212> RNA  
<213> Artificial

<220>  
<223> Antisense sequence

<400> 306  
gagguaggag uagugaaagg ccagagauga acuucagggg cagcuu 46

<210> 307  
<211> 42  
<212> RNA  
<213> Artificial

<220>  
<223> Sense sequence

<400> 307  
guaggaguag ugaaaggcuu gagaugaacu ucagggucag uu 42

<210> 308  
<211> 43  
<212> RNA  
<213> Artificial

<220>  
<223> Antisense sequence

<400> 308  
cugaccuga agucaucuc uggccuuca cuacuccuac cuu 43



**CLAIMS**

- 1 A ribonucleic acid (RNA) for use as interfering RNA in gene silencing techniques to silence a target gene comprising in a 5' to 3' direction at least a first effector sequence, a second effector sequence, a sequence  
5 substantially complementary to the second effector sequence and a sequence substantially complementary to the first effector sequence, wherein the complementary sequences are capable of forming double stranded regions with their respective effector sequences and wherein at least one of these sequences is substantially identical to the predicted  
10 transcript of a region of the target gene.
- 2 An RNA according to claim 1, further comprising a spacing sequence of one or more nucleotides wherein any two of the sequences are spaced by the spacing sequence.
- 3 An RNA according to claim 2, wherein the first effector sequence is spaced  
15 from the second effector sequence by the spacing sequence.
- 4 An RNA according to claim 2, wherein the sequence substantially complementary to the second effector sequence is spaced from the sequence substantially complementary to the first effector sequence by the spacing sequence.
- 20 5 An RNA according to claim 4, further comprising an additional spacing sequence of one or more nucleotides, wherein at least the first effector sequence is spaced from the second effector sequence by this additional spacing sequence.
- 6 An RNA according to claim 3, further comprising an additional spacing  
25 sequence of one or more nucleotides, wherein the sequence substantially complementary to the second effector sequence is spaced from the sequence substantially complementary to the first effector sequence by this additional spacing sequence.
- 7 An RNA according to claims 5 or 6, wherein the spacing sequences are not  
30 annealable.
- 8 An RNA according to any one of claims 1 to 7, having a spacing sequence

of one or more nucleotides forming a loop between the second effector sequence and the sequence substantially complementary to the second effector sequence.

- 9      An RNA according to any one of claims 1 to 8, comprising three effector  
5      sequences and three sequences substantially complementary to the  
effector sequences wherein the sequences substantially complementary to  
the effector sequences are capable of forming double stranded regions with  
the effector sequences.
- 10      An RNA according to any one of claims 1 to 8, comprising four effector  
10      sequences and four sequences substantially complementary to the effector  
sequences wherein the sequences substantially complementary to the  
effector sequences are capable of forming double stranded regions with the  
effector sequences.
- 11      An RNA according to any one of claims 1 to 8, comprising five effector  
15      sequences and five sequences substantially complementary to the effector  
sequences wherein the sequences substantially complementary to the  
effector sequences are capable of forming double stranded regions with the  
effector sequences.
- 12      An RNA according to any one of claims 1 to 8, comprising more than five  
20      effector sequences and the same number of sequences substantially  
complementary to the effector sequences wherein the sequences  
substantially complementary to the effector sequences are capable of  
forming double stranded regions with the effector sequences.
- 13      An RNA according to any one of claims 1 to 12, wherein the effector  
25      sequences are 10 to 200 nucleotides in length.
- 14      An RNA according to any one of claims 1 to 12, wherein the effector  
sequences are 17 to 30 nucleotides in length.
- 15      An RNA according to any one of claims 1 to 12, wherein the effector  
sequences are 21 to 23 nucleotides in length.
- 30      16      An RNA according to any one of claims 2 to 15, wherein the spacing  
sequence includes a sequence selected from the group consisting of AA,



UU, UUA, UUAG, UUACAA, and  $N_1AAN_2$ , wherein  $N_1$  and  $N_2$  are any of C, G, U and A and may be the same or different.

- 17 An RNA according to any one of claims 5 to 7, wherein the additional spacing sequence includes a sequence selected from the group consisting of AA, UU, UUA, UUAG, UUACAA, and  $N_1AAN_2$ , wherein  $N_1$  and  $N_2$  are any of C, G, U and A and may be the same or different.
- 18 A nucleic acid construct encoding an RNA according to any one of claims 1 to 17.
- 19 A nucleic acid construct including a sequence encoding a ribonucleic acid (RNA) suitable for use as interfering RNA in gene silencing techniques to silence a target gene, the construct comprising in a 5' to 3' direction at least a first effector-encoding sequence, a second effector-encoding sequence, a sequence substantially complementary to the second effector-encoding sequence and a sequence substantially complementary to the first effector-encoding sequence, wherein the transcripts of the complementary sequences are capable of forming double stranded regions with the transcripts of their respective effector-encoding sequences and wherein at least one of these sequences is substantially identical to a region of the target gene.
- 20 A nucleic acid construct according to claim 19 further comprising a spacing sequence of one or more nucleotides wherein any two of the encoding sequences are spaced by the spacing sequence.
- 21 A nucleic acid construct according to claim 20 wherein the first effector-encoding sequence is spaced from the second effector-encoding sequence by the spacing sequence.
22. A nucleic acid construct according to claim 20 wherein the sequence substantially complementary to the second effector-encoding sequence is spaced from the sequence substantially complementary to the first effector-encoding sequence by the spacing sequence.
- 23 A nucleic acid construct according to claim 22 wherein the first effector-encoding sequence is spaced from the second effector-encoding sequence by an additional spacing sequence of one or more nucleotides.

- 24 A nucleic acid construct according to claim 21 wherein the sequence substantially complementary to the second effector-encoding sequence is spaced from at least the sequence substantially complementary to the first effector-encoding sequence by an additional spacing sequence of one or more nucleotides.
- 25 A nucleic acid construct according to claim 23 or 24 wherein the transcript of the spacing sequence is not annealable with the transcript of the additional spacing sequence.
- 26 A nucleic acid construct according to any one of claims 19 to 25 comprising a spacing sequence of one or more nucleotides between the second effector-encoding sequence and the sequence substantially complementary to the second effector-encoding sequence.
- 27 A nucleic acid construct according to any one of claims 19 to 26, comprising three effector-encoding sequences and three sequences substantially complementary to the effector-encoding sequence wherein the primary transcripts of the effector encoding sequences are capable of forming double-stranded regions with the sequences complementary to the effector-encoding sequences.
- 28 A nucleic acid construct according to any one of claims 19 to 26, comprising four effector-encoding sequences and four sequences substantially complementary to the effector-encoding sequence wherein the primary transcripts of the effector encoding sequences are capable of forming double-stranded regions with the sequences complementary to the effector-encoding sequences.
- 29 A nucleic acid construct according to any one of claims claim 19 to 26, comprising five effector-encoding sequences and five sequences substantially complementary to the effector-encoding sequence wherein the primary transcripts of the effector encoding sequences are capable of forming double-stranded regions with the sequences complementary to the effector-encoding sequences.
- 30 A nucleic acid construct according to any one of claims 19 to 29, wherein the effector-encoding sequences are 10 to 200 nucleotides in length.





- 31 A nucleic acid construct according to any one of claims 19 to 29, wherein the effector-encoding sequences are 17 to 30 nucleotides in length.
- 32 A nucleic acid construct according to any one of claims 19 to 29, wherein the effector-encoding sequences are 21 to 23 nucleotides in length.
- 5 33 A method of inhibiting expression of a target gene by introducing an RNA according to any one of claims 1 to 18 into a cell.
- 34 A method of inhibiting expression of a target gene by introducing a nucleic acid construct according to any one of claims 19 to 32 into a cell.
- 35 A method of inhibiting expression of a target gene by introducing to the  
10 target gene an RNA according to any one of claims 1 to 18.
- 36 A nucleic acid construct according to any one of claims 19 to 32 further comprising a promoter and a terminator operably linked to the effector-encoding and substantially complementary sequences.
- 37 A method of constructing a nucleic acid construct according to any one of  
15 claims 19 to 30 comprising adding a predetermined oligonucleotide to a polynucleotide, the oligonucleotide being divided into a first sub-sequence and a second sub-sequence, by a polymerase chain reaction process including:
- 20 providing a first primer having at its 3' end a fixing part hybridizable under polymerase chain reaction conditions with at least a first part of the polynucleotide and at its 5' end an effector part identical to the first sub-sequence, and a second primer having at its 3' end a fixing part hybridizable with at least a second part of the polynucleotide that is adjacent the first part of the polynucleotide and at its 5' end an effector part  
25 identical to the second sub-sequence,
- introducing the primers to the nucleotide under polymerase chain reaction conditions such that the fixing parts of each primer hybridizes with the polynucleotide;
- conducting a multiple polymerase chain reaction to produce an  
30 amplification product which includes the effector parts of the primers at the ends of a double-stranded sequence; and



ligating the ends of the effector parts together to form a combined polynucleotide and oligonucleotide sequence.

- 38 A kit for constructing a nucleic acid construct by the method of claim 37 comprising the polynucleotide, a polymerase, a first primer, a second  
5 primer and a ligating enzyme in proportions suitable for the method of claim 37



**A****B****Figure 1**

2/74

**A****B**


Fragment of pU6.ACTB-A hp  
145 bp (molecule 3286 bp)

**C****ACTB-A**

5' -G	UUCA
UGAAGAUCAAGAUCAUUGC	A
3' - UUACUUCUAGUUCUAGUAACG	G
	AGA

**Figure 2**



**Figure 3**

4/74




Figure 4



5/74




Figure 5

6/74




Figure 6









Figure 7

8/74

**A****B****Figure 8**



9/74

**A****B**

UUUG


5' -GGCCUUUCACUACUCCUAC U

3' -UUCCGGAAAGUGAUGAGGAUG G

GAU

**Figure 9**

A




B

Rluc	ACTB
UUA	UUG
5' -GGCCUUUCACUACUCCUAC	UGAAGAUCAAGAUCAUUGC U
3' -UUCCGGAAAGUGAUGAGGAUG	ACUUCUAGUUCUAGUAACG U
GUU	GAUG

Figure 10



A




B

	Rluc	ACTB
5'	-GGCCUUUACACUACUCCUAC	UGAAGAUCAAGAUCAUUGC
3'	-UUCCGGAAAGUGAUGAGGAUG	ACUUCUAGUUUCUAGUAAACG
	UUAG	UUG
	AGUU	GAUG

Figure 11

A




B

	ACTB	Rluc
5' -G	UUA	UUUG
	UGAAGAUCAAGAUCAUUGC	GGCCUUUCACUACUCCUAC
3' -UUACUUCUAGUUCUAGUAAACG	CCGAAAAGUGAUGAGGAUG	U
	GUU	GAUG

Figure 12



A




B

	ACTB	Rluc
5' -G	UUAG	UUUG
	UGAAGAUCAAGAUCAUUGC	GGCCUUUCACUACUCCUAC
3' UUACUUCUAGUUCUAGUAACG	CCGGAAGUGAUGAGGAUG	U
	AGUU	GAUG

Figure 13

A




B

	ACTB	AD1
5' -G	UUAG	UUUG
	UGAAGAUCAAGAUCAUUGC	GACUGAAACCACCUGUUCA
3' -UUACUUCUAGUUCUAGUAACG	CUGACUUUGGUGGACAAGU	G
	AGUU	GAU

Figure 14



A




B

Rluc	ACTB	AD1
UUAG	UUAG	UUUG
5' - GGCCUUUUCACUACUCCUAC	UGAAGAUC AAGAUCAUUGC	GACUGAAACCACCUGUUCA
3' - UUCCGGUUUGUGAUGAGGAUG	ACUUCUAGUUUCUAGUAACG	CUGACUUUUGGUGGACAAGU
AGUU	AGUU	GAUG

Figure 15

A




B

	ACTB	Rluc	AD1
5' -G	UUAG	UUAG	UUUG
	UGAAGAUCAAGAUCAUUUGC	GGCCUUUCACUACUCCUAC	GACUGAAACCACCUUGUUC
3' -UUACUUCUAGUUCUAGUAAACG	CCGGAAAGUGAUGAGGAUG	CUGACUUUGGUGGACAAGU	U
	AGUU	AGUU	GAUG

Figure 16

A




B

	ACTB	AD1	Rluc
5' -G	UUAG	UUAG	UUUG
	UGAAGAUCAAGAUCAUUGC	GACUGAAACCACCGUUGCA	GGCCUUUCACUACUCCUAC
3' UUACUUCUAGUUCUAGUAACG	CUGACUUUGGUGGACAAAGU	CCGGAAAGUGAUGAGGAUG	U
	AGUU	AGUU	GAUG

Figure 17






**B**

	ACTB	AD1	GFP
5' -G	UUAG	UUAG	UUUG
	UGAAGAUCAAGAUAUUGC	GACUGAAACCAACUGUUCA	GCUGACCCUGAAGUUCAUC
3' -UUACUUCUAGUUCUAGUAACG	CUGACUUUGGUGGACAAGU	CGACUGGGACUUCUACAAGUAG	U
	AGUU	AGUU	GAUG

Figure 18



A




B

	ACTB	RLuc	AD1	GFP
5' -G	UUAG	UUAG	UUAG	UUUG
	UGAAGAUCAAGAUCAUUGC	GGCCUUUCACUACUCCUAC	GACUGAAACACCUGUUC	GCUGACCCUGAAGUUC
3' -UUACUUCUAGUUCUAGUAACG	CCGGAAAGUGAUGAGGAUG	CUGACUUUGUGGACAAGU	CGACUGGGACUUCAGUAG	G
	AGUU	AGUU	AGUU	GAU

Figure 20



A




U6 ACTB/AD1/RLuc/GFP hp insert (3-11)  
222 bp

B

	ACTB	AD1	RLuc	GFP
5' -G	UUAG	UUAG	UUAG	UUUG
	UGAAGAUAACAAGAUCAUUGC	GACUGAAACCAACCUUGUUA	GGCCUUUUCACUACUCCUAC	GCUGACCCUGAAGUUCUAUC
3' -UUACUUUCUAGUUCUAGUAACG	CUGACUUUUGGUGGACAAAGU	CCGGAAAGUGAUGAGGAUC	CGACUGGGACUUCUAAAGUAG	G
	AGUU	AGUU	AGUU	GAU

Figure 21

A




U6:ACTB/AD1/GFP/Rluc.hp insert (3-11)  
222 bp

B

	ACTB	AD1	GFP	Rluc
5' -G	UUAG	UUAG	UUAG	UUUG
	UGAAGAUCAAGAUAUUGC	GACUGAAACCACUGUUA	GCUGACCCUGAAGUUAUC	GGCCUUUCACUACUCCUAC
U				
3' -UUACUUCUAGUUCUAGUAACG	CUGACUUUUGGUGGACAAAGU	CGACUGGGACUUAAGUAG	CCGGAAAGUGAUGAGGAUG	G
	AGUU	AGUU	AGUU	GAU

Figure 22

A



U6.ACTB/AD1/GFP/HER2 hp insert (3-11)  
222 bp


B

ACTB		AD1		GFP		HER2	
5' -G	UUAG	UUAG	UUAG	UUAG	UUAG	UUUG	UUUG
UGAAGAUCAAGAUCAUUGC	GACUGAAACCAACCUUUA	GCUGACCCUGAAGUUCAUC	GUGUGCACCGGCACAGACA	U			
3' -UUACUUCUAGUUCUAGUAACG	CUGACUUUGGUGGACAAAGU	CGACUGGGACUUCUAAAGUAG	CACACGUGGCCGUGUCUGU	G			
AGUU	AGUU	AGUU	AGUU	AGUU	AGUU	GAU	GAU

Figure 23



A




B

Rluc		ACTB		AD1		GFP		HER2	
5' -	GGCCUUUCACUACUCCUAC	UGAAGAUCAAGAUCAUUGC	GACUGAAACCACCUGUUC	GCUGACCCUGAAGUUAUC	GUGUGCACCGGCACAGACA	UUUG	UUAG	UUUG	UUUG
3' -	UUCCGGAAAGUGAGGAUG	ACUUCUAGUUCUAGUAAACG	CUGACUUUGGUGGACAAGU	CGACUGGGACUUAAGUAG	CACACGUGGCCGUGUCUGU	AGUU	AGUU	AGUU	GAU

Figure 24

A




B

ACTB		Rluc		AD1		GFP		HER2	
5' -G	UUAG	UUAG	UUAG	UUAG	UUAG	UUAG	UUAG	UUUG	UUUG
UGAAGAUCAAGAUCAUUGC		GGCCUUUCACUACUCCUAC		GACUGAAACCAACUGUUA		GCUGACCCUGAAGUUAUC		GUGUGCACCGGCACAGACA	
3' -UUACUUCUAGUUCUAGUAACG		CCGGAAGUGAUGAGGAUG		CUGACUUUGGUGGACAAGU		CGACUGGGACUUAAGUAG		CACACGUGCCGUGUCUGU	
AGUU		AGUU		AGUU		AGUU		GAU	

Figure 25

**A**



U6:ACTB/AD1RLuc/GFP/HER2 hp insert (3-11)  
268 bp




	ACTB	AD1	Rluc	GFP	HER2	
5' - G	UUAG	UUAG	UUAG	UUAG	UUAG	UUUG
	UGAAGAUCAAGAUCAUUGC	GACUGAAACCACCUGUUCA	GGCCUUUCACUACUCCUAC	GCUGACCCUGAAGUUCAUC	GUGUGCACCCGGCACAGACA	U
3' - UUACUUUCUAGUUCUAGUAACG		CUGACUUUGGUGGACAAAGU	CCGGAAGUGAUGAGGAUG	CGACUGGGACUUCAGUAG	CACACGUGCCGUGUCUGU	G
	AGUU	AGUU	AGUU	AGUU	AGUU	GAU

## Figure 26



A




U6-actin/AD1/GFP/Rluc/HER2 hp insert (3-11)  
268 bp

B

	ACTB	AD1	GFP	Rluc	HER2
5' -G	UUAG	UUAG	UUAG	UUAG	UUUG
	UGAAGAUCAAGAUCAUUGC	GACUGAAACCAACUGUUCA	GCUGACCCUGAAGUUCAUC	GGCCUUUCACUACUCCUAC	GUGUGCACCGGCACAGACA
3' -UUACUUCUAGUUCUAGUAACG	CUGACUUUGGUGGACAAAGU	CGACUGGGACUUCUAGUAG	CCGGAAAGUGAUGAGGAUG	CACACGUGGCCGUGUCUGU	GAU

Figure 27


A



B

	ACTB	AD1	GFP	HER2	RLuc
5' - G	UUAG	UUAG	UUAG	UUAG	UUUG
	UGAAGAUCAAGAUCAUUGC	GACUGAAACCACCUUUCA	GCUGACCCUGAAGUUAUC	GUGUGCACCGGCACAGACA	GGCCUUUCACUACUCCUAC
3' UUACUUCUAGUUCUAGUAAACG	CUGACUUUUGGUGGACAAGU	CGACUGGGACUUCAAAGUAG	CACACGUGGCCGUGUCUGU	CCGGAAAAGUGAUGAGGAUG	GAU
	AGUU	AGUU	AGUU	AGUU	

Figure 28



	ACTB	AD1	GFP	HER2	LAM
5' -G	UUAG	UUAG	UUAG	UUAG	UUUG
	UGAAGAUCAAGAUCAUUGC	GACUGAAACCACCUGUUCA	GCUGACCCUGAAGUUCAUC	GUGUGCACCGGCACAGACA	CUGGACUUC CAGAAGAACA
3'	UUACUUCUAGUUCUAGUAACG	CUGACUUUGGUGGACAAGU	CGACUUGGACUUCAAGUAG	CACACGUGGCCGUGUCUGU	GACCUGAAGGUCUUCUUGU
	AGUU	AGUU	AGUU	AGUU	GAU

## Figure 29









Figure 30

**Figure 31**

**Figure 32**



A




Fragment of pU6.GF-2  
121 bp (molecule 3333 bp)


B

	Akt1	Akt2
5' -G	UUAG	UUUG
	CCAGGACCACGAGAAGCUG	CCAGGACCACGAGCGCCUC
	GGUCCUGGGUGCUCUUCGAG	GGUCCUGGUGCUCGCGGAG
3' -UU	AGUU	GAU


Figure 33

**Figure 34**

A



Fragment of pU6.GG-2  
74 bp (molecule 3286 bp)




## Figure 35



36/74

**A**




Fragment of pU6.GG-3  
75 bp (molecule 3287 bp)



5' -G  
UUUG  
CCAGGACACGAGGCCUC U  
3' -UUUGUCCUGGUGCUCGCCGAG G  
GAU

## Figure 36

A




Fragment of pU6.GG-4  
120 bp (molecule 3332 bp)

B

	Akta	Aktb
5' -G	UUAG	UUUG
	ACUCCUCGGCAAGGCACC	CCAGGACCAAGCGCCUC
		U
3' -UUUGAGGAGCCGUUCCCGAGG	GGUCCUGGUGCUCGCGGAG	G
	AGUU	GAU


Figure 37

**Figure 38**



39/74

A



B





Figure 39


40/74

**A****B****ADAR1-A**

	UUCA	
5' - GACUGAAACCACCUGU	UUA	A
3' - UUCUGACUUUGGUGGACA	AGU	G
	AGA	

**Figure 40**

41/74


**A****B****ADAR 2-C**

	UUCA	
5' - GCAUGAGU	UCCAGCAGCACU	A
3' - UUCGUACUCA	AAGGUCGUCGUGA	G
	AGA	

**Figure 41**




42/74

**A****B****ADAR 2-A**

	UUCA	
5' -GGCGCGUCUGUUCACAGCC		A
3' -UUCCGCGCAGACAAGUGUCGG		G
	AGA	

**Figure 42**

43/74

**A**


Fragment of pU6.AD1/2-B  
158 bp (molecule 3286 bp)

**B****ADAR 1/2-B**

	UUCA	
5' - GACUGCCAUGCAGAAUAA		A
3' - UUGUGACGGUACGUCUUUAUU		G
	AGA	

**Figure 43**

44/74

**A**

Fragment of pU6.AD1&2-A/UU  
199 bp (molecule 3327 bp)

**B**


ADAR 1-A		ADAR 2-A	
	UU		UUCA
5' -GACUGAAACCACCGUUCA		GGCGCGUCUGUUCACAGCC	A
3' -UUCUGACUUUGGUGGACAAGU		CCGCGCAGACAAGUGUCGG	G
	UU		AGA

**Figure 44**



45/74

A




B

ADAR 1-A		ADAR 2-A	
	UUA		UUCA
5' -GACUGAAACCACCUGU	UUA	GGCGCGUCUGUUCACAGCC	A
3' -UUCUGACUUUGGUGGACAAGU		CCGCGCAGACAAGUGUCGG	G
	GUU		AGA

Figure 45

46/74

**A**

Fragment of pU6.AD1&2-A/UUACAA  
207 bp (molecule 3335 bp)

**B**

ADAR 1-A		ADAR 2-A	
	UUACAA		UUCA
5' - GACUGAAACCACCUGUUC		GGCGCGUCUGUUCACAGCC	A
3' - UUCUGACUUUGGUGGACAAGU		CCGCGCAGACAAGUGUCGG	G
	GUUGUU		AGA

**Figure 46**

47/74

**A****pU6.AD1&2-A/UU****ADAR 1-A****ADAR 2-A**

	UU	UUCA	
5' -GACUGAAACCACCUGUUA	GGCGCGUCUGUUCACAGCC	A	
3' -UUCUGACUUUGGUGGACAAGU	CCGCGCAGACAAGUGUCGG	G	
	UU	AGA	

**B****pU6.AD1&2-A/UUA****ADAR 1-A****ADAR 2-A**

	UUA	UUCA	
5' -GACUGAAACCACCUGUUA	GGCGCGUCUGUUCACAGCC	A	
3' -UUCUGACUUUGGUGGACAAGU	CCGCGCAGACAAGUGUCGG	G	
	GUU	AGA	



**C****pU6.AD1&2-A/UUACAA****ADAR 1-A****ADAR 2-A**

	UUACAA	UUCA	
5' -GACUGAAACCACCUGUUA	GGCGCGUCUGUUCACAGCC	A	
3' -UUCUGACUUUGGUGGACAAGU	CCGCGCAGACAAGUGUCGG	G	
	GUUGUU	AGA	


**Figure 47**



48/74

**A****B****Figure 48**

49/74

**A**


Fragment of pU6.AD1-A&ACTB-A/UU  
187 bp (molecule 3327 bp)

**B**

ADAR 1-A		ACTB-A	
	UU		UUCA
5' -GACUGAAACCACCUGUUCA	UGAAGA	UCAAGA	UUGC A
3' -UUCUGACUUUGGUGGACAAGU	ACUUCU	AGUUCU	AGUAACG G
	UU		AGA

**Figure 49**

50/74

**A**

Fragment of pU6.AD1-A&ACTB-A/UUA  
189 bp (molecule 3329 bp)

**B**


ADAR 1-A		ACTB-A	
	UUA		UUA
5' - GACUGAAACCACCUGU	UUA	UGAAGAUCAAGAUC	A
3' - UUCUGACUUUGGUGGACAAGU		ACUUCUAGUUCUAGUAACG	G
	GUU		AGA

**Figure 50**



51/74

A




B

ADAR 1-A		ACTB-A	
		UUAG	UUCA
5'	-GACUGAAACCACCUGUUCA	UGAAGAUCAAGAUCAUUGC	A
3'	-UUCUGACUUUGGUGGACAAGU	ACUUCUAGUUCUAGUAACG	G
		AGUU	AGA

Figure 51

52/74

**A**


Fragment of pU6.AD1-A&ACTB-A/UUACAA  
195 bp (molecule 3335 bp)

**B**


ADAR 1-A		ACTB-A	
	UUACAA		UUCA
5' - GACUGAAACCACCUGUUCA		UGAAGAUCAAGAUCAUUGC	A
3' - UUCUGACUUUGGUGGACAAGU		ACUUCUAGUUCUAGUAACG	G
	GUUGUU		AGA

**Figure 52**

53/74

**A**

Fragment of pU6.ACTB-A&AD1-A/UUA  
184 bp (molecule 3330 bp)

**B****Figure 53**



54/74

**A****pU6.ACTB-A/UUA**

	<b>ACTB-A</b>	<b>stem</b>	
		UUA	UUCA
5'	-UGAAGAUCAAGAUCAUUGC	GACUGAA	A
3'	UUACUUCUAGUUCUAGUAACG	CUGACUU	G
		GUU	AGA

**B****pU6.AD1-A&ACTB-A/UU**

	<b>ADAR 1-A</b>		<b>ACTB-A</b>	
		UU		UUCA
5'	-GACUGAAACCACCUGUUCA	UGAAGAUCAAGAUCAUUGC		A
3'	-UUCUGACUUUGGUGGACAAGU	ACUUCUAGUUCUAGUAACG		G
		UU		AGA

**C****pU6.AD1-A&ACTB-A/UUA**

	<b>ADAR 1-A</b>		<b>ACTB-A</b>	
		UUA		UUCA
5'	-GACUGAAACCACCUGUUCA	UGAAGAUCAAGAUCAUUGC		A
3'	-UUCUGACUUUGGUGGACAAGU	ACUUCUAGUUCUAGUAACG		G
		GUU		AGA

**D****pU6.AD1-A&ACTB-A/UUAG**

	<b>ADAR 1-A</b>		<b>ACTB-A</b>	
		UUAG		UUCA
5'	-GACUGAAACCACCUGUUCA	UGAAGAUCAAGAUCAUUGC		A
3'	-UUCUGACUUUGGUGGACAAGU	ACUUCUAGUUCUAGUAACG		G
		AGUU		AGA

**E****pU6.AD1-A&ACTB-A/UUACAA**


	<b>ADAR 1-A</b>		<b>ACTB-A</b>	
		UUACAA		UUCA
5'	-GACUGAAACCACCUGUUCA	UGAAGAUCAAGAUCAUUGC		A
3'	-UUCUGACUUUGGUGGACAAGU	ACUUCUAGUUCUAGUAACG		G
		GUUGUU		AGA

**F****pU6.ACTB-A&AD1-A/UUA**


	<b>ADAR 1-A</b>		<b>ADAR1-A</b>	
		UUA		UUCA
5'	-G	GAAGAUCAAGAUCAUUGC	GACUGAAACCACCUGUUCA	A
3'	-UUACUUCUAGUUCUAGUAACG	CUGACUUUGGUGGACAAGU		G
		GUU		AGA

**Figure 54**

55/74


**Figure 55**

56/74


**Figure 56**





57/74

**Figure 57**

58/74

**Figure 58**


**A**



## Figure 59



A



B





Figure 60

A




B

EGFP	Rluc
UG	UGU
5' - GCUGACCCUGAAGUUCAUCC	GCCUUUCACUACUCCUACUU G
CGACUGGGACUUC AAGUAGG	CGAAAGUGAUGAGGAUGAA U
3' - UU	GA

Figure 61

A



B












Figure 62




63/74

**A****B****C****D****Figure 63**

64/74

**A****B****C****Figure 64**

A






B

EGFP	Rluc
DVHH	UGU
5' -GCUGACCCUGAAGUUCauc	CCUUUCACUACUCCUACUU G
CGACUGGGACUUCUUAAGUAG	GGAAAGUGAUGAGGAUGAA U
3' -UU	BHHB GA

Figure 65



66/74

**A****B****C****Figure 66**

67/74

**A**

GFP 17 Rluc UUUG  
5' -GCUGACCCUGAAGUUCAGGCCUUUCACUACUCCUAC U  
CGACUGGGACUUCAAGUCCGGAAAGUGAUGAGGAUG G  
3' -UU GAU

**B**

GFP 18 Rluc UUUG  
5' -GCUGACCCUGAAGUUCAUGGCCUUUCACUACUCCUAC U  
CGACUGGGACUUCAAGUACCGGAAAGUGAUGAGGAUG G  
3' -UU GAU

**C**

GFP 19 Rluc UUUG  
5' -GCUGACCCUGAAGUUCAUCGGCCUUUCACUACUCCUAC U  
CGACUGGGACUUCAAGUAGCCGGAAAGUGAUGAGGAUG G  
3' -UU GAU

**D**

GFP 20 Rluc UUUG  
5' -GCUGACCCUGAAGUUCAUCCGGCCUUUCACUACUCCUAC U  
CGACUGGGACUUCAAGUAGGCCGGAAAGUGAUGAGGAUG G  
3' -UU GAU

**E**

GFP 21 Rluc UUUG  
5' -GCUGACCCUGAAGUUCAUCCUGGCCUUUCACUACUCCUAC U  
CGACUGGGACUUCAAGUAGGACCGGAAAGUGAUGAGGAUG G  
3' -UU GAU

**F**

GFP 22 Rluc UUUG  
5' -GCUGACCCUGAAGUUCAUCUCUGGCCUUUCACUACUCCUAC U  
CGACUGGGACUUCAAGUAGAGACCGGAAAGUGAUGAGGAUG G  
3' -UU GAU

**G**

GFP 23 Rluc UUUG  
5' -GCUGACCCUGAAGUUCAUCUGCGGCCUUUCACUACUCCUAC U  
CGACUGGGACUUCAAGUAGACGACGGAAAGUGAUGAGGAUG G  
3' -UU GAU

**H**

GFP 24 Rluc UUUG  
5' -GCUGACCCUGAAGUUCAUCUGCCUGGCCUUUCACUACUCCUAC U  
CGACUGGGACUUCAAGUAGACGGACCGGAAAGUGAUGAGGAUG G  
3' -UU GAU

**I**


GFP 25 Rluc UUUG  
5' -GCUGACCCUGAAGUUCAUCUGCACUGGCCUUUCACUACUCCUAC U  
CGACUGGGACUUCAAGUAGACGUGACCGGAAAGUGAUGAGGAUG G  
3' -UU GAU

**J**

GFP 26 Rluc UUUG  
5' -GCUGACCCUGAAGUUCAUCUGCACCTGGCCUUUCACUACUCCUAC U  
CGACUGGGACUUCAAGUAGACGUGGACCGGAAAGUGAUGAGGAUG G  
3' -UU GAU



**Figure 67**

68/74

**Figure 68**



69/74

**A****B****Figure 69**

70/74









Figure 70

71/74


**A****B****C****Figure 71**




72/74

**A****B****Figure 72**

73/74

**A**

5' - GCUGACCCUGAAGUUCAUCUCAAGCCUUUCACUACUCCUACUU - 3'

**B**


5' - GAGGUAGGAGUAGUGAAAGGCCAGAGAUGAACUUCAGGGUCAGCUU - 3'

**C**

5' - G  
CUGACCCUGAAGUUCAUCUCAAGCCUUUCACUACUCCUACUU - 3'  
3' - UUCGACUGGGACUUCAAGUAGAGACCGGAAAGUGAUGAGGAUG - 5'


**Figure 73**

74/74

**A**

T7 GR-22-1-AA-sense template rc  
51 bp

5' - GUAGGAGUAGUGAAAGGCUUGAGAUGAACUUCAGGGUCAGUU - 3'

**B**

T7 GR22 antisense template rc  
51 bp

5' - CUGACCCUGAAGUUCAUCUCUGGCCUUUCACUACUCCUACCUU - 3'

**C**

5' - CUGACCCUGAAGUUCAUCUCUGGCCUUUCACUACUCCUACUU - 3'  
3' - UUGACUGGGACUUCAAGUAGAGUUCGGAAAGUGAUGAGGAUG

**Figure 74**